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The effect of phytoestrogens on bone and T cells differentiation and activity 
Sahar S. Karieb 
Abstract 
The fall in circulating oestrogen (E2) after the menopause leads to an increased rate of 
bone remodelling, excessive osteoclast activity and a greater fracture risk. Until recently 
hormone replacement therapy (HRT) was prescribed to post-menopausal women to 
prevent bone loss, however HRT is associated with an elevated incidence of 
cardiovascular disease, stroke and cancer. These side-effects led to an interest in 
naturally occurring compounds with oestrogenic action such as phytoestrogens (PEs), 
which are non-steroidal-plant derived compounds. Human trials and animal studies 
suggest a beneficial effect of PEs on bone mass, although their ability to modify 
osteoclast formation in response to key inflammatory cytokines has not been examined. 
The aim of the following studies was to determine the effect of physiologically relevant 
concentrations of genistein, coumestrol and daidzein on TNF-α-induced osteoclast 
formation, osteoblasts differentiation and T cell activity.  
Genistein (10
-7
 M), daidzein (10
-5
 M), and coumestrol (10
-7 
M) significantly reduced 
TNF-α-induced TRAP positive osteoclast formation and bone resorption, which was 
prevented by the E2 antagonist ICI 182,780. The suppressive action on osteoclast 
formation was associated with a significant reduction in TNF-α-induced c-fos and 
NFATc1 mRNA expression and NFATc1 nuclear translocation. Constitutive c-fos 
expression prevented the inhibitory action of PEs on osteoclast differentiation, 
resorption and NFATc1 expression. 
The effect of PEs, in the presence or absence of the anabolic nutritional factor zinc, on 
osteoblasts differentiation and bone nodule formation was examined in-vitro. 
v 
 
Coumestrol (10
-5
 to 10
-7
 M), daidzein (10
-5
 to 10
-6
 M) and genistein (10
-5
 M) enhanced 
bone nodule formation and ALP activity in human osteoblasts, and this effect was 
significantly augmented in the presence of zinc (10
-5
 M). Furthermore, PEs and zinc 
increased Runx2 mRNA expression and Zn
2+
 augmented the inhibitory effect of PEs on 
RANKL/OPG ratio. This suggests that in addition to the direct inhibitory effect on 
osteoclast formation PEs also in-directly reduce the osteoblastsic stimulus for osteoclast 
formation and promote bone formation.  
E2 deficiency is thought to promote osteoclastogenesis by modifying Thelper1 (Th1) 
cell proliferation and inflammatory cytokine production in particular TNF-α. I therefore 
examined the effect of PEs on T cell proliferation and inflammatory cytokine 
production. All PEs prevented the augmentative effect of con A stimulated T cells on 
osteoclast formation in co-culture. However the mechanism of action varied, genistein 
reduced con A stimulated TNF-α, IL-1β and RANKL expression with little effect on 
viability, coumestrol decreased cell viability and TNF-α expression whereas the 
inhibitory effect of daidzein was mediated via suppression of viable T cell number.  
This study provides novel evidence that PEs have multiple effects on bone cell activity, 
directly inhibiting TNF-α-induced osteoclast formation, reducing the osteoblasts and T 
cell derived stimulus for osteoclast formation and augmenting osteoblasts differentiation 
and bone formation. Thus, PEs have a potential role in the treatment of post-menopausal 
osteoporosis and inflammatory skeletal disorders and that the beneficial effect noted in 
previous studies is mediated through multiple mechanisms.  
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1.1 Introduction   
Bone is a dynamic and specialised connective tissue that is able to resist deformation, 
but at the same time be flexible enough to allow energy absorption during impact 
loading. There are five categories of bones: long bones, short bones, flat bones, 
sesamoid and irregular bones. Bone has a variety of functions: firstly, protective and 
supportive functions shielding vital internal organs such as bone marrow and brain. 
Second, mechanical loading and movement. The third function of bone is in the 
maintenance of mineral homeostasis, as bone serves as a reservoir of calcium and 
phosphate (Clarke, 2008).  
Bone serves as a mineral reservoir for calcium and phosphorus and releases these 
minerals to the blood to maintain homeostatic balance. Calcium plays an important role 
in skeletal mineralisation and its deficiency can lead to osteomalacia (Sambrook, 2001).  
Bone also plays an important role in movement providing articulation for skeletal 
muscles tendons, ligaments and joints. In addition, bone has a metabolic function 
through storage of fat via yellow bone marrow (adipose cells) which provides a local 
energy reservoir in the bone (Gimble et al., 1996, Lecka-Czernik, 2012).  
Recent publications suggest that in addition to classic roles bone can also be considered 
an endocrine organ. Evidence has been accumulating that bone cell derived FGF23 and 
osteocalcin have important roles in regulating kidney function and glucose metabolism.  
Osteoblast derived osteocalcin has an endocrine action on pancreatic β-cells, stimulating 
proliferation and insulin production (Fukumoto and Martin, 2009). A positive 
relationship was found between osteocalcin levels and insulin production and glucose 
tolerance. Animal studies also suggest an additional peripheral effect of osteocalcin 
promoting insulin sensitivity and reducing the accumulation of adipose tissue.  It is 
therefore unsurprising that lower levels of osteocalcin are found in diabetics than 
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healthy individuals and this may contribute to disease progression (Hwang et al., 2012, 
Hwang et al., 2009, Pollock et al., 2011). Furthermore, osteocytic FGF23 promotes 
renal phosphorus secretion by inhibiting the 1alpha hydroxylation of vitamin D. 
Bones are not static entities, bone structure is constantly altered during growth, or in 
response to changes in mechanical stress, circulating mineral or in response to damage.  
This structural change occurs through a process of remodelling, which involves bone 
resorption followed by bone formation. Remodelling occurs through the action of 
osteoclast which are responsible for the production of HCl and proteases which enable 
the formation of resorption pits, and osteoblasts which secret the organic and inorganic 
components of bone matrix to form new bone. During bone formation a proportion of 
osteoblasts become encapsulated in the matrix becoming osteocytes which have a role 
in mechano-transduction (Matsuo and Irie, 2008). 
1.2 Bone Structure   
There are two types of bone tissue: cortical bone (also termed compact bone) that has a 
primary role in resisting mechanical loading and trabecular bone (also termed spongy or 
cancellous bone) which is the major site of calcium exchange and also has a secondary 
mechanical role. Cortical bone is the out layer of bone and composes 80% of the adult 
human skeleton; it has a low porosity and provides protection and support. Cortical 
bone is composed of osteons, which are the basal structural unit of bone, also called 
Haversian systems, these are formed from concentric lamella of bone tissue that also 
contain blood vessels and nerve fibres (Clarke, 2008). The outer surface of cortical bone 
is coved by a membrane termed the periosteum (Figure 1.1). 
Trabecular bone consists of an irregular lattice of thin columns which are typically 
orientated in the same direction as the predominate strain direction experienced by that 
bone. Trabecular bone composes 20% of the human skeleton and has a number of 
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functions such as mineral homeostasis (Sambrook, 2001), it can also withstand 
compressive load better than cortical bone due to the absorbance of energy efficiently. 
The strength of trabecular bone depends on the extent of connectivity between adjacent 
trabeculae and loss of this leads to a drastic reduction in mechanical competence 
(Chavassieux et al., 2007).   
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Figure 1.1. Long Bone structure and anatomy. Adapted from http://phsgirard.org/Anatomy.html.     
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1.3 Bone Tissue  
Bone tissue has both organic and inorganic elements. The organic component of bone 
matrix is composed mainly from type I collagen, a range of non-collagenous proteins 
and proteoglycan. Type I collagen forms from two identical α1 chains and a single α2 
chain which combine to form a molecule of type I collagen that provides the flexibility 
and strength of bone. Type I collagen then undergoes various post-translation 
modifications to form mature fibres. The organic component of the matrix is 
synthesized first and is subsequently mineralised with inorganic calcium hydoxyapatite 
crystals (Ca[PO4]6[OH]2) that increase the material stiffness of bones (Follet et al., 
2004). Collagen fibrils provide the flexibility and elasticity to bone whereas the bone 
mineral provides rigidity (Chavassieux et al., 2007). Moreover, the direction of collagen 
fibres is often related with the direction of load (Martin and Boardman, 1993).  
In addition to collagen, there are also non-collagenous proteins which are synthesized 
by bone cells and make up 15% of bone protein. Osteoblasts produced several proteins 
that play an important role in bone matrix mineralisation including enzymes such as 
alkaline phosphatase (ALP), calcium binding proteins, carboxyglutamic acid (GLa), 
prophosphatase, ion channels, signal transduction molecules such as 14-3-3 family 
members and other related proteins. Modulation of these proteins’ expression may 
effect bone formation and resorption (Xiao et al., 2007).     
1.4 Osteoblasts  
Osteoblasts are derived from mesenchymal stem cells and are responsible for the 
synthesis and deposition of the organic and inorganic components of bone matrix. The 
formation of a mature bone forming osteoblasts is a sequential process that involves the 
development of immature osteoblasts prior to the formation of mature cells. Mature 
osteoblasts are characterised by the expression of several markers including ALP and 
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type-I collagen which are both important for bone matrix synthesis and mineralisation 
(Murshed et al., 2005). Osteoblasts also secrete other proteins characteristic of bone 
including osteocalcein (OCN), osteopontin (OPN), matrix Gla proteins (MGP), bone 
sialoprotein (BSPs), osteonectin, proteoglycan and growth factors such as bone 
morphogenetic proteins (BMPs) and TGF-β (Young et al., 1992, Mundlos and Olsen, 
1997, Young, 2003, Olsen et al., 2000, Harada and Rodan, 2003, Ralston and de 
Crombrugghe, 2006). Following the completion of bone formation, osteoblasts can 
either undergo apoptosis, become osteocytes by embedding in the matrix or transform 
into lining cells that cover inactive bone surface (Clarke, 2008). Osteoblastsic lineage 
cells respond to various hormonal, growth factors and cytokines such as BMPs, IGF, 
parathyroid hormone and prostaglandin E2 (PGE2), which modify the expression of 
osteoblastsic transcriptional factors such as Runx2 and Osterix which are some of the 
earliest osteoblastsic markers and play a critical role in osteoblast differentiation 
(Mackie, 2003, Karsenty, 2003). Moreover, Runx2 in turn regulates expression of genes 
encoding VEGF, osteocalcin, RANKL and collagen (Lian et al., 2006). In addition to 
their important role in bone formation, osteoblasts also play a role in osteoclast 
differentiation by secreting cytokines such as M-CSF, RANKL and OPG which bind to 
specific receptors expressed by osteoclast precursors and subsequently promoting 
osteoclast formation. 
1.4.1 Osteoblast differentiation  
Osteoblast differentiation from mesenchymal cells is under the control of numerous 
transcription and growth factors. Mesenchymal cells are pluripotent having the capacity 
to differentiate under appropriate conditions into several lineages such as osteoblasts, 
chondrocytes, adipocytes, myoblasts and fibroblasts (Barry and Murphy, 2004, Baksh et 
al., 2004) (Figure 1.2). The proliferation and differentiation of osteoblast is dependent 
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on the coordinated expression of multiple transcription factors such as Runx2 and 
osterix (osx) (Nakashima et al., 2002, Karsenty and Wagner, 2002). In brief, 
preosteoblast reside near the bone surface and express the early marker of osteoblast 
differentiation ALP (Luu et al., 2007, Karsenty, 1999). Subsequently preosteoblast 
differentiate into active mature osteoblast which display characteristic changes: a large 
nucleus, extensive endoplasmic reticulum and enlarged Golgi which is important to 
support the secretion of matrix proteins such as type I collagen (Olsen et al., 2000).  
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Figure 1.2. Mesenchymal cells differentiate into osteoblasts under Runx2 and osterix control. 
Mesenchymal cells also give rise to adipocyte, myocyte and chondrocytes under the control of 
specific transcriptional factors. Osteoblast is differentiated under the control of Runx2, a key 
regulator of osteoblast differentiation pathway, while osterix is downstream of Runx2 and is 
important for osteoblast maturation. From (Harada and Rodan, 2003). 
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1.5 Key Regulators of Osteoblast Formation 
1.5.1 TGF/BMP  
Transforming growth factors (TGF) are a family of 30 secreted dimeric polypeptide 
cytokines that regulate numerous cellular functions including differentiation, 
proliferation and apoptosis (Blobe et al., 2000, Feng and Derynck, 2005, Mishra et al., 
2005). These include TGFβ, TGFα and BMPs. With regards to TGFβ there are  three 
major isoforms TGFβ1, 2 and 3, which are conserved in mammals (Massague, 1998). 
TGFβ members affect cellular function through two types of receptor I and II 
transmembrane serine/therionine kinase. 
TGFβ has been reported to play a critical role in mammalian cellular function and the 
disruption of TGFβ signals has a detrimental  effect on the  cardiovascular, skeletal, and 
muscular systems (Serra and Chang, 2003). Furthermore, it has been shown that 
fibrodysplasia ossificans progressiva, a rare genetic disorder associated with ectopic 
formation of bone, is caused by a gain of function  mutation in the TGFβ type I receptor 
ACRVI (Shore et al., 2006). Additionally, BMPs, provide further important signals that 
are essential for full osteoblast differentiation and maturation (Krane, 2005, Chen et al., 
2004). Moreover, it has been reported that Wnt/β-catenin signalling synergises with 
BMP signalling to promote osteoblast differentiation (Mbalaviele et al., 2005). BMPs 
also have the capacity to stimulate endochondral bone formation (Okamoto et al., 2006, 
Cao and Chen, 2005). For instance BMPs 1-7 are expressed in skeletal tissues, while 
BMP 2, 4 and 6 are detected in cultures of osteoblastsic cells (Canalis et al., 2003, 
Anderson et al., 2000). BMP-2, 6, 7 and 9 have been shown to induce osteogenesis in-
vivo and in-vitro (Kang et al., 2004, Luu et al., 2007), whereas BMP3 acts as a negative 
regulator of bone formation (Daluiski et al., 2001). Interestingly, BMPs induce Runx2 in 
mesenchymal progenitors through the action of BR-Smad to promote osteoblast 
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differentiation (Maeda et al., 2004). In contrast, BMP2 has been shown to induce the 
expression of osx in chondrocytes and mouse progenitors through a Runx2-independent 
mechanism (Lee et al., 2003, Yagi et al., 2003). In addition, BMP2 can effect osx 
expression via p38 and ERK pathways in osteogenic culture (Celil et al., 2005).  
The mothers against decapentaplegic (Smad) transcription factors play a critical role in 
TGF-β and BMP signalling (Miyazawa et al., 2002). Smad consist of three major 
classes: receptor-regulator-Smad (R-Smad), common partner BMP and TGF-β mediator 
Smad (Co-Smad), and inhibitory Smad (I-Smad). R-Smad act as activator of BMP or 
TGF-β thus called also (BR-Smad or TR-Smad). Co-Smad (Smad 4 and 3) act as a 
partner of BMP and TGF-β activity, while I-Smad (Smad 7) acts as an inhibitor of R-
Smad phosphorylation. 
BMP signal transduction involves both Smad-dependent and independent pathways 
such as ERK, JNK and MAP kinase (Derynck et al., 2001). Following receptor 
activation, receptor Smads are phosphorylated and then form complexes with co-Smad 
members (3 &4) (Dennler et al., 2002). This exposes nuclear localisation signals on the 
surface of the dimer which enables nuclear translocation (Moustakas et al., 2001, Li and 
Cao, 2006, Wrana, 2000). Inhibitory Smads (Smad 7) prevent receptor Smad binding by 
binding to Smad 4, to activated receptors and also promote the proteolytic destruction of 
activated Smad. 
1.5.2 Wnt Signalling 
Wnts are a family of secreted glycoproteins and are ligands for 7-transmembrane-
spanning frizzled (FZD) receptors. These proteins are involved in numerous aspects of 
cellular biology, cell proliferation and differentiation. Wnt proteins released from cells 
or expressed on the surface of activated cell bind to FZD/LRP5/6 to form a complex. 
Wnt are important for the development of numerous tissues including bone, and its 
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pathways are keys to osteoblast differentiation. Aberrant signalling  in this pathway 
causes a wide range of diseases such as cancer and degenerative diseases (Reya and 
Clevers, 2005, Clevers, 2006). Multiple pieces of evidence suggest that Wnt signalling 
plays a critical role in the promotion of osteoblast differentiation and bone development 
(Bergwitz et al., 2001, Fischer et al., 2002). Wnt proteins effect bone biology through 
effects on cell growth, proliferation, differentiation and lifespan by several pathways 
such as Wnt/β-catenin or canonical pathway (Westendorf et al., 2004, Rawadi and 
Roman-Roman, 2005). 
Wnt proteins are divided into different classes: the first group activates the Wnt/β-
canoncial signalling pathway that is implicated in the formation of complexes between 
Wnt-FZD proteins and LDL-receptor protein 5 or 6 (LRP5 or 6 receptors) (Tamai et al., 
2000, He et al., 2004). Both LRP5 and 6 contain extracellular domain with a consensus 
with EGF (epidermal growth factor), while non-canoncial Wnt5a class binds to FZD 
and activates heterotrimeric G proteins, which in turn increase intracellular calcium via 
protein kinase C-dependent mechanisms or stimulate c-Jun N-terminal kinase (JNK)-
dependent changes in cytoskeletal structure (Veeman et al., 2003) (Figure 1.3). 
Canonical Wnt pathway occurs when Wnt3a bind to the receptor complex of frizzled 
and LRP5 or LRP6; signals are generated through dishevelled, Axin and Frat-1 proteins 
that disrupt the protein complex and inhibit the activity of glycogen synthase kinase 3 
(Gsk3) causing hypophosphorylation of its substrate β-catenin followed by stabilization 
of β-catenin followed by its accumulation in the cytosol. The accumulated β-catenin 
translocates into nucleus and work together with TCF/LEF induces the expression target 
genes of osteoblast (Hay et al., 2005). Non-canonical Wnt pathway start after Wnt5a 
binding to Frizzled and Ror1 or Ror2 receptors which in turn activates the Planar cell 
polarity pathway and calcineurin-dependent mechanism (Takahashi et al., 2011) (Figure 
1.3). The Wnt5a pathway may also play an important role in RANKL-induced 
                                                                                         Chapter 1 
 
13 
 
osteoclast formation (Maeda et al., 2012). While β-catenin decreases bone resorption by 
up regulating OPG expression and decreasing RANKL expression in-vitro (Spencer et 
al., 2006).      
Wnt/β-catenin signalling plays an important role in osteoblast differentiation as well as 
in fracture healing and osteoclast differentiation. Recent studies examining the 
importance of Wnt/β-catenin signalling in osteoblasts formation using conditional 
inactivation of this pathway, it’s revealed that β-catenin activity is critical for 
osteoblasts maturation and consequently for bone formation and development in 
endochonderal and intramembranous bone (Day et al., 2005, Hill et al., 2005, Hu et al., 
2005). However, it has been showed that Wnt/β-catenin signalling in osteoblasts may 
coordinate postnatal bone formation by controlling both osteoclast and osteoblast 
differentiation (Holmen et al., 2005). Canonical Wnt signalling is modulated by Runx2 
and osx. Furthermore, β-catenin/TCF1 increases Runx 1 and 2 promoter activity (Gaur 
et al., 2005). Recent studies have shown there is a possibility to use Wnt signalling as an 
anabolic agent in bone. Interestingly, humanised monoclonal antibody against sclerostin 
improved bone anabolism in post-menopausal men and women (Padhi et al., 2011). 
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Figure 1.3. A schematic diagram of Wnt signalling pathway. The canonical pathway starts after 
binding of Wnt to  FZD, LRP5/6 complex receptor and this activated Dsh and causing β-catenin 
phosphorylation. β-catenin accumulation and translocation to the nucleus and binds to 
transcriptional factors such as T-cell factor (TCF)- and lymphoid enhancer-binding protein 
(LEF)-family transcription factors mediated transcription of target genes. The noncanonical Wnt 
(Wnt5a) binds to of Frizzled and Ror1 or 2 receptor complex, and this binding activates planar 
cell polarity through RhoA Rac and JNK. From (Takahashi et al., 2011).  
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1.5.3 Osteoblastsic transcription factors (Runx2, Osterix, TAZ and ATF4) 
Runt-related transcription factor 2 (Runx2) (also called cbfa1 OSF-2 and AML3) is a 
master transcription factor for osteoblast differentiation. Runx2 is one of three 
transcriptional factors belonging to Runt transcription factor family which consists of 
Runx1(cbfa2, PEBP2AB, cbfa2 and AML1), Runx2 (PEBP2aA, cbfa1 and AML3) and 
Runx3 (PEBP2aC, cbfa3 and AML2) (Lian et al., 2003). There are two isoforms of 
Runx2, type I and type II, which have different N-terminal sequences. Runx2 is 
expressed in several organs and tissues such as thymus, bone tissues and calcified 
cartilage (Ogawa et al., 1993, Banerjee et al., 1997) and is essential for cartilage 
mineralisation and skeletal development. Runx2 contains a 128 amino acid DNA 
binding motif and a binding domain that is necessary for dimerization with several other 
transcription factors (Karsenty, 2000). Cbfβ (core-binding factor) is a co-transcription 
factor that modifies the DNA-binding affinity of Runx family members. Both Runx2 
isoforms have a similar activity in the presence of cbfβ, while in the absence of cbfβ, 
Runx2-II activity was higher that Runx2-I, suggesting that Runx2 isoforms exert their 
activity via cbfβ-dependent mechanism (Kanatani et al., 2006).   
Runx2 has been identified as a master transcription factor for controlling skeletal 
formation and mineralisation by promoting osteoblast differentiation at early stages of 
differentiation (Karsenty, 2000, Kern et al., 2001). Runx2 also plays an important role 
in maturation and maintenance of chondrocytes as well as vascular invasion into 
cartilage (Komori, 2005, Zelzer et al., 2001). Interestingly, Runx2 is also important in 
terminal stages of chondrocytes maturation (Drissi et al., 2002, Iwamoto et al., 2005, 
Dong et al., 2006). The expression of Runx2 during bone formation regulates osteoblast 
gene expression (Komori et al., 1997, Otto et al., 1997), and loss of Runx2 activity 
results in a lack of bone formation. Runx2 regulates several genes indicative of 
osteoblast differentiation and function including ALP and osteocalcin (Otto et al., 1997, 
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Choi et al., 2001, Kim et al., 1999, Komori, 2005). Furthermore, in-vitro studies showed  
that Runx2 expression in skin fibroblast leads to osteoblast specific gene expression 
demonstrating that Runx2 is sufficient to induce the initial stage of osteoblast 
differentiation (Ducy et al., 1997). 
The critical role of Runx2 in bone development was demonstrated through gene 
ablation experiments and Runx2-null mice die soon after birth and have reduced bone 
formation and mineralisation rates (Komori et al., 1997, Otto et al., 1997). Moreover, 
Runx2 overexpression induced a lethal skeletal phenotype including dwarfism and 
precocious mineralisation (Ueta et al., 2001). Over-expression of Runx2 in 
chondrocytes results in chondrocyte hypertrophy and endochondral ossification.  
Several transcription factors co-operate with Runx2 to regulate its action on osteoblast 
differentiation, and some of these factors provide co-stimulatory signals while others 
repress Runx2 activity by affecting DNA binding activity or transactivation potential. 
For instance CBFβ (PEP2β) enhances Runx2 activity to induce osteoblastsic 
transcription genes, and lack of this protein during embryonic skeleton development 
blunts bone formation (Yoshida et al., 2002). Moreover, Distal-less homeobox (Dlx5) 
and msh homeobox 2 (Msx2) expressed in early stage of osteoblast differentiation can 
also interact with Runx2 activity. Dlx5 functions as a co-activator while Msx2 act as a 
transcriptional repressor, and they are also described as essential factors for 
intramembranous ossification and skeleton development (Bendall and Abate-Shen, 
2000). Runx2 is also activated by MAP kinase pathways (Franceschi et al., 2003). 
In contrast several proteins repress Runx2 activity via different mechanism including 
binding to the Runt domain to prevent DNA binding, removing cytoplasmic Runx2 or 
binding to the nuclear matrix targeting Runx2 domain. ATJ18 (zing finger-containing 
factor) was shown to reduce Runx2 during osteoblast differentiation through DNA 
binding competition and decreased ALP activity and Runx2-mediated osteacalcin 
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promoter activation (Jheon et al., 2001). Collectively, these findings indicate that Runx2 
plays a critical role in bone development and expression of major bone matrix genes in 
early stage of osteoblastsogenesis.   
Osterix (Osx) is a zinc-finger-containing transcription factor expressed by osteoblasts 
during embryonic development and is essential for bone formation (Komori, 2006, 
Nakashima et al., 2002). Osterix has a DNA binding domain that consists of three C2H2-
type zinc fingers at its C-terminus. It also contains a proline and serine-rich 
transcription domain and activates genes, amongst others that encode for type I collagen 
and osteocalcein. Osx is well established as an important regulator of osteoblast 
differentiation during intramembranous and endochondral ossification. Osx-null mice 
have no cortical or trabecular bone and mesenchymal cells can not differentiate into 
osteoblasts in these mice (Nakashima et al., 2002), while the formation of cartilage is 
normal in osx-null mice (Inada et al., 1999). In addition, osx mutants exhibited a lack of 
osteoblast markers such as osteocalcin, osteopontin and bone sialoprotein as well as a 
reduction in the expression of Colla1 (Nakashima et al., 2002).  
Osterix expression appears to be dependent on Runx2 during osteoblast differentiation 
as osx is not expressed in Runx2-null mice, whereas Runx2 is expressed in osx-
deficient mice (Nakashima et al., 2002). In addition osx expression in response to BMP-
2 and insulin-like growth factor I (IGF-I) in mesenchymal cells occurs via MAPK and 
protein kinase D (PKD) signalling (Celil and Campbell, 2005). Moreover, this study 
observed that Runx2 is important but not sufficient for the induction of BMP-2 
mediated osx expression, suggesting that other factors may be involved. Interestingly, it 
has been reported that NFATc1 signalling cooperates with osx to accelerate osteoblast 
differentiation (Koga et al., 2005). 
The transcription factor TAZ is a recently described co-activator that regulates 
mesenchymal differentiation into osteogenic or adipocyte lineages (Komori, 2006). 
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TAZ modifies various cellular functions including differentiation, cell cycle progression 
and apoptosis via binding to 14-3-3 proteins (Hong et al., 2005). TAZ contains a 
ubiquitin-associated protein (UAP)-like domain that binds to pro-pro-amino acid-Try 
motifs found in Runx2 and the adipogenic transcription factor PPARγ (Hong and Yaffe, 
2006). TAZ has an important role in osteoblast differentiation enhancing the 
transcriptional activity of Runx2-driven genes in terminal stages of osteoblast 
differentiation, and suppressing adipocyte differentiation via inhibition of adipogenic 
PPARγ-induced gene transcription (Hong et al., 2005). This leads to the selective 
expression of genes associated with osteoblast differentiation and thereby reinforces 
osteoblastsic lineage switching. 
Activating transcription factor 4 (ATF4) is a basic domain-leucine zipper protein (bZip) 
which has been shown to be a key regulator of osteoblast differentiation (Komori, 2006). 
ATF4 has been reported to induce the expression of osteoblast-specific genes such as 
type I collagen and osteocalcin (Yang et al., 2004). Furthermore, ATF4 stimulation in 
non-osteoblastsic cells induced osteocalcin promoter luciferase construct activity and 
osteocalcin expression suggesting that ATF4 similar to other osteoblastsic factors has 
the ability to induce osteoblast-specific gene expression in non osteoblastsic cells (Yang 
and Karsenty, 2004). Additionally, cooperative interaction between Runx2 and ATF4 
promotes osteoblast-specific osteocalcin gene expression and this may present a novel 
intramembranous mechanism regulating Runx2 activity and osteoblast differentiation 
(Xiao et al., 2005). The activity of ATF4 is modified by the inhibitor FIAT, elevated 
FIAT levels reduce ATF4 activity, and transgenic FIAT mice are osteopenic and display 
reduced markers of osteoblastic differentiation (Yu et al., 2006). The inhibitory action 
of FIAT is primarily due to leucine zipper mediated dimerization with ATF4 and 
thereby prevents transcription of osteoblastsic genes.   
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In addition to the various pathways and transcription factors mentioned above other 
factors may also play a significant role in the regulation of osteoblast differentiation and 
bone formation such as c-fos, Fra1, Jun, homeobox-containing transcription factors Msx 
(1,2,3), Knox-20 and SP3 (Harada and Rodan, 2003, Komori, 2006). Furthermore, 
NFATc1 signalling may play an important role in osteoblasts formation. Interestingly 
NFATc1 can interact with osx and form a complex that activates osx-mediated collagen 
expression but not Runx2-mediated osteocalcin formation (Koga et al., 2005). Recent 
studies demonstrated that skull formation as well as osteoclast formation was impaired 
in NFATc1-deficient mice, suggesting that NFATc1 may regulate bone formation by 
affecting both osteoblast and osteoclast (Winslow et al., 2006).  
1.6 Osteoclast  
Osteoclasts are giant multinucleated cells that form from haematopoietic stem cells and 
are responsible for bone resorption. Osteoclast differentiation and activation is regulated 
by local and systemic factors such as RANKL, OPG, TNF-α, IL-1, IL-6, M-CSF, 
parathyroid hormone and 1,25(OH) D3. These stimuli are synthesised by a range of cell 
types including osteoblasts, stroma and lymphocytes (Teitelbaum and Ross, 2003, Blair 
and Athanasou, 2004). Activated osteoclast expresses multiple markers which enable 
their identification such as TRAP, Cathepsin K and calcitonin receptors.  
Resorption begins when mature osteoclast become polarized and attach to the bone 
surface via αvβ3integrin interactions with RGD containing proteins in the bone matrix to 
create a sealed zone (Ross and Teitelbaum, 2005). Subsequently, the ruffled border 
which is a complex structure of folds of the plasma membrane secretes a range of 
factors that breakdown the organic and inorganic components of the matrix. The release 
of HCl  via the action of V class-ATPase proton pumps and chloride channels acidifies 
the sealed zone to pH 4.5 which helps solubilise bone mineral (Blair et al., 2002) 
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(Figure 1.4). Then, osteoclast produce TRAP, cathepsin K and metalloproteinase 9 
(MMP-9) to digest the organic matrix (Boyle et al., 2003). TRAP (tartrate-resistant acid 
phosphatase) is a metalloenzyme that plays an important role in bone resorption. TRAP 
is proposed to dephosphorylate bone matrix proteins including osteopontin and bone 
sialoprotien, and generates reactive oxygen species (ROS). Although, transgenic mice 
overexpressing TRAP developed a mild osteoporosis with increased osteoblasts activity 
(Angel et al., 2000). Phosphorylation of osteopontin facilitates osteoclast migration and 
may promote bone resorption (Ek-Rylander and Andersson, 2010). TRAP also 
generates ROS due to its redox activity which is required for bone desorption and 
degradation. Once the osteoclast has finished forming a 4-5μm resorption pit, it 
detaches from the bone surface and either moves onto a new surface to start the process 
again or undergoes apoptosis.   
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Figure 1.4. Bone matrix degradation mechanism by osteoclast. Osteoclast attach to bone matrix 
and create a sealed zone via integrin interactions. Osteoclast acidifies the resorption lacunae by 
secreting H
+
 and Cl
-
 ions via osteoclast-specific V-ATPase. Chloride Channel 7 (CLCN-7) for 
demineralisation and Cathepsin K starting the dissolution of bone components. From (Rodan 
and Duong, 2008).   
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The regulation of bone resorption is a complex process controlled by various local and 
systemic factors. The major day to day systemic regulator of osteoclast formation is 
parathyroid hormone, but other steroid and polypeptide hormones also regulate 
osteoclast formation and bone resorption. Many systemic factors regulate osteoclast 
differentiation by modifying the expression of cytokines which in turn directly or 
indirectly effect osteoclast formation and activity including TNF-α, IL-1, IL-6, RANKL 
and OPG.  
1.6.1 Systemic Regulators of Osteoclastogenesis 
1.6.1a Parathyroid hormone (PTH) 
PTH is a hormone produced from the parathyroid glands in response to hypocalcaemia 
and acts as a potent stimulator of bone resorption, renal calcium reabsorption and 
calcium uptake from the gut. This acts to restore circulating serum calcium levels. PTH 
has a dual effect on bone metabolism depending on the administration profile, 
continuous PTH administration stimulates resorption while intermittent PTH exerts an 
anabolic effect on bone formation (Frolik et al., 2003, Li et al., 2007). PTH was found 
to induce osteoclast formation from murine haematopoietic cells by an in-direct effect 
mediated via stromal or osteoblastsic cells (Mcsheehy and Chambers, 1986, Fuller et al., 
1998). This indirect action involves the modification of osteoblastsic receptor activator 
of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) expression. PTH 
may also increase osteoclastic receptor activator of nuclear factor kappa-B (RANK) 
mRNA expression (Lee and Lorenzo, 1999). In co-cultures of murine bone marrow 
osteoblasts, PTH treatment increases osteoblastsic RANKL expression and inhibits 
osteoblastsic OPG expression and this change in RANKL/OPG ratio is associated with 
increased osteoclast formation (Huang et al., 2004). All these findings suggest that the 
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pro-osteoclastic action of PTH occurs indirectly through an effect on the regulation of 
osteoblastsic modification of RANKL and OPG expression.    
1.6.2b Calcitonin 
Calcitonin is a polypeptide hormone secreted by the parafollicular cells of the thyroid 
gland in response to elevated calcium levels and has an inhibitory action on bone 
resorption but no effect on bone formation. The physiological effect of calcitonin is 
mediated by calcitonin receptors (CTR). Calcitonin inhibits osteoclast formation via 
binding to CTR, stimulating cAMP accumulation which reduces osteoclast motility and 
induces the retraction of osteoclast from the bone surface (Gorn et al., 1995). In addition, 
CTR-knockout mice have a significant increase in osteoclast number (Kauther et al., 
2011). Calcitonin’s action on Ca2+ homeostasis in humans however is secondary to that 
of PTH. 
1.6.1c 1,25-Dihydroxyvitamin D3 (1,25-(OH)2D3) 
The active form of vitamin D3 (1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) acts as a 
potent stimulator of bone formation and resorption and has a stimulatory effect on 
osteoclast differentiation in-vitro and in-vivo. This is mediated via vitamin D receptors 
(VDR) expressed by osteoblasts and osteoclasts. Interestingly, vitamin D3 is important 
for bone growth and mineralisation and has a regulatory effect on calcium and 
phosphate levels.  
1,25(OH)2D3 plays an important role in osteoclast formation. In contrast, VDR
-
/
-
 mice 
failed to induce osteoclastogenesis in the presence of 1,25(OH)2D3 (Takeda et al., 1999). 
Moreover, in-vitro studies using SaoS2 osteoblastsic cells treated with 1,25(OH)2D3 
showed an up-regulation of RANKL mRNA expression, and also increased 
osteoclastogenesis from peripheral monocyte, indicating that the RANKL promoter 
contains vitamin D responsive elements (Kitazawa et al., 2003). Similar results were 
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detected in co-culture of bone morrow macrophage and ST2 stromal cells (Kitazawa 
and Kitazawa, 2002). Furthermore, 1,25(OH)2D3 can modify the production of 
cytokines such as IL1α, M-CSF and TGF-β which are implicated in osteoclastogenesis 
(Lee et al., 2002, Rubin et al., 1996).   
1.6.2 Local Regulators of Osteoclastogenesis  
1.6.2a RANK /RANKL and OPG axis  
The effect of many pro-resorptive factors such as PTH is mediated through modification 
of RANKL/OPG expression. RANKL also known as osteoprotergerin ligand (OPG-L), 
TNF-related activation-induced cytokine (TRANCE) and osteoclast differentiation 
factor (ODF), is a 38 kDa protein belonging to the tumour necrosis factor (TNF)-
superfamily and is encoded by the TNFSF11 gene (Lacey et al., 1998). RANKL is 
primarily expressed by osteoblasts but is also expressed by activated T cells, fibroblasts 
and mammary tissue (Anderson et al., 1997) (Figure 1.5). RANKL exists as a 
membrane-bound protein and also as a secreted soluble C-terminal form. RANKL binds 
to its receptor RANK expressed on the surface of monocytic osteoclast precursors and 
mature osteoclasts to stimulate osteoclast differentiation and bone resorption (Lee et al., 
2006a). In addition to the critical role of RANKL in osteoclastogenesis it is also plays a 
pivotal role in the regulation of dendritic cell survival, lymphocyte development, and 
lymph node organogenesis (Kong et al., 1999). RANK deficiency causes severe 
osteopetrosis due to an absence of osteoclast. Furthermore, osteoclast precursors in 
these mice are unable to differentiate to osteoclast in-vitro in the presence of RANKL 
and M-CSF (Dougall et al., 1999). The treatment of RANK mutant mice with IL-1, 
1,25(OH)D3 did not induce osteoclast formation, suggesting that the resorptive activity 
of these factors is mediated through the RANK signalling pathway, while TNF-α 
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induced osteoclast formation is still relatively unaffected suggesting that TNF-α may act 
through alternative pathway to induce osteoclast differentiation (Li et al., 2000). 
The binding of RANKL to RANK initiates a complex network of intracellular signal 
transduction cascades that stimulate the expression of a number of osteoclastic genes 
(Boyle et al., 2003). This initially involves the recruitment of TNFR-associated proteins 
2, 5 & 6 (TRAFs) to RANK which in turn activate mitogen-activated protein kinases 
ERK, JNK (c-jun N-terminal kinases), AP-1 transcription factors, NFκB and NFATc1 
(Lee and Kim, 2003, Leibbrandt and Penninge, 2008). Loss of many of these factors 
prevents osteoclast differentiation but key to the differentiation process is NFATc1 
which is considered by many to be a master regulator of osteoclast genes. 
Osteoprotegerin (OPG) is a 110kDa secreted glycoprotein that is a member of the TNF 
receptor superfamily (Hofbauer and Heufelder, 1997). OPG consists of 401 amino acids 
residues, it is different from other members of TNF-receptor superfamily because it 
lacks a tansmembrane domain (Suda et al., 1999). OPG acts as a decoy receptor for 
RANKL and blocks the interaction between RANKL and RANK thereby inhibiting 
osteoclast differentiation and activation (Lacey et al., 1998, Tsuda et al., 1997). OPG 
administration to ovx mice significantly impaired bone loss and increased trabecular 
bone density and prevents bone loss after ovariectomy (Shimizu-Ishiura et al., 2002) 
suggesting that OPG could be used in the treatment of osteoporosis (Bekker et al., 2001). 
Histological analysis of OPG treated mice showed that OPG significantly inhibited 
osteoclast number and rescued the osteoporotic defect in OPG deficient mice (Min et al., 
2000). Furthermore, OPG prevents ovariectomy-induced osteoclast formation and bone 
resorption in rats (Simonet et al., 1997). 
In addition to RANK derived signals further co-stimulatory inputs from 
immunoreceptor tyrosine-based activation motifs (ITAM) containing immunoglobulin 
like receptors are also required for osteoclast formation. These include osteoclast-
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associated receptors (OSCAR) and Triggering receptor expressed on myeloid cells 2 
(TREM2) which interact with immunoreceptor tyrosine-based activation motifs 
(ITAM)-bearing adaptors FcRγ and DAP12 respectively (Paloneva et al., 2003, Kim et 
al., 2002b). Phosphorylation of these ITAM residues by RANK or unknown ligands 
leads to activation of SYK, Zap70 and phospholipase Cγ (Kaifu et al., 2003, Merck et 
al., 2004, Koga et al., 2004, Kim et al., 2002b, Lanier et al., 1998, McVicar et al., 1998). 
This in turn leads to an increase in intracellular Ca
2+
 levels which regulate the nuclear 
accumulation of key osteoclastic transcription factor NFATc1 via stimulation of 
calmodulin and calcineurin (Kim et al., 2008) (Figure 1.6). The nature of the ligands for 
TREM2 and OSCAR is still open to debate, although it has been suggested that specific 
motifs within fibrillar collagen on bone surfaces may represent one potential stimulus 
(Barrow et al., 2011). 
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Figure 1.5. Role of RANKL and its receptor RANK in osteoclast differentiation. From (Roux 
and Orcel, 2000).  
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Figure 1.6. TNF-α receptor, RANK/RANKL and ITAM motifs signalling in osteoclast 
differentiation pathway. The binding of RANKL to RANK activates several transcription 
factors including NFATc1 expression, a master key regulator of osteoclast differentiation. 
Another co-stimulatory ITAM pathways are required for calcium-dependent NFATc1 activation. 
These co-stimulatory pathways are mediated through FcRγ or DAP12 and their co-receptor 
OSCAR and TREM2. After the interaction of RANK/RANKL and undefined ligands, ITAM 
motifs are phosphorylated and this phosphorylation increased NFATc1 nuclear accumulation 
and lead to stimulate osteoclast differentiation. From (Baron, 2004). 
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1.6.2b Macrophage-colony stimulating factor (M-CSF) 
Macrophage-colony stimulating factor (M-CSF) is haematopoietic growth factor for 
differentiation of monocytes and macrophage lineages. It is produced by stromal cells, 
macrophages and T lymphocyte and acts on cells expressing the M-CSF receptor called 
c-fms (Douglass et al., 2008). M-CSF can affect osteoclast precursors directly or 
indirectly via stromal cells. Its primary mode of action occurs at the inception of 
osteoclast formation where it directly acts on non-committed monocytes to enable 
RANK expression and promote survival. Thus, it is essential for the initial stages of 
osteoclast formation. Fuller et al. (1993) also demonstrated that M-CSF modulates 
osteoclast survival and motility at later stages of differentiation. In addition, M-CSF 
plays a central role in TNF-α-induced osteoclastogenesis and bone resorption (Kitaura 
et al., 2007). 
1.6.2c Transforming growth factor-beta (TGF-β) 
Transforming growth factor-beta (TGF-β) belongs to a superfamily of related proteins 
that include bone morphogenic proteins (BMPs). It controls proliferation, cellular 
differentiation and other functions in many cell types. In the mononuclear phagocyte 
system, TGF-β helps maintain precursor responsiveness to activators of osteoclast 
formation, facilitates migration and exerts an anti-inflammatory effect (Fuller et al., 
2000). Thus, TGF-β1 may act as a commitment factor in osteoclast differentiation, 
priming precursors for osteoclast formation, but once this priming stimulus has been 
received no further inputs are required other than activation stimuli (Koseki et al., 2002). 
This facilitative action would appear to be dependent on the ability of TGF-β to 
antagonise a range of inflammatory cytokines that prime precursors to alternate 
macrophage lineages, thereby maintaining a RANKL responsive pool (Fox et al., 2000).  
In addition to this action on osteoclast precursors, TGF-β has been shown to modify 
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osteoblastsic RANKL/OPG expression. This effect appears to be dose dependent with 
low levels elevating RANKL expression whereas higher concentrations decrease 
RANKL and promote OPG expression (Karst et al., 2004). In addition this response 
may be skewed to elevated RANKL expression in osteoporotic women (Jurado et al., 
2010). Thus the effect of TGF-β on osteoclast formation is complex and it is likely that 
the precise effect on osteoclast formation is dependent on concentration, the primary 
site of synthesis/release and stage of the remodelling cycle, with higher levels likely to 
be present at the end of the osteoclastic phase feeding back on osteoblasts to limit the 
resorptive stimulus and thereby prevent excess resorption. 
1.6.2d Interferons 
IFNγ is a type II inflammatory cytokine belonging to a diverse family of inflammatory 
cytokines with pleiotropic effects (Tak, 2004). IFNγ is produced by activated T 
lymphocytes and has multiple effects on many cell types. However, with respect to 
osteoclast formation, IFNγ has been shown to have an anti-osteoclastic action. IFN-γ 
also interferes with RANK/RANKL signalling via degradation of TRAF6 resulting in 
inhibition of RANKL-induced activation of NFκB and JNK (Takayanagi et al., 2000) 
and then priming monocytes to alternative macrophage lineages. Mice lacking IFN-γ 
receptor (IFNGR1) display notable increases in osteoclast formation and bone 
destruction (Takayanagi et al., 2000, Takayanagi et al., 2002b). Moreover, IFN-γ 
inhibits TNF-α and RANKL-induced osteoclast formation and activation (Fox et al., 
2000).  
Similarly, several observations indicate that IFN-β has an important autocrine inhibitory 
role in osteoclast formation, limiting the number of osteoclasts that form and preventing 
excessive resorption. Moreover, IFNβ has been shown to inhibit osteoclastogenesis by 
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suppressing c-fos levels which is an essential transcription factor mediating the effect of  
RANKL (Takayanagi et al., 2002b). 
1.6.2e Interleukins 
The interleukin family includes several pleiotropic cytokines that have multiple cellular 
effects such as IL-1 and IL-6. IL-1 is secreted by bone marrow stromal cells and 
osteoclast and plays an important role in multiple altered health states such as 
rheumatoid arthritis, post-menopausal osteoporosis and certain cancers (Kitazawa et al., 
1994). It has been shown to promote bone resorption by activation of osteoclast 
formation via different mechanisms (Lee et al., 2010, Trebec-Reynolds et al., 2010). It 
is produced by monocyte, bone marrow stromal cells and osteoblasts and is known as 
one of the most potent inducers of bone resorption.  
IL-1 also promotes osteoclast survival by inhibiting apoptosis (Jimi et al., 1999). IL-1 
also acts as co-stimulator for TNF-α-induced pit resorption, and anti-IL-1α antibodies 
inhibit resorption (Kudo et al., 2002). Therefore, TNF-α and IL-1 are considered to be 
critical cytokines in the development of inflammatory joint diseases and are known to 
promote the formation of osteoclast-like cells and increase osteoclast activity indirectly 
in bone marrow culture (Pfeilschifter et al., 1989). In addition, blocking either IL-1 or 
TNF alone was not as effective in inhibiting inflammatory bone loss as blocking both 
cytokines (Dayer, 2002, Zwerina et al., 2004). However, IL1α-induced 
osteoclastogenesis may be RANKL-dependent (Ma et al., 2004), as IL-1 can only 
induce osteoclast fusion but not differentiation in the absence of RANKL. Additionally, 
IL-1α can also upregulate the expression of several other cytokines which can stimulate 
osteoclastogenesis such as M-CSF, IL-6 and RANKL. 
IL-6 is a multipotent cytokine produced by many cells including 
monocyte/macrophages and osteoblasts and has been found to induce osteoclast 
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differentiation. IL-6 belongs to a family of cytokine which share gp130 as a common 
signal transducer including leukaemia inhibitory factor (LIF) and IL-11. The role of   
IL-6 production in bone resorption has been clearly defined, it is produced in response 
to bone resorptive agents such as TNF-α and IL-1 (Ohsaki et al., 1992). Moreover, IL-6 
has been suggested to promote bone loss in oestrogen deficiency. Ishimi (1990) showed 
that IL-6 significantly stimulated osteoclast formation in foetal mouse calvarial cultures. 
IL-6-null mice display no bone loss following oestrogen deficiency (Poli et al., 1994). It 
has been reported that IL-6 acts as co-stimulator of PGE2-induced osteoclastogenesis 
via a mechanism involving an effect on RANKL and OPG expression (Liu et al., 2005).  
In addition to the cytokines mentioned above there are many other cytokines belonging 
to the interleukins family involved in the regulation of osteoclast differentiation and 
activity such as IL-7, IL-8, IL-10, IL-12, IL-18 and IL-17 (Dai et al., 2004, Yamada et 
al., 2002, Roato et al., 2006). 
1.6.2f Tumour necrosis factor-α (TNF-α) 
Tumour necrosis factor-α (TNF-α) is a multifunctional pro-inflammatory cytokine 
belonging to the tumour necrosis factor ligand superfamily, with a wide variety of 
activities such as regulation of differentiation, proliferation and apoptosis. TNF has two 
forms (α & β) which have similar biological effects. TNFα is a central modulator of the 
acute inflammatory response to injury or infection but excessive or prolonged TNF-α 
production contributes to the development of chronic diseases including bone resorption 
(Azuma et al., 2000). TNF-α promotes inflammatory gene expression via multiple 
signal pathways including NFκB (Beutler, 1999, Screaton and Xu, 2000, Kobayashi et 
al., 2000). TNF-α induces chemokine production, recruiting monocyte and lymphocyte 
to the site of infection and inducing apoptosis in different types of cells. The biological 
effect of TNF-α is mediated by transmembrane receptor TNFR1 (p55r) and TNFR2 
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(p75r). P55 contains a death domain and a third domain that can trigger apoptosis, while 
p75 lacks a death domain (Kobayashi et al., 2000). TNFR1 (p55r) is the major receptor 
involved in osteoclast differentiation and bone resorption, and treatment with anti-p55r 
antibody completely inhibits TNF-α-induced osteoclastogenesis (Kobayashi et al., 2000, 
Azuma et al., 2000). Furthermore, bone marrow derived from transgenic mice 
expressing p55
+
/
+
 had an increased capacity to form osteoclast, while p55
-
/
-
 p75
+
/
+
 cells 
induced fewer osteoclast, suggesting the crucial role of p55 but not p75 in TNF-α’s 
effect (Abu-Amer et al., 2000). Binding of TNF-α to its receptor causes activation of a 
TNF receptor associated death domain which in turn stimulates two pathways, JNK, 
protein kinase C and IkB leading to activation of NFκB which subsequently translocates 
to the nucleus and induces the transcription of TNFα-responsive genes (Kruppa et al., 
1992). TNF-α can also activate the Fas activated death domain which triggers the 
apoptotic signalling cascades (Nanes, 2003).  
The mechanism by which TNF-α can affect bone remodelling is complex, and it has 
both direct and indirect actions as it is able to cooperate with other signals pathways via 
TARF and NFκB. Injection of TNF-α induced the formation of TRAP positive 
osteoclast on the surface of bone in the absence of RANKL suggesting that TNF-α may 
act independently of the RANKL/RANK axis (Kim et al., 2005b). Similarly, TNF-α 
induced osteoclast formation in cultures of M-CSF dependent precursors by a TNFR1 
dependent but RANKL-independent mechanism (Kitaura et al., 2005). In addition, 
Kudo (2002) showed that TNF-α directly induced human osteoclast formation by a 
RANKL-independent mechanism, and Zou (2001) showed that TNF-α was sufficient to 
induce osteoclast formation in the presence of M-CSF (but was less potent than 
RANKL), while RANKL increased TNF-α expression in RAW264.7 and Balb/c cell 
lines.  
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TNF-α can also in-directly affect osteoclast differentiation via an action on several cell 
types This indirect action is mediated through up regulation of RANKL expression in 
several cell types such as synoviocytes, osteoblasts, endothelial cells, human 
microvascular endothelial cells, T cells, and B cells (Cenci et al., 2000, Kanematsu et al., 
2000, Page and Miossec, 2005). This in conjunction with TNF-α’s direct stimulatory 
action is thought to be one of the mechanisms leading to the augmentation of osteoclast 
formation after oestrogen withdrawal (Hofbauer, 1999, Zhang et al., 2001). TNF-α also 
effects OPG expression in osteoblasts (Nakashima et al., 2000), endothelial cells 
(Collin-Osdoby et al., 2001) and in RA synoviocytes (Marotte et al., 2005). Moreover, 
TNF-α enhanced RANKL-induced osteoclast differentiation by stimulating MAP kinase, 
p38 and JNK pathways. TNF-α also elevated c-fms expression, the receptor of M-CSF 
in osteoclast precursors (Yao et al., 2006).   
In addition to its ability to directly induce osteoclast formation or have a synergistic 
effect with RANKL, TNF-α may also increase bone resorption by stimulating the 
expression of other pro-inflammatory cytokines (Kurokouchi et al., 1998). TNF-α 
increases the expression of IL-1 from synovial mononuclear cells which could underpin 
some of the resorption associated with rheumatoid arthritis (Brennan et al., 1989). IL-1 
is incapable alone of inducing osteoclastogenesis directly, however it is able to increase 
the resorptive activity of TNF-α or RANKL-induced osteoclast formation. Similarly, 
TNF-α has also been shown to induce the expression of osteoblastsic IL-6 (Tokuda et 
al., 2004) which is able to directly stimulate osteoclast formation (Kudo et al., 2003). It 
is also reported that TNF-α augments the stimulatory effect of PGE2 on 
osteoclastogenesis in bone marrow systems. 
In addition to its effect on osteoclast, TNF-α can also influence osteoblasts activity and 
bone formation, reducing bone anabolism. TNF-α decreases osteocalcin mRNA 
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expression in osteoblastsic cell lines due to the suppression of NFκB (Li and Stashenko, 
1992, Kuno et al., 1994). TNF-α also inhibits ALP production which is required for 
bone mineralisation (Kuroki et al., 1994, Nakase et al., 1997). Furthermore, TNF-α can 
promote osteoblasts apoptosis and increase the expression of genes associated with 
matrix degradation such as proteolytic enzymes that degrade the bone surface such as 
matrix metalloproteinase (Panagakos and Kumar, 1994).  
The role of TNF-α in pathological process is a key area of research. Dysregulation of 
TNF-α level contributes to chronic autoimmune diseases such as rheumatoid arthritis 
and psoriatic diseases. TNF-α is also implicated in the development and progression of 
various cancers and is suggested to act as an autocrine and paracrine tumour promoter in 
ovarian cancers (Fujiki et al., 2002, Wu et al., 1993). It has also been reported that 
TNF-α plays a critical role in ovariectomy-induced bone loss via a stimulatory effect on 
osteoclast formation and through regulation of various pro-inflammatory cytokines 
implicated in bone resorption (Kimble et al., 1997). Evidence would suggest that TNF-α 
plays a critical role in the pathogenesis of bone resorption and osteolytic disorders 
(Nanes, 2003, Kwak et al., 2005, Weitzmann and Pacifici, 2005). In bone, TNF-α can 
be released from many cells including stroma and osteoblasts (Chaudhary et al., 1992, 
Ralston 1994). Mononuclear cells derived from post-menopausal women also produce 
increased amounts of TNF-α in comparison to pre-menopausal subjects (Pacifici et al., 
1991, Ralston et al., 1990). Similarly, production of TNF-α, IL-1, IL-4, IL-6, and  IFN-γ 
by blood cells are inversely correlated with oestrogen levels in post-menopausal women 
(Zheng et al., 1997). T cells and B cells appear to be a major source of TNF-α in post-
menopausal women as elevated numbers of activated T cells produce increased amounts 
of TNF-α in comparison to oestrogen replete women (Nanes, 2003). This would appear 
at least in animal models to be a critical event in the bone loss associated with oestrogen 
                                                                                         Chapter 1 
 
36 
 
deficiency as nude mice, which are T-lymphocyte deficient, are resistant to bone loss 
after ovariectomy and mice lacking p55 TNF receptor do not display oestrogen 
deficiency bone loss (Cenci et al., 2000). Similarly, transgenic mice expressing soluble 
TNF-α receptor are protected against oestrogen deficiency bone loss (Ammann et al., 
1997). TNF has also been implicated in other skeletal disorders including rheumatoid 
arthritis where it is a key therapeutic target. Treatment of RA patient with monoclonal 
anti-TNF-α antibodies (infliximab) caused a significant improvement in symptoms 
(Elliot et al., 2008, Maini et al., 1999, St. Clair et al., 2004). The positive effect of 
infliximab is thought to be due to a reduction in inflammation and a suppression of 
osteoclastogenesis which may arise in part due to a reduction in synovial NFκB 
signalling and RANKL expression. 
1.6.3 Intracellular regulators of osteoclast differentiation  
Osteoclast differentiation, survival and function are tightly controlled by a network of 
signalling pathways and transcription factors that are required for osteoclast 
differentiation and maturation. The next section will discuss key elements relating to 
these factors. 
1.6.3a TNFR-associated factors (TRAFs) 
RANK is a member of the TNF superfamily and it does not have intrinsic enzyme 
activity, thus it associates with TNFR-associated factor (TRAF) adaptor proteins to 
transduce intracellular signals after ligand binding. The TRAF family includes TRAF 1, 
2, 3, 4, 5, 6, and 7 that mediate signals induced by a variety of TNF receptors (Inoue et 
al., 2000). TRAFs have the ability to bind to various regions on the cytoplasmic tail of 
TNF receptors (Inoue et al., 2000). The cytoplasmic tail of RANK contains multiple 
sites for TRAF binding, the region spanning between 235-258- primarily interacts with 
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TRAF6, while TRAF 2 and 5 associate with amino acids 532-625 (Darnay et al., 1998, 
Wong et al., 1998).  
TRAF6 is the major adaptor molecule mediating RANKL-induced osteoclast formation 
and transduces signals to several downstream pathways including NFκB and c-Jun NH2-
terminal kinase (JNK). The essential role of TRAF6 in RANKL-induced osteoclast 
formation is highlighted by the development of a severe osteopetrosis in TRAF6-
knockout-mice due to the absence of osteoclast similar to that seen in RANK
-
/
-
 or 
RANKL
-
/
-
 mice (Naito et al., 1999, Lomaga et al., 1999). However, there is a degree of 
redundancy in this system as disruption of TRAF6 activity completely abolishes 
activation of NFκB but not JNK pathway (Wong et al., 1998, Lee et al., 2000). 
However the role of TRAF 2 and 5 in osteoclastogenesis is minor in comparison to 
TRAF6. TRAF5-deficient mice have a mild inhibition of osteoclastogenesis and these 
animals display a near normal level of NFκB and JNK activation RANKL activation 
(Kanazawa et al., 2003, Kanazawa and Kudo, 2005). 
1.6.3b NFκB 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) are a family of 
dimeric transcription factors that recognize a common sequence of DNA called the κB 
site (Asagiri and Takayanagi, 2007). NFκB is a transcription factor that regulates 
expression of many genes involved in inflammatory responses (Baldwin, 1996). There 
are five NFκB proteins in mammals: Rel (cRel), RelA (p65), RelB, NFκB1 (p50) and 
NFκB2 (p52) (which are processed from their precursors p105 and 100 respectively) 
(Takayanagi, 2007). NFκB is a vital transcription factor that is important for immune 
cell development and activation, inflammation and osteoclastogenesis. Following 
RANK/RANKL binding a signalling cascade mediated through TRAF6 is initiated that 
results in the activation of NFκB (Franzoso et al., 1997, Xing et al., 2003). In particular, 
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p50 and p52 have a major role in osteoclast differentiation as p50
-
/
-
 and p52
-
/
-
 mice 
develop osteopetrosis due to defective osteoclast formation (Franzoso et al., 1997, 
Iotsova et al., 1997). 
NFκB proteins reside in the cytoplasm of non-stimulated cell but enter the nucleus upon 
stimulation with different agonists including RANKL (Boyle et al., 2003). Activation of 
NFκB is controlled by sequential phosphorylation and ubiqutin mediated degradation of 
its inhibitory subunits (Miyazaki et al., 2000). NFκB drives expression of many 
important osteoclastic genes and is critical but not sufficient for osteoclast formation. 
The activation of NFκB occurs through classical and alternative pathways. The classical 
pathway involves the activation of inhibitor of κB kinase (IkB) complex which 
phosphorylates and enables the ubiquitin mediated destruction of inhibitory kB which 
masks nuclear localisation sequences on NFκB. IKK consists of two subunits: IKKα 
and IKKβ and a regulatory subunit IKKα NFκB essential modulator (NEMO) 
(Leibbrandt and Penninge, 2008). The classical pathway is responsible for the activation 
of p50:RelA which is dependent on IKBβ while the alternative pathway activates 
p52:RelB which is dependent on IKBα (Novack et al., 2003, Hayden and Ghosh, 2004, 
Hayden and Ghosh, 2008), both pathways are important for osteoclastogenesis. In 
contrast, IKKα and IKKβ are essential for osteoclastogenesis, although IKKβ but not 
IKKα may be essential for osteoclast formation in-vivo (Ruocco et al., 2005). Thus, it 
seems that NFκB classical activation pathways may be the major pathway through 
which RANK/RANKL signalling can affect osteoclastogenesis. 
 1.6.3c Activator protein (AP-1) 
Activator protein (AP-1) is a transcriptional factor that is formed from a range of homo 
and hetro dimers which has a key role in osteoclast differentiation (Wagner and Eferl, 
2005, Takayanagi et al., 2002a). AP-1 dimers are composed of a range of transcription 
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factors including c-fos (c-fos, c-fosB, Fra-1, Fra-2), Jun, (c-Jun, JunB, JunD), and ATF 
(ATFa, ATF2, ATF3, ATF4, B- ATF) proteins (Wagner and Eferl, 2005). AP-1 dimers 
bind to a range of osteoclastic gene promoters and this interaction is modulated by 
interaction with other transcription factors and kinases that generates a complex level of 
regulation (Eferl et al., 2004). For instance evidence suggests that c-fos may cooperate 
with NFATc1 to induce osteoclastogenesis (Macián et al., 2000). 
c-fos is a cellular proto-oncogene and is upregulated during a range of cellular activities 
including osteoblast and osteoclast differentiation. c-fos-deficient mice develop 
osteopetrosis due to the blockade of osteoclastogenesis (Wang et al., 1992, Grigoriadis 
et al., 1994).  This defect in osteoclast differentiation can be reduced by expression of c-
fos-related protein Fra-1, suggesting the critical function of c-fos and Fra-1 in osteoclast 
formation (Fleischmann et al., 2000). The Jun family also plays a role in addition to c-
fos, mice lacking Jun proteins such as c-Jun and JunB display a minor decrease in 
osteoclast differentiation, suggesting that members of Jun can substitute for each other 
during osteoclastogenesis (Kenner et al., 2004, Wagner and Eferl, 2005).  
1.6.3d NFAT and Ca
2+
 calmodulin-calcineurin 
Nuclear factor of activated T cells (NFAT) is a transcription factor family that consists 
of several members including NFATc1 (NFAT2), NFAT1 3, 4, and 5 which are involved 
in regulating cellular differentiation in several different biological systems such as the 
cardiovascular, muscular and immune system (Crabtree and Olson, 2002).  NFATc1 is 
considered to be a key regulator of the expression of osteoclastic genes (Takayanagi, 
2007) as NFATc1
-
/
-
 embryonic stem cells do not differentiate into osteoclast and loss of 
NFATc1 function decreases the capacity to form osteoclast after RANKL stimulation 
(Takayanagi et al., 2002a). NFATc1 levels display a biphasic profile during 
osteoclastogenesis, this is characterised by an initial small increase followed by a more 
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pronounced level of expression after NFATc1 activation, nuclear translocation and 
auto-regulation of its own gene. 
The initial expression of RANKL-induced NFATc1 is dependent on NFkB and c-fos 
(Asagiri et al., 2005). In contrast NFAT activation and secondary expression is 
dependent on intracellular Ca
2+
 levels which modify the activity of the serine/threonine 
phosphatase calcineurin. RANKL binding to RANK and co-stimulatory inputs provided 
by DAP12 and FcRγ stimulate the release of Ca2+ from intracellular stores which 
stimulate Ca
+2
/calmodulin-dependent calcineurin which promotes NFATc1 nuclear 
translocation (Figure 5). Unsurprisingly, calcineurin inhibitors such as FK506 and 
cyclosporine A therefore prevent osteoclastogenesis (Takayanagi et al., 2002a, Kim et 
al., 2005c). 
In addition to promoting the expression of its own gene NFATc1 regulates a range of 
other transcriptional targets such as TRAP (Kim et al., 2005c, Matsuo et al., 2004), 
cathepsin K (Matsumoto et al., 2004, Kim et al., 2005c), calcitonin receptor (CTR) 
(Anusaksathien et al., 2001, Takayanagi et al., 2002a), and β3 integrin (Crotti et al., 
2006). NFATc1 in many cases also co-operates with other transcription factors such as 
PU.1, MITF, and AP-1 to augment the transcription of genes (Takayanagi et al., 2002a). 
Moreover, osteoclast-specific co-stimulatory immunoreceptor expression (OSCAR) is 
one of the first targets for NFATc1 (Kim et al., 2005a, Kim et al., 2005c). It is not 
completely clear how the coordinated expression of NFATc1 target genes promotes the 
differentiation of osteoclast, but it has been reported that NFATc1-induced DC-STAMP 
expression is essential for cell-cell fusion of osteoclast (Kukita et al., 2004, Yagi et al., 
2005). Osteoclast precursors lacking DC-STAMP are unable to fuse and only 
mononuclear TRAP positive cells are noted in these mice (Yagi et al., 2005). 
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1.7 Osteocytes 
Osteocytes are mature osteoblasts that have become embedded during matrix deposition. 
They share some morphological and functional characteristics with osteoblasts. 
Osteocytes are not isolated and form complex connections via canniculi with adjacent 
osteocytes and other cells especially on the bone surface; in addition to enabling 
communication this also facilitates the supply of nutrients. Osteocyte formation and 
maturation takes about three days during which the production of extracellular bone 
matrix and the formation of dendritic processes occurs (Knothe Tate et al., 2004, Noble, 
2008). The precise function of osteocytes is unclear but they are thought to have a role 
in the adaptive response to mechanical loading, sensing changes in mechanically 
induced strain and modifying the activity of cells on the bone surface. Osteocytes may 
also be important for the diffusion of oxygen and nutrients through bone tissue by 
preventing mineralisation in its environment. Osteocytes have also been demonstrated 
to produce matrix proteins osteocalcin, osteopontin and osteonection in culture (Aarden 
et al., 1996), although the in-vivo relevance of this is uncertain. 
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2.1 Introduction 
Menopause is a natural process that occurs due to reduced ovarian function, leading to 
decreased oestrogen (E2) and progesterone levels, which lead to reduced fertility. 
Hormonal changes during the menopause result in a decline in E2 levels, and play a 
pivotal role in the generation of chronic disease. One of these is post-menopausal 
osteoporosis in which reduced E2 levels lead to increased rates of bone remodelling 
(Schot and Schuurs, 1990, Seeman, 2004). Osteoporosis is a systemic skeletal disease 
characterized by low bone mineral density, with the World Health Organisation (WHO) 
defining osteoporosis as a bone mineral density 2.5 S.D below normal T score. 
Osteoporosis is a serious problem for post-menopausal women and is associated with an 
increased fracture risk at the distal radius and ulna, vertebral bodies and hip. Multiple 
treatments are available for post-menopausal bone loss such as calcitonin, 
bisphosphonates, hormone replacement therapy (HRT) and selective E2 receptor 
modulators (SERMs) such as rolaxifene (Scharbo-Dehaan, 1996). For a long time 
hormone replacement therapy (HRT) was the first choice treatment (Gallagher, 2001). 
However HRT is now not normally prescribed in light of evidence suggesting that long 
term HRT is associated with a greater risk of developing breast and endometrial cancer, 
cardiovascular disease and stroke (Hulley et al., 1998, Rossouw et al., 2002). There are 
also drawbacks with many of the other forms of therapy for instance bisphosphonates 
have been suggested to cause kidney damage, osteonecrosis of the jaw and atypical 
fractures. Therefore there is a need to find alternative treatments to control aberrant 
remodelling or restore oestrogenic activity (Ruggiero et al., 2004, Migliorati et al., 2005, 
Cole et al., 2008). 
Research from nutritional studies has shown that several dietary compounds may 
represent a strategy for the treatment of osteoporosis. These include a wide range of 
vitamins, minerals and other compounds including phytoestrogens (PEs). This chapter 
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aims to detail the biology relating to E2 and remodelling and the literature examining 
the effect of phytoestrogens and other selected nutritional factors on bone.   
2.2 Oestrogen and bone remodelling 
Steroid hormones such as E2 play a pivotal role in skeletal growth and bone 
homeostasis and a lack of circulating E2 after the menopause leads to the development 
of several diseases including post-menopausal osteoporosis (Riggs et al., 1998, 
Weitzmann and Pacifici, 2006a). Thus it is important to understand the cellular and 
molecular mechanisms through which E2 deficiency causes bone loss. Multiple studies 
indicate that E2 has the ability to regulate bone homeostasis through an interaction with 
the immune system, oxidative stress and direct actions on both osteoclast and osteoblast 
formation and activity. However, the precise mechanism through which E2 deficiency 
increases fracture risk is still a subject to debate. However, one thing that is clear is that 
reduced E2 levels lead to an increase in the number of resorptive osteoclasts which then 
remove excessive amounts of bone and E2 replacement prevents this. For instance E2 
administration in post-menopausal women blunted levels of the bone turnover markers, 
carboxyl-telopepetide of type 1 collagen (NTX) and telopepetide of type 1 collagen, 
while bone formation marker amino-terminal propeptide of type 1 collagen (P1NPP) 
was increased (Charatcharoenwitthaya et al., 2007). The mechanism underpinning these 
changes in cellular activity are not so clear and several hypotheses have been put 
forward to explain the changes in remodelling activity. These include changes in 
immune profile, inflammatory and anti-inflammatory cytokine production, disruption of 
RANKL/RANK/OPG axis, changes in reactive oxygen species (ROS) and direct effects 
on osteoclast function and lifespan. However, there is little consensus on the precise 
mechanism through which E2 deficiency exerts it effect on bone tissue and it is likely 
that multiple actions mediate this effect. 
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2.2.1 Inflammatory mediators and immune cells 
Recently, the interactions between bone and immune cells has been suggested to play a 
role in the bone loss associated with ovarian dysfunction (Clowes et al., 2005). Many 
bone and immune cells such as T-cells and B-cells express ERs and are therefore targets 
for E2 (Cenci et al., 2003, Weitzmann and Pacifici, 2005) and increased levels of pro-
inflammatory cytokine expression is as an early change associated with E2 deficiency 
(Pfeilschifter et al., 2002). Elevated levels of IL-1, IL-7, IL-6, and TNF-α levels have 
been described in E2 deficiency (Weitzmann et al., 2002, D'Amelio et al., 2008), and 
these cytokines could potentially mediate changes in osteoclast formation (Zallone, 
2006, Weitzmann and Pacifici, 2007). E2 has been shown to reduce IL-6 expression 
through an ERα-dependent mechanism that prevents NFκB mediated IL-6 promoter 
activation (Stein and Yang, 1995). E2 also decreases TNF-α levels in cultures of 
osteoblastsic-like cells (Pfeilschifter et al., 2002), which may relate to the E2 dependent 
production of the repressor of the TNF-α promoter GRIP1 (Cvoro et al., 2006).   
In contrast to an increase in inflammatory mediator production E2 deficiency has been 
shown to suppress anti-inflammatory cytokine synthesis. E2 promotes osteoblastsic 
TGF-β production which in turn stimulates osteoclast apoptosis, suggesting that E2 
deficiency may prolong osteoclast life span via a loss of TGFβ-induced apoptosis 
(Hughes et al., 1996). This is supported by the ability of E2 to inhibit osteoclast 
formation in cultures of osteoclast precursors and osteocyte-like MLO-Y4 cells in the 
presence of TGFβ antibodies (Heino et al., 2002).    
One important mechanism through which E2 deficiency may stimulate bone loss is 
through increased T cell number. E2 deficiency increases the proliferation and function 
of CD4
+
 and CD8
+
 cells producing TNF-α in post-menopausal women and 
ovariectomised mice (Cenci et al., 2000, Roggia et al., 2001, Roggia et al., 2004) and 
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ovariectomized mice lacking the TNF p55 receptor fail to display bone loss. Moreover, 
transgenic mice over expressing soluble TNF or mice treated with TNF inhibitory 
binding protein show decreases in bone resorption (Ammann et al., 1997, Kimble et al., 
1997). In addition, E2 dependent changes in TNF-α production in human peripheral 
blood cells have been noted (Ito et al., 2001). TNF-α production is increased in post-
menopausal or oophorectomised individuals (Pacifici et al., 1991, D'Amelio et al., 
2004), and HRT suppresses TNF-α production in-vivo (Bernard-Poenaru et al., 2001).  
These changes in TNF-α will directly stimulate osteoclast formation and may also have 
additional in-direct actions to increase RANKL expression or augment the sensitivity of 
osteoclast precursors to RANKL (Pacifici, 2008).  
Expansion of the T cell pool after E2 deficiency could be the main mechanism 
increasing proinflammatory cytokine levels after loss of ovarian function. How this 
increase in T cell number occurs is unclear but it has been suggested to potentially relate 
to changes in follicle stimulating hormone and inflammatory cytokine production or the 
redox state within bone (Iqbal et al., 2006, Lean et al., 2005). E2 deficiency is 
negatively associated with thiol antioxidant enzyme levels in bone including glutathione 
peroxidase, the main intracellular antioxidant, and glutathione peroxidise expression is 
augmented following E2 treatment (Lean et al., 2005). Furthermore, E2 increases the 
expression of antioxidants such as glutathione and thioredoxin in various cells including 
osteoclast (Lean et al., 2003). In addition, ROS stimulate antigen presentation by 
dendritic cells, while antioxidants prevent dendritic and T cell activation by repression 
of MHCII in response to antigen (Maemura et al., 2005). These data are consistent with 
the concept that E2 deficiency is associated with lower antioxidant levels and increased 
TNF secretion via stimulation of antigen presenting cell (APC)-induced expansion of T 
cell pools (Figure 2.1). 
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Other evidence suggests that the increase in T cell number occurs due to increased 
antigen presentation by macrophage and dendritic cells (Cenci et al., 2003). This 
mechanism involves up-regulation of MHC II (CIITA) and costimulatory CD80 
expression on macrophage and dendritic cells as a consequence of modified changes in 
IL-7, TGF-β and IFN-γ levels (Figure 2.1). This leads to presentation of self-antigens to 
T cell subsets leading to activation and clonal expansion within the T cell pool. CIITA 
is an immune modulator, which induces MHC II expression (Boss and Jensen, 2003). 
The increase in CIITA expression itself is dependent on changes in the cytokine profile 
following decreases in circulating E2 levels.  
E2 deficiency up-regulates TNF-α-producing T cells by a complex pathway. In brief, E2 
deficiency enhances IL-7 production which suppresses TGF-β secretion followed by 
activation of IFN-γ production. The high levels of IFN-γ elevates MHCII expression by 
enhancing the amplification of transcription factor CIITA and then increasing self-
antigen presentation to T cells. This promotes the release of TNF-α which directly 
promotes osteoclast formation and augments the effect of RANKL- (Pacifici, 2008) 
(Figure 2.1).  
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Figure 2.1. Schematic of potential mechanisms by which E2 deficiency causes bone turnover. 
Follicle-stimulating hormone (FSH) stimulates the production of TNF-α by monocyte. E2 
deficiency increases IL-7 production in target lymphoid organs such as bone, thymus, and 
spleen by at least in part inhibition of TGF-β. This leads to the activation of T cells and the 
production of proinflammtory cytokines such as IFN-γ which increases antigen presentation by 
up-regulation of MHCII expression. E2 deficiency also stimulates bone loss by down regulation 
of antioxidant pathway and thus increasing of reactive oxygen species (ROS) and resulting 
antigen presenting activation and TNF production. Also, RANKL and TNF production increases 
osteoclast formation. From (Pacifici, 2008).  
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2.2.2 Regulation of osteoclast lifespan 
E2 deficiency has also been suggested to increase the lifespan of osteoclast. This 
hypothesis suggests that E2 attenuates resorption by inducing osteoclast apoptosis 
through the ERα dependent induction of osteoblastsic Fas ligand expression. Interaction 
of osteoblastsic FasL with Fas on the surface of osteoclast will activate executioner 
caspase leading to DNA fragmentation and the formation of apoptotic bodies. Moreover, 
SERMs such as tamoxifen and rolaxifene also stimulate FasL expression in osteoblasts 
via recruitment of ERα to the FasL promoter, and decreases in trabecular osteoclast and 
apoptotic profiles was noted in WT but not osteoclast-ERα knockout mice (Krum et al., 
2008, Nakamura et al., 2007). This suggests that E2 regulates osteoclast lifespan 
through modulation of Fas/FasL. 
Recent studies investigated the role of Fas expression in bone resorption. These 
revealed that Fas expression was significantly increased in osteoblasts and decreased in 
osteoclast of wild type ovariectomised mice. Furthermore, following ovariectomy the 
number of osteoclast was elevated in wild type but was unchanged in mice lacking Fas 
(Kovacic et al., 2010). 
2.2.3 Modification of the RANKL/RANK/OPG axis 
In-vivo and in-vitro studies have demonstrated that E2 modifies the ratio of RANKL to 
OPG in osteoblasts, T and B cells (Shevde et al., 2000, Srivastava et al., 2001, Taxel et 
al., 2008). E2 can modulate the expression of both RANKL and OPG in osteoblasts. E2 
suppresses osteoblastsic RANKL expression supporting the inhibitory effect of E2 on 
osteoclast formation (Bord et al., 2003). E2 also increases osteoblastsic OPG production 
(Hofbauer et al., 1999), OPG levels increased in mouse ST-2 stromal cells treated with 
E2 (Saika et al., 2001). In addition, bone marrow precursors incubated with RANKL 
and E2 formed fewer TRAP-positive osteoclasts than cells without E2 (Garcia Palacios 
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et al., 2005). The mechanism through which these changes in RANKL expression 
occurs is debatable and may occur as a direct effect of E2 on bone cells or as an indirect 
response to changes in other cytokine levels. Whatever the answer it is clear that the 
interaction of RANKL with RANK is central to menopausal bone loss. This is 
highlighted by the effect of the anti-RANKL monoclonal antibody therapy denosumab. 
Denosumab is a new option for the treatment of post-menopausal osteoporosis in 
patients with high risk of bone fractures (Moen and Keam, 2011). It binds to RANKL 
and inhibits osteoclast formation and survival. Long term denosumab treatment reduces 
bone resorption significantly increasing bone mineral density (BMD) at different 
skeletal sites and reduces fractures in post-menopausal women (Bone et al., 2008, 
Lewiecki et al., 2007, Miller et al., 2008). Recent studies found that denosumab 
promotes a greater increase in BMD than alederonate in post-menopausal women 
(Kendler et al., 2010). All these data suggested that disruption of RANKL signalling has 
a key role in post-menopausal bone loss.   
In conclusion, E2 regulates bone remodelling through several mechanisms including 
repression of osteoclastogenic cytokines secreted from bone marrow stroma, osteoblasts, 
and T-cells. However an overarching mechanism of action has yet to be established. 
Further studies are needed to fully elucidate the underlying mechanisms.   
2.3 Phytoestrogens (PEs)   
Phytoestrogens (PEs) are polyphenolic non-steroidal plant-derived compounds that 
possess oestrogenic agonist and antagonist-like activity. PEs have been the focus of 
much attention as they are postulated to have protective properties on human health. 
Publications refer to their potential effect against hormone-dependent breast and 
prostate cancer, bone resorption, cardiovascular disease and menopausal symptoms 
(Setchell and Cassidy, 1999, Messina, 2003). It has been noticed that populations 
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consuming high levels of PE-rich foods have a lower incidence of post-menopausal 
osteoporosis, certain cancers and cardiovascular disease (Adlercreutz, 1995, Somekawa 
et al., 2001, Kris-Etherton et al., 2002). Asian populations consume 10-20 times the 
amount of PEs in comparison to Western populations. This high intake of PEs has been 
suggested to lower the risk of developing several altered health states, including post-
menopausal osteporosis, atherosclerosis, and certain cancers (Messina, 1999, Messina 
and Bennink, 1998, Clarkson and Anthony, 1998). PEs exhibit weak oestrogenic 
activity about 10-100 fold less than that of E2 requiring a higher concentration to 
produce an equivalent biological effect (Zava and Duwe, 1997, Santell et al., 1997).  On 
the other hand they may be present in much greater quantities in the body than E2 
depending on an individual’s diet (100 to 1000 times) (Adlercreutz et al., 1986). 
PEs are a diverse group of compounds that belong to a family of substituted phenolic 
compounds known as flavonoids. PEs oestrogenic effect is dependent on two main 
properties. First the presence of a phenolic ring A, that mimics E2’s receptor binding A 
ring, and second, a similar distance between the 7- and 4'-hydroxyl groups in 
isoflavones and the C3 and C17 hydroxyl groups of oestradiol (Dixon, 2004) as shown 
in (Figure 2.2). The presence of a phenolic ring enables PEs to bind to oestrogen 
receptors (ERs) and provides the major basis of their oestrogenic action (Wuttke et al., 
2003). In addition to their oestrogenic effect, PEs also function as antioxidants and 
many such as genistein can modify tyrosine kinase activity (Anderson and Garner, 
1998).  
PEs are structurally classified as isoflavones or non-isoflavones (Table 2.1). There are 
also several sub-groups, including coumestans which possess high oestrogenic activity, 
whilst non-flavones including lignans have been also identified as PEs as they exert 
oestrogenic actions but they lack a flavone backbone so are not classed as flavonoids 
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(Cornwell et al., 2004). Isoflavones included genistein (5,7,4' trihydroxyisoflavone) and 
daidzein (7,4' dihydroxyisoflavone); coumestans include coumestrol (3,9-dihydroxy-6-
benzofurano [3,2-c] chromenone, while lignans include entradiol and enterolactone as 
well as secoisolariciresinol and mataresinol. Plant-based foods including fruits and 
vegetables are thought to be the main source of PEs in most Westerns diets. PEs are also 
found in leguminous plants such as soy bean (Glycine max), which contain isoflavones, 
while the major source of coumestans are alfalfa sprouts (Medicago sativa) and flaxseed 
(linum usitatissimum) is rich in lignans (Table 2.1). Isoflavones are described as most 
important type of PEs and their usage has been suggested to be beneficial in a wide 
range of human health states (Heim et al., 2002).  
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Figure 2.2. Chemical structures of E2, genistein, daidzein, coumestrol and glycitein. The 
phenolic ring A in isoflavones is responsible for selective high-affinity binding to oestrogen 
receptors (ERs), and through this interaction with ERs, isoflavones exert their agonist or 
antagonist action on target cells and tissues. Purple circles highlight the hydroxyl groups (Chen 
and Anderson, 2002).   
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Table 2.1. Phytoestrogens of human interest: classes, subtype, and sources (Chiechi and Micheli, 
2005). 
Class Subtypes Source 
Isoflavones Genistein 
Daidzein 
Glycein 
Fomononetein 
Biochanin A 
Legumes 
Soy beans 
Peanut 
Clover 
Sunflower seed 
Walnut 
Coumestans Coumestrol 
Plicadin 
Repensol 
Mung beans 
Soy spouts 
Alfalfa spout 
Clover 
Lignans Enterolactone 
Enterodiol 
Lignan A 
Flaxseeds 
Rye bread 
Cereals 
Grains 
Fruits 
Vegetables 
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2.3.1 Phytoestrogen Metabolism  
The efficacy of PEs is affected by many factors such as age, diet, gender, dose and the 
mode of administration. PEs also differ in their rates of absorption, metabolism and 
excretion (Rowland et al., 2003). Many PEs within food are biologically inactive and 
many PEs require metabolism to active and bio-available forms before absorption 
occurs and they can influence cell function (Puupponen-Pimia et al., 2004). For instance, 
genistein and daidzein are found in the food as glucosides (conjugated forms) which are 
converted to active forms by β-glycosidase hydrolysis (Figure 2.3) (Setchell et al., 
2002b). β-glycosidase is derived from intestinal bacteria (Lactobacillus, Bacteroides) 
and plays an important role in the hydrolysis of PEs and in turn may affect health status 
as a consequence (Hawksworth et al., 1971). On consumption, intestinal bacteria may 
further metabolise PEs to their metabolites, for example genistein is hydrolyzed into 
dihydrogenistein (4',5,7 trihydroxyisoflavones) and further metabolised to 6'-hydroxyl-
O desmethylangolesin (6'-hydroxy-O-DMA) (2',4',6', 4'' tetrahydroxy-α-
methylhydroxybenzoin), whilst daidzein is hydrolyzed into dihydrodaidzein (4', 7 
dihydroxyisoflavones) which is further metabolised to O-desmethylangolsin (O-DMA) 
(4', 6', 4'' trihydroxy-α-methyldeoxybenzoin) and equol which both have oestrogenic 
activity (Heinonen et al., 1999, Heinonen et al., 2003). Equol is more structurally 
similar to 17β-oestradiol than daidzein and is therefore more potent. Several studies 
report that equol and O-DMA bind to ERα and ERβ with a higher affinity than daidzein 
which only has a low affinity for ERβ (Kinjo et al., 2004, Morito et al., 2001). In 
keeping with this, equol has been shown to have more oestrogenic activity than daidzein 
(Setchell et al., 2002a). In-vitro, equol and O-DMA were also found to be 100 fold 
more potent than daidzein at modifying growth and E2 responsive protein expression in 
breast cancer cells (Kinjo et al., 2004) (Figure 3.3). The absorption of PEs is also 
metabolically dependent, as unconjugated forms of PE are more rapidly absorbed and 
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more bio-available than polar conjugated forms due to their lipophilic properties 
(Cassidy, 1996). PEs are absorbed from the small intestine and in the case of genistein 
this is typically via passive diffusion from the intestine (Crespy et al., 2003). 
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Figure 2.3. Intestinal metabolism of daidzein and genistein. From (Hwang et al., 2006).  
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2.3.2 Mechanism of action  
PEs have multiple mechanisms of action including oestrogen agonist and antagonist 
activity. In addition they are able to influence the production of sex steroid binding 
proteins, the presence of hydroxyl groups in the 4', 5 position of the aromatic ring gives 
them antioxidant activity (Adlercreutz et al., 1993) and they are able to alter cell 
function through modification of tyrosine kinase activity (Kurzer and Xu, 1997). 
However, the mechanism and potency of action of individual PEs is differs (Kuiper et 
al., 1998, Hwang et al., 2006, Gallo et al., 2005). For instance genistein has been 
suggested to suppress osteoclast formation in-vitro by inhibiting tyrosine kinase activity 
whereas other PEs shown to inhibit osteoclast formation lack this effect (Gao and 
Yamaguchi, 2000).  
2.3.2.1 Oestrogenic activity  
The presence and position of the hydroxyl groups and phenolic ring in PEs and E2 is 
considered important for their oestrogenic activity (Martucci and Fishman, 1993). The 
effect of PEs on human health is partly explained through ER-mediated actions 
(genomic action) due to the capacity of PEs to bind with enzymes and receptors 
(Adlerceutz, 1998). ERs are expressed in several tissues including bone, but usually at 
lower levels than that expressed in the reproductive system (Zallone, 2006). ERα and 
ERβ receptors differ in their C-terminal ligand-binding domain and N-terminal 
transactivation domain but both interact with specific DNA promoter sequences called 
oestrogen response elements (EREs). This alters the expression of a raft of genes and 
proteins modifying cell proliferation and differentiation. The expression profile of ERα 
or ERβ in a tissue can differ and is also modified in many altered health states. For 
example prostatic epithelial cells typically express ERβ while prostatic stroma cell 
express ERα (Ho, 2004). In addition it would appear that ERs may regulate the 
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expression of each other, ERβ down regulates ERα expression as ERα is elevated in 
ERβ-knockout mice (Lindberg et al., 2003). 
The cellular response elicited by ERα or ERβ also typically differs. However the precise 
response is contextual depending on the E2 concentration and receptor expression 
profile. For instance ERβ is expressed in many breast cancers (Fuqua et al., 2003), and 
it’s expression is associated with a proliferative response in breast epithelium in ERβ-
knockout mice but not in ERα-/- mice (Gustafsson and Warner, 2000). In contrast, ERα 
is associated with more differentiated tumours and MCF-7 human breast cancer cells 
seem to be sensitive to ERα and genistein increases the growth of MCF-7 cells in an 
ERα dependent manner (Maggiolini et al., 2001). The administration 750ppm of 
genistein also increased mammary tumour growth in ovariectomised rats via an ERα-
mediated effect (Allred et al., 2004). Moreover, genistein increased malignant 
adenocarsinoma proliferation, while no cancer progression was found in ERα-knockout 
mice (Day et al., 2001).  
In bone ERα and ERβ are expressed by osteoblasts and osteoclasts, and both receptors 
modulate gene expression in these cells, although evidence suggests that ERα has the 
major role in protecting bone mass. For instance, cortical bone density still decreased in 
the absence of ERβ in ovariectomised animal models (Windahl et al., 2001). Moreover 
E2 had no effect in ERα-knockout mice (Sims et al., 2003). Whereas bone density 
increased in the absence of ERα in female mice (Sims et al., 2002). Similarly in human 
MG63 osteoblasts cells E2 increased ALP and bone matrix collagen expression via ERβ 
(Cao et al., 2003).  
PEs bind ERs in a different manner to that of E2 as PE such as genistein and daidzein 
lack the lipophylic binding region present within E2 (Poulsen and Kruger, 2008). In 
addition, PEs show a spectrum of affinities for ER, some PEs such as genistein and 
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coumestrol are good ligands while others bind with a lower affinity (Kuiper et al., 1996). 
Coumestrol however may have a stronger affinity for ER than genistein due to the 
presence of a carbonyl group at position 2 and the distance between position 2' and 4 
being more similar to E2 which may make coumestrol more potent than genistein in 
some instances (Morito et al., 2002). PEs have differential affinities for ERα and ERβ 
and this plays a crucial role in the agonist and antagonist effect of these compounds. 
However, the precise role of ERα and ERβ in the response to PE is not fully understood 
and may depend on the concentration and relative level of receptor expression. 
Genistein and many other PE’s oestrogenic response are primarily mediated via ERβ 
(Bemis et al., 2004, Kuiper et al., 1997), although this does not preclude actions via 
ERα. Several studies suggesting that PEs exert agonist effects via ERβ and antagonist 
effects via ERα. For instance while genistein, apigenin, naringenin, and kaempferol 
have a stronger affinity for ERβ than ERα, E2, coumestrol and equol only have a partial 
affinity for ERβ rather than ERα (Kostelac et al., 2003). In contrast daidzein has a low 
affinity for ERβ (Kinjo et al., 2004, Morito et al., 2001). While the precise role of ERα 
and ERβ in PE’s action is unclear there is certainly evidence for an agonist oestrogenic 
component to PE’s bone effect. For example E2 inhibitors prevented the suppressive 
effect of genistein on IL-6, RANKL and OPG expression in human and mouse 
osteoblasts cell lines (Chen et al., 2003a, Viereck et al., 2002). In addition to agonist 
actions, PEs can also act as antagonists opposing the action of 17-β oestradiol and other 
sex hormones. PEs can stimulate sex hormone binding globulin synthesis, which would 
cause a decrease in 17-β oestradiol levels in peripheral blood (Ibarreta et al., 2001). 
Furthermore, the antagonist activity of PEs may also include competitive binding to ER, 
down regulation of ER, reduced E2 synthesis and inhibition of ER phosphorylation.  
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2.3.2.2 Non oestrogenic actions  
In addition to oestrogenic activity several PEs have been reported to exert various non 
ER-related actions including inhibition of tyrosine kinase activity, inhibition of protein 
kinase C, inhibition of DNA topoisomerases I and II, inhibition of angiogenesis, 
antioxidant effects and modification of prostaglandin synthase activity (Kurzer and Xu, 
1997, Arora et al., 1998, Markovits et al., 1995). Most of these actions require a PEs 
concentration over 10 μM for an effect. The inhibition of tyrosine kinase by genistein 
may explain the mechanism by which it impedes cancer cell growth (Ibarreta et al., 
2001). PEs can also affect steroid bioavailability by interacting with key enzymes 
involved in the steroid synthesis such as 5α reductase, 17β-OH-steroid-dehydrogenase 
and aromatase (Makela et al., 1995, Kao et al., 1998, Rice et al., 2006, Lacey et al., 
2005). In addition, PEs stimulate the production of sex hormone binding globulin (Pino 
et al., 2000), suggesting that may alter steroid hormone bioavailability. 
The antioxidant activity of PEs is related to the presence of free hydroxyl groups in the 
aromatic ring and ability to bind between aromatic rings (Burda and Oleszek, 2001). 
The hydroxyl group in the B-ring is important to enable the scavenging of reactive 
nitrogen or oxygen species (Sekher et al., 2001). The mechanism by which PEs are able 
to scavenge free radicals is dependent on the ability of these compounds to donate a 
hydrogen atom or transfer an electron from C-3-OH in the B-ring to hydroxyl to peroxy 
and peroxynitrite radicals. This stabilizes the reactive species and gives rise to a 
relatively stable PE radical (Heim et al., 2002). Studies suggest that the antioxidant 
capacity of flavonoids strongly correlates with the number of hydroxyl groups in the B-
ring, whereas hydroxyl groups in the A-ring may have little correlation with antioxidant 
activity (Heim et al., 2002). Interestingly, isoflavones such as genistein have also been 
known to donate hydrogen atoms from the phenolic group (Heim et al., 2002). Thus, the 
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capacity of PEs to scavenge free radicals is primarily attributed to the reactivity of 
hydroxyl substitutes that participate in the following reaction:- 
 
F-OH + R
·
                  F-O
·
 + RH (Heim et al., 2002).  
(F= phytoestrogens)  
 
Additionally, genistein may also prevent oxidative stress by increasing the production 
of antioxidant enzymes such as glutathione peroxidase, which maintains the reduction-
oxidation reaction (redox) state by reducing oxygen peroxide, thus protecting against 
oxidative DNA damage (Suzuk et al., 2002, Raschke et al., 2006).   
2.4 Phytoestrogens and human health  
E2 deficiency during menopause can lead to an increased risk of developing several 
altered health states such as osteoporosis, cardiovascular disease and cancer. These 
disorders were commonly treated with hormone replacement therapy (HRT) or other 
compounds such as calcitonin, raloxifene or bisphosphonates (Alekel et al., 2000). HRT 
was used for many years as the first line treatment for menopausal symptoms (Gallagher, 
2001), however, observations from large scale clinical trials indicate that long term 
HRT may increase the risk of breast and endometrial cancer and cardiovascular disease 
in elderly women (Beral, 2007, Rossouw et al., 2002). Therefore, it is important to find 
alternative therapies that exert beneficial effects on bone health without unwanted side 
effects. PEs represents one group of compounds that could be employed due to their 
structural similarity with E2 and data suggesting a protective action on human health. 
Several epidemiological studies suggest that PEs can alleviate diseases associated with 
E2 deficiency such as cardiovascular disease and menopausal symptoms (Tikkanen et 
al., 1998, Nestel et al., 1997). Moreover, multiple investigations indicate a lower 
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incidence of cardiovascular disease, breast and prostate cancer and osteoporosis in 
Asian populations with a PEs-rich diet (Adlercreutz, 1998, Clarkson and Anthony, 
1998). However, other confounding aspects of the Asian lifestyle could contribute to the 
beneficial effect of soy-rich diets confusing the precise benefit of these compounds in 
clinical settings (This et al., 2001). Furthermore, due to the complexity of their 
biological effect it is unclear what aspect of PE’s action mediate any change in skeletal 
or cardiovascular health (Kronenberg and Hughes, 1999). The situation is further 
confused by wide differences in the ability to metabolise the conjugated inactive PEs 
form to active metabolites. It is likely that many negative results in clinical trials could 
at least in part be attributed to not accounting for these non-responders. Collectively, 
whether PEs can be effective, reliable and safe form of HRT, whether they have 
additional benefits, and the mechanism of action need to be confirmed with controlled 
trials to explain the action of PEs on human health. 
2.4.1 Cardiovascular Diseases 
Following the menopause the risk of coronary heart disease (CHD) is much higher due 
to the fall in E2 levels (Reckelhoff and Fortepiani, 2004, Reckelhoff, 2006). Multiple 
studies have examined the association between PEs consumption and improvement of 
lipid profile, vascular reactivity, and cell proliferation in CHD (Anderson et al., 1999). 
Dietary soy and PEs have been well documented to reduce the risk of CHD, suppress 
circulating cholesterol and triglyceride levels and increase high density lipoprotein 
(HDL) (Anderson et al., 1995). Several epidemiological and clinical investigations 
examined the mechanism by which PEs may reduce the progression of atherosclerosis 
showing that PEs improve the profile of plasma low density lipoprotein LDL-
cholesterol, triglyceride lipids, reduce thrombus formation (including a reduction in 
platelet action) and enhance antioxidant activity (van der Schouw et al., 2000). In 
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addition, other mechanisms are reported to explain the effect of PEs on 
hypercholestremia including reducing cholesterol synthesis and enhanced cholesterol 
receptor activity (Glazier and Bowman, 2001). PEs may also improve lipid profiles by 
modifying LDL levels which are associated with cardiovascular disease. This stems 
from the ability of PEs to increase bile production and hepatic metabolism both of 
which lower LDL (Wroblewski Lissin and Cooke, 2000).  
In addition, PEs can inhibit LDL oxidation which decreases the likelihood that LDL 
will be retained in the endothelia where it can promote atherosclerotic lesion 
development (Steinberg, 1997, Ruiz-Larrea et al., 1997, Mitchell et al., 1998). Healthy 
adults administrated genistein, daidzein or equol showed inhibition of LDL oxidation 
due to the antioxidant properties of PEs (Wiseman et al., 2000). Similarly, 
administration of soy protein to post-menopausal monkeys decreased the risk of 
coronary artery constriction (Honoré et al., 1997). Also in-vivo and in-vitro 
observations report that PEs act as antioxidant compounds by increasing levels of 
antioxidant enzymes such as catalase, superoxide dismutase, glutathione peroxidase, 
and glutathione dismutase (Kurzer and Xu, 1997). Genistein has been shown to 
decrease platelet action due to its tyrosine kinase inhibitory action (Tham et al., 1998). 
Clinical studies have suggested that isoflavones act as antioxidant agents and can reduce 
the oxidation of LDL (Ruiz-Larrea et al., 1997). However, the relationship between PEs 
and the lower incidence of cardiovascular disease and the mechanism of action still 
remain to be determined. 
2.4.2 Breast cancer  
Breast cancer is the most common cancer in women in Western countries. 
Epidemiological studies of dietary intake and cancer risk have been recently reviewed 
concluding that there is some evidence of a protective role of PEs on breast cancer 
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although the picture is more complex than first appreciated (Velentzis et al., 2008). The 
data from in-vitro studies, animal experiments, and human trials revealed that PEs are 
oestrogenic agonists in breast epithelium (Petrakis et al., 1996). It is found that 
enterolactone is associated with a lower risk of breast cancer (Sonestedt et al., 2009). 
Recent analyses also shown a protective role of isoflavone intake an breast cancer 
incidence (Trock et al., 2006, Qin et al., 2006, Wu et al., 2008), pre- and post-
menopausal Asian women eating the highest amount of dietary isoflavones had a 29% 
reduction in breast cancer risk when compared to low-level isoflavone consumers. 
Similar results have been noted in other studies examining dietary intake (Fink et al., 
2007, McCann et al., 2004, Silva et al., 2004). Furthermore, the administration of 
flaxseed has been shown to reduce tumour proliferation and stimulate apoptosis 
(Thompson et al., 2005).  
Several in-vitro studies with breast cancer cells have shown a positive correlation 
between PEs and inhibition of tumour growth at high concentrations (Peeters et al., 
2003, Ziegler, 2004). Genistein in the presence of E2 competes to bind with ERs and 
slightly decreased cellular proliferation. Moreover, genistein at doses more than 10 μM 
inhibited cell proliferation via inhibition of tyrosine kinase activity. (This et al., 2001). 
Similarly, low concentrations of quecertin and genistein reduced proliferation or had no 
stimulatory effect on ER-negative MDA-MB-231 cells (Balabhadrapathruni et al., 
2000). 
Tumour development in animal models is also influenced by PEs, however the response 
is not necessarily always a positive one. The growth of E2 responsive tumours in mice 
is promoted by genistein (Allred et al., 2001, Hsieh et al., 1998), and administration of a 
genistein-rich diet to ovariectomized nude mice stimulated MCF-7 tumour number and 
burden (Hsieh et al., 1998). Whereas other studies report that treatment of new born 
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female rats with genistein reduces the incidence and number of mammary tumours 
induced by carcinogenic agents (Lamartiniere et al., 1995, Brown et al., 1998).  
There are several potential mechanisms through which the beneficial effect and anti-
proliferative action of PEs on breast cancer risk could be mediated. PEs may reduce the 
risk of breast cancer by effecting endogenous sex-hormone levels or the length of 
menstrual cycle. Numerous studies in-vivo and in-vitro suggest that PEs stimulate the 
production of sex-hormone binding globulin (SHBG) by liver cells. The increase in 
SHBG would be expected to reduce free circulating sex-hormone concentrations and 
prolong the menstrual cycle and thus lower the risk of breast cancer (Lu et al., 1996, Wu 
et al., 2000, Pino et al., 2000).  
Another mechanism involves ERα and ERβ mediated actions by binding with ERs and 
eliciting a weak-oestrogenic effect. PEs tend to bind to ERβ with a higher affinity than 
ERα whereas E2 typically does not show a selective action (Kostelac et al., 2003, 
Margeat et al., 2003, Brzezinski et al., 1997), and for this reason PEs may function 
more like selective E2 receptor modulators (SERMs). Other possible mechanisms 
included inhibition of tyrosine kinase activity, inhibition of angiogenesis, inhibition of 
several enzymes such as s13β- hydroxysteroid, 17β-hydroxysteroid, 5α-reductase, 
topoisomerase I and II, and reduction of oxidative stress (Kurzer and Xu, 1997, Makela 
et al., 1995, Kao et al., 1998). In addition, genistein has the ability to stimulate 
apoptosis of cancer cells in-vivo and in-vitro (Pettersson and Gustafsson, 2001, 
Adlercreutz and Mazur, 1997). Collectively epidemiological studies suggest that PEs 
rich diets may reduce the risk of developing breast cancer. The role of PEs in reducing 
established tumours is less clear and may be dependent on dosage, E2 status and if the 
tumour expresses ERα or ERβ. 
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2.4.2.1 Safety of phyotoestrogens and breast cancer  
Evidence in recent years has increased attention on PEs as an alternative to HRT. HRT 
is associated with an increased risk of breast cancer, however to date there is no 
recorded adverse effect associated with short or long time of use PEs in humans and in 
some cases beneficial actions have been noted. The action of PEs and E2 depends on 
many factors including target tissue, endogenous E2 and ER status.  
The anti-cancer effect of PEs can be explained by a dual mechanism suppressing steroid 
hormone biosynthesis and promoting of E2 metabolism. Many breast cancers are E2-
dependent and a large proportion express ERs ER-dependent mechanism could 
modulate tumour progression or inhibition. E2 in breast tumour present 20 fold than in 
circulating while it is with 5 levels in pre-menopausal women (Nakata et al., 2003, 
Pasqualini and Chetrite, 2005). The loss of ovarian function stimulates local E2 
production through the action of key enzymes such as 17β-hydroxysteroid 
dehydrogenase (17β-HSD) and aromatase that catalyses E2 formation from circulating 
androgens (Labrie, 2003). PEs have been shown to inhibit aromatase and 17β-
hydroxysteroid dehydrogenase activity, genistein has been shown to inhibit 17β-HSD 2, 
while coumestrol inhibit 17β-HSD 1 (Brooks and Thompson, 2005). This would reduce 
E2 levels and reduce the tumour promoting effects of E2.  However, high concentration 
of PEs are required to inhibit local E2 synthesis and the relative contribution of this to 
their action is uncertain. 
ERα and ERβ are expressed in a cell and tissue specific manner in distinct tissue so E2 
has different effects in different tissues, and many complications are involved to explain 
the diverse action of ERs. The relative binding affinity of PEs and E2 to ERs differs and 
this may effect their agonist and antagonist activity; it was found that E2 has the same 
affinity to both ERs, while PEs typically have a higher affinity for ERβ (Kuiper et al., 
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1998), with genistein, daidzein and biochanin A having a 16-fold higher affinity for 
ERβ compared with ERα (Liu et al., 2001a). Interestingly tumour development is 
associated with ERα activation and tumour inhibition ERβ activation. Furthermore, the 
ERα:ERβ ratio is increased in tumours (Skliris et al., 2003). This suggests that ERβ 
could silence ERα by forming ERα/β heterodimers (Lindberg et al., 2003). The affinity 
of PEs for ERβ may be a possible protective mechanism antagonising the promoting 
effects of ER. Through modulation of ERβ isoforms genistein may inhibit E2-induced 
cell growth, silencing ERα-dependent promoting effects. However, further studies are 
needed to determine the interaction of PEs with ERβ isoforms and determine the 
importance of this interaction on breast tumour progression. Moreover, the biological 
activity of PEs may depend on the formation of dimers between both ERα and ERβ 
because these receptors may form homo- or heterodimers. Moreover, genistein at high 
concentration can inhibit breast tumour growth while at low concentration induced 
tumour growth (de Lemos, 2001). Thus, the effect of PEs depends on the level 
expression of ERs and physiological dose. 
In addition to the direct effect of PEs on ER they also reduce levels of available 
hormones by increasing the expression of human sex hormone binding globulin (HSBG) 
which reduces active hormone levels (Adlercreutz et al., 1998). PEs through anti-
oxidant activity also reduces reactive oxygen species that play a crucial role in the 
development and growth of breast cancer (Wei et al., 1995, Wilson et al., 2002). 
Genistein can also effect on cell growth via inhibition of protein tyrosine kinase.  
Therefore most evidence suggests a protective effect of PEs on breast cancer through an 
action on ER, reduction of free active hormone, anti-oxidant activity and inhibition of 
cell signalling. In conclusion, at the present time is not possible to decide if PEs are 
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completely safe since further experiments are needed to determine the long-term action 
of PEs at therapeutically relevant concentrations.     
2.4.3 Prostate cancer   
Prostate cancer is the one of the most common cancers in men in Western countries 
with a much higher incidence in comparison with Asian populations (Severson et al., 
1989). The protective effects of PE-rich diets and lower risk of prostate cancer has been 
demonstrated (Alonso et al., 2009, Chen et al., 2009, Zhang et al., 2008, Syed et al., 
2007). Many different environmental and genetic factors are associated with the 
development of prostate cancer including age, race, diet and infection (Tominaga and 
Kuroishi, 1997). Higher urinary concentrations of daidzein and genistein have been 
noted in healthy individuals in comparison to prostate cancer patients, suggesting a 
inverse link with disease development (Park et al., 2009). High plasma concentrations 
of genistein have also been associated with a lower subsequent risk of prostate cancer 
progression (Travis et al., 2009). Furthermore, additional studies have evaluated the 
effect of isoflavones on prostate specific antigen (PSA) levels, which is a diagnostic 
marker of prostate cancer. Some of these studies revealed that a low PSA levels was 
associated with consuming 83 mg isoflavones/day in men (Adams et al., 2004). A 
further study in which 28 men diagnosed with prostate cancer were given 50g of bread 
supplemented with heat-treated soy grits found a significant decrease in PSA in the 
supplemented group supporting the protective hypothesis that PEs reduce prostate 
cancer progression (Dalais et al., 2004). Another study using 450mg/day of genistein 
and aglycan showed variable results, seven patients had a 50% reduction in PSA levels 
while eight patients showed no effect (deVere White et al., 2004). In-vitro studies have 
shown that genistein and biochanin A inhibit androgen sensitive LNCaP and androgen 
insensitive PC-3 prostate cancer cell proliferation at least in part by stimulating 
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apoptosis (Davis et al., 1999, Raffoul et al., 2006, Peterson and Barnes, 1993). Similar 
effects have been noted in LNCaP treated with enterolactone (Chen et al., 2007), and 
genistein inhibits tumour progression in animal cancer models (Landström et al., 1998, 
Mentor-Marcel et al., 2005) and metastasis of tumours to distant sites (Lakshman et al., 
2008) potentially by inhibiting matrix metalloproteinase production (Xu and Bergan, 2006). 
However a minority of studies indicate that PEs may also promote prostate cancer 
growth. Similar actions of genistein have been noted in animal models where it has been 
shown to increase tumour burden and augment metastatic potential (El Touny and 
Banerjee, 2009).  
Several mechanisms may mediate the effect of PEs on prostate cancer growth. PEs can 
exert oestrogenic effects on prostate cancer cells through binding to ERs in particular 
ERβ, as activation of ERβ has been suggested to suppress cell proliferation and induce 
differentiation in prostate cells in-vitro and in-vivo (Morrissey and Watson, 2003, Usui, 
2006). Isoflavones have also been shown to modify sex steroid receptor expression, 
feeding male rats 25 and 250 mg genistein/Kg decreased the expression of androgen 
receptors (AR), ERα and ERβ. Thus, the protective action of dietary PEs in Asian 
populations may be attributable to the down-regulation of sex steroid receptors (Fritz et 
al., 2002). Furthermore, genistein at a high concentration can inhibit protein-tyrosine 
kinase (PTK) activity which plays an important role in cell proliferation and apoptosis, 
and this may be one of several mechanism by which PEs effect cell growth (Kyle et al., 
1997, Sarkar and Li, 2002). Decreases in prostaglandin synthesis have also been noted 
after PE treatment and this has been proposed as a potential mechanism mediating their 
suppressive action on mitosis (Swami et al., 2009). The antioxidant capacity of PE has 
also been shown to protect prostate cells from DNA damage caused by a range of 
factors through the ability to modify glutathione transferase and reductase levels 
(Raschke et al., 2006, Steiner et al., 2007).  
                                                                                         Chapter 2 
 
71 
 
Thus the majority of in-vitro and in-vivo experiments suggest a chemoprotective role of 
PEs on prostate cancer progression. Whether PEs have antagonist or adverse effects in 
human is not clear yet. However further long term intervention studies need to be 
performed to confirm these results in the clinical setting. 
2.4.4 Phytoestrogens and osteoporosis 
There is much evidence that osteoblast and osteoclast activity is dependent on a range of 
signalling inputs to maintain bone mass. Interestingly, the expression of ERs in bone 
and the biological properties of PEs provide evidence that they may play an important 
role in modifying bone remodelling. E2 deficiency after the menopause can lead to the 
development of an osteoporotic skeleton that is prone to fracture. There is much 
evidence to support the use of HRT and SERMs to attenuate and prevent bone loss in 
post-menopausal women. However, observations from large scale clinical trials indicate 
that long term HRT may increase the risk of breast and endometrial cancer and 
cardiovascular disease in elderly women (Beral, 2007, Rossouw et al., 2002). HRT may 
also increase the risk of stroke through elevation of venous thrombosis formation (Rank 
et al., 2012). Therefore, PEs have been suggested as an alternative therapy to protect 
bone mineral density in post-menopausal women (Rod, 2010).   
A number of studies have been published investigating the beneficial effect of several 
PEs in post-menopausal women and most of these suggest that PEs protect or increase 
BMD (Dalais et al., 1998, Ho and Liao, 2002, Morabito et al., 2002). Epidemiological 
and clinical studies show a positive correlation between PEs consumption and bone 
mineral density (Yuebin et al., 2006, Kanno et al., 2004, Lee and Choi, 2005, Uchiyama 
and Yamaguchi, 2007). A positive association between PEs intake and skeletal health 
has been reported in Japanese and Chinese post-menopausal women and some studies 
using Western populations (Ho et al., 2003, Horiuchi et al., 2000). Additionally, in 
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Asian populations isoflavone consumption is associated with a higher BMD (Sebastian, 
2005, Gallagher et al., 2004, Uesugi et al., 2002, Yamori et al., 2002). Epidemiological 
studies on post-menopausal Chinese women showed a positive association between PEs 
intake and BMD in lumbar spine and femur (Mei et al., 2001). Similarly, genistein 
administration in post-menopausal Japanese women positively correlates with lumbar 
BMD (Greendale et al., 2002). Another study revealed a significant increase in lumbar 
BMD in early post-menopausal women supplemented with 54 mg/day of genistein for 
12 months (Morabito et al., 2002), markers of bone resorption were significantly 
reduced while markers of bone formation were increased in these subjects suggesting an 
anti-resorptive and anabolic action (Morabito et al., 2002). BMD in post-menopausal 
women was also increased after six months of isoflavone administration (Potter et al., 
1998).  
Animal models of bone loss show a similar bone sparing and anti-osteoclastic action of 
PEs. Soy protein rich diets prevented bone loss in ovariectomised rats but had no effect 
on ALP, a marker of bone formation, suggesting that this may have occurred due to 
decreased resorption (Arjmandi et al., 1998). In addition, subcutaneous injection of 
isoflavones at 0.4 mg/day increased BMD but not with 0.7 mg/day (Ishimi et al., 2000). 
A low dose of genistein (0.5 mg/day) was also shown to decrease femoral bone loss in 
ovariectomised rats (Anderson et al., 1998). Genistein (10
-7
 to 10
-5
 M) inhibited PTH-
induced bone resorption which could be related to increased osteoblast formation or 
increased osteoclast apoptosis (Gao and Yamaguchi, 2000). Picherti et al. (2000) 
reported similar effects with genistein and daidzein, which both prevented ovariectomy-
induced bone loss and an even great suppressive action of daidzein was noted on bone 
resorption. This may reflect the strong oestrogenic action of equol a metabolite of 
daidzein (Setchell et al., 2002a), which has been shown to directly inhibit osteoclast 
formation in RAW264.7 cells (Hwang et al., 2006). Ishida et al. (1998) also found that 
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genistein and daidzein 50 mg/Kg/day increased BMD and calcium/phosphorous content 
in ovariectomised rats, although no direct comparison was made between potency. The 
administration of genistein for five weeks reduced ovariectomy-induced increases in 
body weight in mice and also decreased RANKL and cathepsin K mRNA expression and 
enhanced OPG expression in the tibial head, which is suggestive of a positive effect of 
genistein on bone mass (Zhang et al., 2009). In addition to genistein and daidzein, other 
PEs exhibit beneficial effects on bone mass and inhibit osteoclast differentiation such as 
ferutinin (Palumbo et al., 2009), stilbene, matairesnol, and 8-prenylnaringenin 
(Cornwell et al., 2004). Other studies suggest that PEs such as quercetin and kaempferol 
may also influence osteoclast differentiation (Wattel et al., 2003, Wattel et al., 2004), 
resveratol, a phenolic compound found in grape skin, and red wine has also been shown 
to increase osetoblastic differentiation and proliferation (Mizutani et al., 1998). 
Moreover, it has been observed that quercetin, myricetin, kaemferol, isohamnetin, 
curcumin, hesperdin, and astaxanthin decreased PTH-induced osteoclast formation, 
while only quercetin significantly increased diaphyseal calcium contents in-vitro 
(Yamaguchi et al., 2007). In addition to suppression of bone resorption PE have also 
been suggested to promote osteoblasts activity. PEs consumption increased BMD and 
bone formation markers, administration of genistein to post-menopausal women 
increased bone-specific ALP and osteocalcin (Morabito et al., 2002, Atkinson et al., 
2004). .  
However, not all data shows a positive effect of PEs on the skeleton. For instance,  
supplementation of post-menopausal Chinese women with 40 mg/day of daidzein had 
no effect on BMD (Chen et al., 2003b). Similarly, studies using isoflavones at doses 40-
150 mg/day for up to nine months observed no effect on BMD (Chiechi et al., 2002, 
Uesugi et al., 2004, Potter et al., 1998). These discrepancies are likely to reflect 
differences in the nature and concentration of the PE delivered, there metabolism and 
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the stage of menopause. For instance not all individuals are able to metabolise daidzein 
to its more potent metabolite equol. Further human studies are required before a clear 
relationship between PEs and bone health is established. 
The cellular mechanism mediating the effect of PE on bone resorption is not clear but is 
likely to involve a suppressive effect on osteoclast differentiation and cytokine 
production. A plethora of in-vitro studies demonstrate several potential mechanisms 
through which PEs regulate osteoclast activity. Genistein and daidzein have been shown 
to suppress osteoclast activity by inducing apoptosis, modifying protein tyrosine kinase 
activity, altering intracellular [Ca
2+
], membrane depolarization and changes in pro-
osteoclastic cytokines (Blair et al., 1996, Williams et al., 1998, Okamoto et al., 2001, 
Gao and Yamaguchi, 1999c, Gao and Yamaguchi, 2000). In osteoblastsic cells isolated 
from young piglets daidzein increased the production of OPG and decreased soluble 
RANKL by an ER-mediated mechanism (de Wilde et al., 2004). Genistein has also 
been shown to reduce osteoclast formation in healthy pre or post-menopausal women by 
increasing OPG/RANKL ratio in bone marrow stromal cells, suggesting that changes in 
these important regulators of osteoclast differentiation may mediate the effect of 
genistein on bone resorption (Heim et al., 2004, Crisafulli et al., 2004). Interestingly, 
genistein has been shown to modulate the action of PTH on osteoblastsic SaoS-2 cells. 
It was found that the stimulatory effect of PTH on RANKL expression and suppressive 
action on OPG expression was abolished by pre-treatment with genistein, suggesting 
that genistein may block the stimulatory action of PTH on osteoclast formation (Chen 
and Wong, 2006). Inflammatory cytokines can also stimulate osteoclast or osteoblasts 
apoptosis and in addition many also directly influence bone cell differentiation. 
Genistein and daidzein suppress the synthesis of the pro-inflammatory cytokine IL-6 
and prostaglandin E2 (PGE2) which are able to directly stimulate osteoclast formation 
(Suh et al., 2003, Chen and Anderson, 2002) . With genistein inducing ER binding to 
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specific IL-6 promoters to repress IL-6 transcription and synthesis (Chen et al., 2002). 
Genistein also significantly inhibited the production of IL-1 and TNF-α in post-
menopausal women supplemented with soy-rich diet (Huang et al., 2005) as well in 
ovariectomised rats (Li and Yu, 2003).   
In addition it has been reported that genistein decreases osteoclast formation by 
inhibition of DNA topoisomerase I and II, 5-α reductase, aromatase and MAPKs in 
murine cell culture (Makela et al., 1995, Kao et al., 1998, Yamagishi et al., 2001). 
Williams et al. (1998) demonstrated an inhibitory effect of genistein on hydrochloric 
acid transport via suppression of Cl
-
 channel activity and inhibition of tyrosine kinase 
activity. Daidzein has similar actions inhibiting bone resorption and osteoclast 
formation via ER-dependant apoptosis of osteoclast progenitors (Rassi et al., 2002). 
Daidzein as well as E2 reduce the life span of osteoclast progenitors by inducing 
apoptosis via a selective caspase-8 mediated mechanism (Earnshaw et al., 1999). 
Genistein acts at high doses as a tyrosine kinase inhibitor and also induces apoptosis as 
a consequence (Sandy et al., 1998), while at lower concentrations it appears to act as a 
weak oestrogenic agonist which may explain why cells display a biphasic response to it 
(Anderson et al., 1998). 
Several in-vitro studies using different osteoblastsic cell lines have investigated the 
cellular and molecular mechanism mediating the effect of PEs on bone formation. 
While genistein and daidzein increased osteoblastsic proliferation, coumestrol only 
slightly increased proliferation (Kanno et al., 2004). In addition, enterolactone, 
enterodiol and coumestrol at various concentrations increased ALP activity, bone 
mineralisation, and extracellular Ca
2+
 and phosphorous content in cultured osteoblastsic 
cells (Kanno et al., 2004, Feng et al., 2008). The culture of osteoblastsic MC3T3-E1 
cells with daidzein stimulated osteoblast differentiation and activity by elevating DNA 
and protein content and ALP activity which was prevented in the presence of 
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cyclohexamide, a protein synthesis inhibitor. Similarly, the isoflavone biochanin A 
stimulated MC3T3-E1 cell growth, ALP activity, osteocalcin production and type I 
collagen expression. Moreover, the effect of biochanin A was blocked by 
cyclohexamide and tamoxifen indicating that this effect on protein synthesis was 
mediated by an ER dependent. These findings indicate that PEs may have a stimulatory 
effect on cell proliferation by increasing DNA and protein content (Sugimoto and 
Yamaguchi, 2000b, Sugimoto and Yamaguchi, 2000a).  
The anabolic effect of genistein on osteoblastsic proliferation and maturation has also 
been examined in primary culture using mouse bone marrow-derived cells (Okumura et 
al., 2006, Liao et al., 2007, Pan et al., 2005). Genistein increased NO synthase and 
cGMP activity which was associated with increasing of osteoblast differentiation and 
Runx2 expression, which was prevented by ICI 182,780, an ER antagonist (Pan et al., 
2005). Other PEs have also been shown to promote osteoblasts activity. Resveratrol 
increased ALP activity, elevated DNA synthesis and inhibited prostaglandin E2 
production in MC3T3-E1 cells (Mizutani et al., 1998). In addition, stimulatory effects 
on the differentiation and proliferation of MC3T3-E1 cells have also been noted with 
kaempferol, glabridin, apigenin, and luteolin (Miyake et al., 2003, Choi, 2005, Choi, 
2007a, Choi, 2007b). Collectively, much of the data points towards a positive effect of 
PEs on osteoblast differentiation and activity, although the primary mechanism through 
which this occur is still to be fully ascertained. 
2.5 Zinc and bone 
Zinc (Zn
2+
) plays an important physiological role in cell function (Yamaguchi et al., 
1992, Yamaguchi, 1995). It is widely found in different sources: meat, milk, bread and 
cereal products. It is also known as an essential factor for growth in humans and 
animals (Chan et al., 1998, Ryz et al., 2009, Shinde et al., 2006). Zn
2+
 is found within 
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the bone matrix, being concentrated in the osteoid layer before calcification. Zn
2+
 also 
occurs in the mineralised component of bone tissue and is released during resorption to 
affect bone cell activity or to be subsequently reincorporated back into mineral during 
bone formation (Drzazga et al., 2007). Studies suggest that urinary Zn
2+
 excretion can 
be used as a marker for bone resorption in post-menopausal women (Herzberg et al., 
1990, Herzberg et al., 1996, Colpan et al., 2005). Thus, in addition to fluctuations in the 
level of dietary sources, the local concentration of Zn
2+
 is at least in part dependent on 
the resorption rate.  
Zn
2+
 has an important role in bone development and remodelling and the effect of Zn
2+
 
on bone mass is summarised in (Figure 2.4). Multiple studies have investigated the 
association between Zn
2+
 and skeletal health (Ryz et al., 2009, Hosea et al., 2004). 
These studies showed that Zn
2+
 deficiency was associated with a reduction in BMD and 
impaired skeleton maturation. Furthermore, Zn
2+
 blunted osteocalcin and type I collagen 
levels, and also decreased bone development and recovery in rats feed a Zn
2+
-deficient 
diet. Zn
2+
 deficient diets have also been shown to modulate the expression of genes 
involved in bone formation and induce a significant reduction in femur weight, ALP 
expression, femoral calcium and phosphorus content (Sun et al., 2011). Furthermore, 
Zn
2+
 deficiency reduces Runx2 expression in osteoblastsic MC3T3-E1 cells and also 
decreases ALP production in these cultures (Kwun et al., 2010). Zn
2+
 accumulates in 
bone tissues and starts to induce ALP production, collagen synthesis and calcification. 
Zn
2+
 sulphate has also been shown to stimulate a significant increase in osteoblasts 
proliferation, ALP activity, calcium and collagen expression in MC3T3-E1 cells 
(Yamaguchi and Matsui, 1996, Seo et al., 2010). This is supported by reports showing 
that Zn
2+
 increases osteoblasts proliferation and differentiation as inferred from 
increased ALP activity, osteocalcin, and TGF-β (Yamaguchi and Ohtaki, 1991, 
Yamaguchi and Hashizume, 1994, Hashizume and Yamaguchi, 1993). Similar effects of 
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Zn
2+
 sulphate on protein synthesis in bone of new-born rats has been reported, which 
was abolished by cyclohexamide (Ma and Yamaguchi, 2001). More recent studies 
found that osteoblasts mineralisation was augmented after Zn
2+
 treatment which may 
occur as a consequence of increased ALP production (Kawakubo et al., 2011). Similarly, 
culturing of human osteoblastsic SaoS-2 cells with Zn
2+
 significantly increased 
osteoblast differentiation and enhanced ALP activity and mineralised nodule formation 
(Cerovic et al., 2007). Collectively these studies suggest a positive effect of Zn
2+
 in 
skeleton growth primarily but not exclusively via an action on osteoblast differentiation. 
The stimulatory effect of Zn
2+
 on osteoblast differentiation appears to be mediated via 
several potential responses. For instance Zn
2+
 has been shown to promote bone growth 
via a mechanism involving enhanced expression of IGF-I, TGF-β1 or osteocalcin 
expression as well as protein tyrosine phosphate activity in-vitro (Yamaguchi and 
Fukagawa, 2005). Additionally, Zn
2+
 has been shown to stimulate Runx2 mRNA 
expression which induces pre-osteoblast differentiation (Yamaguchi et al., 2008). Zn
2+
 
also impacts on osteoclast differentiation and activity. In the presence of M-CSF, Zn
2+
 
has a suppressive effect on RANKL-induced osteoclastogenesis in mouse marrow 
culture (Yamaguchi and Uchiyama, 2004). Zn
2+
 decreased TRAP-positive osteoclast 
formation from mouse bone marrow cells in-vitro induced by PTH, IL-1α or PGE2 
(Kishi and Yamaguchi, 1994). Furthermore, Zn
2+
 reduced mRNA expression of RANK, 
c-fos, cathepsin K and c-Jun, and through an extracellular signal-regulated kinase (ERK) 
dependent mechanism (Hie and Tsukamoto, 2011). Yamaguchi et al. (2008) showed a 
stimulatory effect of Zn
2+
 on OPG mRNA expression in osteoblastsic lineages. A recent 
study also demonstrated a suppressive effect of Zn
2+
 on NFκB activation in osteoblast 
and osteoclast, and Zn
2+
 also antagonises the inhibitory effect of TNF-α on Smad 
activation induced osteoblast differentiation through TGFβ/BMP-dependent mechanism 
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suggestion that Zn
2+
 can act as skeletal protective agent (Yamaguchi and Weitzmann, 
2011).  
There is many diet sources can include both PEs and zinc with different amounts 
depending on the sources; these sources including soybeans, peanuts, cheese, sesame 
products, cereals, green beans, chick peas, vegetables and meat (Institute of Medicine, 
2001, U.S. Department of Agriculture, 2011). The concentration of zinc ingested 
depends on the nature and amount of food consumed. In meat product such as beef it is 
7 mg per 85 g and chicken breast 1.33 mg per 140 g, cereals 3.7 mg per 30 g, chickpeas 
1.66 mg per 240 g, beans 15.79 mg per 254 g, green peas 1.12 mg per 170 g, peanut 
1.08 mg per 28.35 g, walnut 0.88 mg per 28.35 g and 0.88 mg per 28.35 g in cheese 
(cheddar). 
Several studies investigated the serum zinc concentration in relationship to its 
consumption by individuals. The supplementation of 7.7 µmol of zinc sulphate to 28 
hemodialysis patients for 90 days was associated with 6.1x10
-6 
M of serum zinc on day 
90 after treatment (Jern et al., 2000). Similar result were found in another study, zinc 
sulphate supplementation increased serum zinc concentration from 4.89x10
-6 
M at to 
6x10
-6 
M (Chevalier et al., 2002). Moreover, the supplementation of hemodialysis 
patients with 220 mg of zinc sulphate capsule for 42 days increased serum zinc 
concentration from 3.55x10
-6 
M to 5.47x10
-6
 M on 42 day (Rashidi et al., 2009). 
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Figure. 2.4. The effect of zinc on osteoblast differentiation and mineralisation. Zinc stimulates 
key regulators which are controlled this differentiation and bone formation such as RUNX2, 
ALP, type-I collagen and osteocalcin expression. From (Yamaguchi, 2010).   
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2.6 Aim of study 
Consumption of PEs and other nutritional factors by post-menopausal women may 
prevent bone loss and other age-related diseases. Several human and animal studies 
suggest a beneficial effect of supplementation on bone mass. However, the effect of PEs 
on bone metabolism needs to be established to generate an accurate therapy 
recommendation for prevention and treatment of post-menopausal osteoporosis. 
The aim of the following studies is to examine the effect of physiologically relevant 
concentration of key PEs such as genistein, coumestrol and daidzein on bone resorption 
and formation. These studies will be divided into three strands, first their effect on 
TNFα-induced osteoclast formation; second the effect on osteoblasts formation and 
bone matrix generation and finally the effect of PEs on Th-lymphocyte number and 
cytokines production. The studies will also look at potential interactions between PEs 
and Zn
2+
.   
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3. Materials and Methods 
3.1 Media and reagents 
Dulbecco’s minimum essential medium, RPMI 1640 phenol red free was obtained from 
Invitrogen (GIBCO, UK). The non-selective oestrogen antagonist ICI 182,780 was 
obtained from Tocris Biosciences (Bristol, UK). Recombinant murine TNF-α and anti-
human TNF-α antibodies were purchased from Insight Biotechnology (Wembley, UK). 
Genistein, daidzein and coumestrol were purchased from Sigma (Poole, Dorset, UK). 
Cell Titer 96 AQeous non-reactive cell proliferation assay kit was purchased from 
Promega (Promega, Madison, WI, USA). Antibiotics and other chemicals, reagents and 
assay kits were obtained from Sigma Aldrich (Poole, Dorset, UK) unless stated. All 
plastic-wear flasks or tubes were purchased from Fisher scientific (Nunc, UK).  
3.2 Cell culture  
Murine RAW264.7 TIB.71 monocytic cell line was obtained from American Type 
Culture Collection (ATCC, UK), human osteogenic sarcoma cells (SaoS-2) and human 
leukemic T cell lymphoblasts (Jurkat E6.1) were purchased from European Collection 
of Cell Culture (ECCAC, UK). All experiments were performed in medium without 
phenol red supplemented with 10% charcoal stripped foetal calf serum (Autogen 
Bioclear, UK), 2mmol/l glutamine, 100IU/ml benzylpenicillin and 100mg/ml 
streptomycin (all from Sigma, Poole, Dorset, UK). Incubations were performed at 37
o
C 
in a humidified 5% CO2 incubator. Cultures were fed every 2-3 days by replacing half 
of the culture medium with fresh medium and cytokines. 
3.3 Cell cryopreservation and reanimation 
Cells of passage 3-7 were cryopreserved and then used for experiments as required. In 
brief, adherent cells were passaged using trypsin-ethylenediaminetetraacetic acid 
(EDTA) solution for no longer than 5 minutes at 37
o
C. After detachment, cells were 
                                                                                         Chapter 3 
 
84 
 
washed with the culture medium to deactivate trypsin and centrifuged at 1000rpm for 5 
minutes at room temperature. After centrifugation, cells were resuspended in sterile 90% 
FCS and 10% dimethyl sulphoxide (DMSO) solution, placed in cryopreservation tube 
and frozen at -80°C for 24 hour before transfer to liquid nitrogen for long term storage. 
To reconstitute frozen cells, vials were removed from liquid nitrogen and rapidly 
thawed and then immediately transferred into 5ml of cell culture media, centrifuged to 
remove DMSO and then cultured in 25cm
2
 flasks until 80% confluence was reached. 
3.4 Phytoestrogens concentrations  
PEs concentrations between (10
-5
-10
-10
 M) have been shown to be effective at 
modifying bone cell and tissue function and my concentrations were chosen to reflect 
this range (Crisafulli et al., 2004, Chen and Wong, 2006, Kanno et al., 2004, Sugimoto 
and Yamaguchi, 2000b). Genistein (10
-7
-10
-9 
M) inhibited osteoclast formation in 
murine bone marrow cultures and reduced RANKL/OPG ratios in osteoblastic cells 
(Sliwiński et al., 2005). PTH-induced osteoclast formation was also prevented by 
genistein (10
-5
-10
-7 
M) (Gao and Yamaguchi, 1999b, Gao and Yamaguchi, 1999c) and  
genistein (10
-5
-10
-8 
M) decreased pit formation on bone slices (Li and Yu, 2003). This 
concentration range also appears to be effective at modifying bone cell function in 
animal models of bone remodelling and loss.  Subcutaneous injection of genistein 
(2.5x10
-6
 M) which generated serum concentrations of 1x10
-9
 M partially prevented 
ovariectomy-induced trabecular bone loss with no uterine effects noted (Ishimi et al., 
2000). Furthermore, TRAP+ cell number was reduced in the presence of genistein (10
-6
-
10
-9 
M) and serum ALP and osteocalcin levels significantly increased in ovariectomised 
rats while TNF-α and IL-1β levels were reduced after OVX rats were administered 
genistein 45 mg/kg/day. Genistein and daidzein at (10
-5 
M) induced ALP expression and 
calcium content in bone tissue of female rats (Gao and Yamaguchi, 1999a); and 
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osteoblast PGE2 and IL-6 production was blunted by genistein (10
-5 
M) (Suh et al., 
2003). The range of concentrations used in these studies also reflect those measured in 
the serum of Asian and Western populations (Morton et al., 2002). In Japanese 
individuals plasma concentrations of genistein were 4.9x10
-7 
M whereas those in 
Western Europeans 3.3x10
-8 
M (Morton et al., 2002). Similarly Valentin-Blasini 
recorded genistein and daidzein serum concentrations of 1.7x10
-8
 and 1.5x10
-8
 M 
respectively (Valentin-Blasini et al., 2003) and genistein and daidzein serum 
concentrations of 1.4x10
-8
 and 1.1x10
-8 
M were associated with a reduced incidence of 
breast cancer in post-menopausal women (Verheus et al., 2007).  
Several studies have assessed the relationship between dietary PE intake and serum 
concentration in Asian and Western population. For instance an investigation on 
Japanese males and females found that the serum concentration of daidzein and 
genistein was 1.2x10
-7
 M and 4.7x10
-7
 M in those receiving either 18.3 mg/day daidzein 
or 31.4 mg/day genistein (Yamamoto et al., 2001). A further study showed that 
increasing soy milk intake in pre-menopausal British women was associated with higher 
plasma concentration of genistein and daidzein; consuming 149 ml or 248 ml of soy 
milk resulted in serum concentrations of 3.9x10
-8 
M and 1.3x10
-7 
M for daidzein and 1.1 
x10
-7 
M and 3.7x10
-7 
M for genistein (Verkasalo et al., 2001). Similar results was found 
in Frankenfeld’s (2003) study, which revealed that intakes ofof 8.1 mg/wk or 6.9 mg/wk 
of genistein and daidzein by post-menopausal women was associated with plasma 
concentration of 1.2x10
-8 
M and 6.9x10
-8
 M of genistein and daidzein respectively. 
Therefore, data provides evidence for a positive relationship between the intake of 
phytoestrogens and subsequent serum or plasma levels.  These concentrations are 
similar to those in the mid-range of my dose response and are similar to the genistein 
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and coumestrol concentrations that had the most pronounced effect on osteoclast 
differentiation. 
3.5 Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) activity 
Osteoclast formation was evaluated by staining for the specific osteoclastic marker 
tartrate resistant acid phosphatase-positive (TRAP) using a modification of the method 
of Burstone (Burstone, 1958) using  a acid phosphatase, leukocyte (TRAP) kit (Sigma, 
Poole, Dorset, UK) and naphthol AS-BI phosphate as a substrate. The assay was 
performed following manufacturer’s instructions. Briefly, after treatment, cells were 
fixed onto the bottom of well plates with 10% formaldehyde/PBS for 10 minutes at 
room temperature, then washed twice with distilled water (dH2O) and stained with AS-
BI phosphate and fast garnet (GBS) base as a chromogen for 1 hour at 37
o
C in a 
humidified incubator. Cultures were then rinsed with dH2O and osteoclast 
differentiation scored using the following method. The number of TRAP-positive 
mononuclear and multinuclear cells containing three or more nuclei was measured using 
an inverted light microscope fitted with an eyepiece graticule using an objective of x20 
(Olympus, Japan). Five defined areas for each well were counted for TRAP-positive 
mono- and multi-nucleated osteoclast and the results expressed as the mean number of 
cells per cm
2 
± S.E.M. All experiments were performed in triplicate.    
3.6 Bone resorption  
Bone resorption was measured using slices of bovine cortical bone (kind gift of Dr 
Karen Fuller). Bovine cortical bone slices were cut using diamond saw (Buehler, 
Coventry, UK) according to Klein et al. (Klein et al., 1994) method. Bovine bone was 
cut into slices 30 μm in thickness followed by cleaning in distilled water by 
ultrasonication for 15 minutes. Then, bone slices were washed with acetone for 10 
minutes and immersed in Hank’s balanced salt solution (HBSS). Slices were then 
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sterilised in 70% ethanol at room temperature and cut into small squares 20mm
2
 in area. 
Slices were stored at -20
o
C until used. RAW264.7 cells were seeded onto the slices in 
24 well plates at 10
5
 cells per well. After incubation, cells were removed from the 
surface of the slices by immersion in 10% (vol/vol) sodium hypochlorite for 10 minutes, 
followed by washing in distilled water and dehydration in 70% ethanol. After drying 
slices were mounted onto glass slides and stained with 1% toluidine blue to enable 
visualization of resorption pits. The percentage of bone surface resorbed was quantified 
by reflected light microscopy using an eyepiece gratitude and magnification of x100 on 
an Olympus BHB microscope with a Schott KL1500 light source.  
3.7 Measurement of cell proliferation and apoptosis 
Cell proliferation was measured using the Cell Titer 96 AQeous non-reactive cell 
proliferation assay kit (Promega, Madison, WI, USA). This assay measures proliferation 
using mitochondrial NADH/NADPH-dependent dehydrogenase activity as a marker of 
cell proliferation, this enzyme converts a substrate (3-(4,5-dimethylthiazol-2-gl)-5-(3-
carboxymethoxylphenyl)-2-(4-sulphophenyl-2H) tetrazolium compound (MTS) into an 
formazan dye which can then be quantified at A490. The absorbance of the formazan is 
linearly proportional to the number of viable cells.  
At the end of an experiment 20μl of MTS solution was added to each well and 
incubated for 4hr at 37
o
C. After incubation, the absorbance in each well was measured 
at 490nm using a 96 well plate reader (Molecular Devices, USA). The viable cell 
number in each well was then calculated using the equation of the line y = mx + c and a 
standard curve plotted from absorbance of wells containing know cell numbers. All 
experiments were performed in triplicate and data expressed as the mean ± S.E.M.  
Apoptosis was determined using an Apo-One Homogeneous caspase 3/7 kit (Promega, 
Madison, WI, USA) that measured caspase 3/7 activity in osteoclast following the 
                                                                                         Chapter 3 
 
88 
 
manufacture’s protocol. After incubation 100μl of apo-one caspase-3/7 reagent was 
added to each well and the plate incubated for 18 hour with shaking at 37
o
C. 
Fluorescence was then measured using a fluorescence multi-well plate reader 
(Perseptive Biosystem, USA) at excitation wave length of 490 nm and emission wave 
length 521 nm on a. Experiments were performed in triplicate. 
3.8 NFATc1 immunofluorescent staining 
RAW 264.7 cells at (1x10
4
 cell/well) density were seeded overnight onto glass 
coverslips and then incubated with appropriate treatments. The distribution of NFATc1 
protein 24 and 48 hours after stimulation was assessed according to previously 
published protocols (Evans and Fox, 2007). Coverslips were removed, washed in PBS, 
fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, incubated with 
1% goat serum and incubated with a specific anti-mouse NFATc1 monoclonal antibody 
(1:50, Santa Cruz, USA) for 1 hour. Cells were washed in PBS, incubated for 2 hours 
with biotinylated goat anti-mouse secondary (Vector Labs, USA) and then incubated for 
15 minutes with fluorescein conjugated streptavidin (Vector Labs, USA). Fluorescence 
was visualized using a Leica HC microscope. The percentage of cells displaying nuclear 
staining was then quantified and 100 cells per group were measured from 3 separate 
coverslips per group. Photographs were taken with a JVC digital camera linked to 
image pro-plus at a magnification of x400. Results are displayed as mean ± S.E.M from 
three separate experiments. 
3.9 Measurement of mineralisation and alkaline phosphatase (ALP) activity 
ALP activity was measured by staining cultures with p-nitrophenyl phosphate (1 mg/ml) 
in 0.2 M tris buffer at 37ºC for 30 min (Sabokbar et al., 1994). The effect of coumestrol 
(10
-5
 to 10
-9 
M), daidzein (10
-5
 to 10
-9 
M) and genistein (10
-5
 to 10
-9 
M) in the presence 
or absence of zinc sulphate (10
-5 
M) on ALP activity was assessed as follows. SaoS-2 
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cells (1x10
4
 per well) were incubated in 96 well plates for 24 hr to enable cells to adhere. 
Cultures were then incubated in relevant treatments in presence of β-glycerophosphate 
(β-GP) (10 mM) and L-ascorbic acid (L-AA) (50 mg/l) for four days. Absorbance was 
measured at 405 nm and results were then normalised to total cell number and 
expressed as the amount of ALP required to liberate 1 mmol of p-nitrophenol / min / 10
4
 
cells.  
Mineralisation was assessed using a modification of Hale’s methodology (Hale et al., 
2000). This enables the rapid and direct quantification of mineralisation by measuring 
calcein incorporation into mineralised nodules. Cells were treated with β-GP (10 mM) 
and L-AA (50 mg/l) to initiate mineralisation and the medium supplemented with 
genistein, daidzein or coumestrol (10
-5
-10
-9 
M) with or without zinc sulphate (10
-5 
M). 
After 18 days of incubation culture medium was aspirated, the monolayer washed with 
PBS and incubated in culture medium containing 1 µg/ml calcein for four hours at 37ºC. 
Cultures were then washed three times in PBS and fluorescence measured by a 
cytofluor II fluorescence multiwell plate reader (Perseptive Biosystem, USA) at 485 nm 
excitation and 530 nm emission. 
3.10 Molecular biology 
3.10.1 RNA extraction and reverse transcription   
Total RNA was isolated using a commercially available GenElute
TM
 mammalian total 
RNA miniprep kit (Sigma, Poole, Dorset, UK), which utilizes a column based technique 
to isolate and purify RNA. After incubation, cells were washed with DPBS and total 
RNA extracted according to the manufacture’s protocol. All consumables and reagents 
used were free of contaminating DNAase and RNAase. Genomic DNA was removed 
using an on-column DNase-I treatment step. RNA and DNA quantity and purity was 
measured using a nandrop spectrophotometer (ND-1000) (Labtech, UK). Absorbance 
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was measured with A260 for nucleic acid and the ratio A260:A280 was used to assess 
sample purity. RNA concentrations were then adjusted to 250μg/μl in molecular biology 
grade H2O, RNA (1μg) was reversed transcribed to cDNA using M-MLV reverse 
transcriptase reaction in thin walled PCR tubes (Sigma, Poole, Dorset, UK) using a 
GeneAmp PCR System 9700 machine. RNA was denatured at 70°C for 10 min in the 
presence of dNTPs (0.5mM) (dATP, dCTP, dGTP, TTP) and random nonamers (1μM). 
Reactions were cooled on ice for 5 minutes and then 1 unit of MMLV-reverse 
transcriptase was added to each reaction. Reactions were then incubated at room 
temperature for 10 min, 37°C for 50 min and 94°C for 5 min. RTs were stored at 4º
 
C 
until used. Negative controls consisting of reactions lacking RT were run in all 
experiments.  
3.10.2 Verification of PCR primers and RT 
Primer sequences were designed using the NCBI website and according to the mRNA 
sequence of each gene published in the same website using primer blast software. 
Designed primers were purchased from Eurofins MWG Operon (Germany). 2 µl of 
cDNA was used for each PCR reaction. Each reaction contained 10μM of forward and 
reverse primers, dNTPs (0.5mM), Taq DNA polymerase (5 unit/µl) and PCR buffer 
(10x) in a final volume of 25μl. Reaction conditions were 94oC for 2 minutes, followed 
by 40 cycles at 94
o
C for 30 seconds, 60
o
C for 30 seconds and 72
o
C for 30 seconds.  
Product size and primer specificity was then confirmed using agarose gel 
electrophoresis. PCR samples had 2.5 μl of loading buffer (orange G dye) added and 
was then loaded onto a 2% (w/v) TAE agarose gel. Gels were made by dissolving 
agarose (electrophoresis grade, Fisher scientific) in an appropriate volume of TAE 
buffer (40mM Tris-base, l0mM EDTA and 0.1% acetic acid) which was heated in a 
microwave for 2 minutes and then cooled to 50°C. 1μl of ethidium bromide (10mg/ml) 
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was then added to the gel to enable visualization of DNA under UV light. Gels were run 
at 60-100V according to the size of the product for an appropriate time. Bands were 
checked for presence and size using UV gel documentation system (UVi Tech, Japan) 
linked to a PC (Toshiba, Japan).  
3.10.3 Real-time quantitative polymerase chain reaction (RT-PCR)    
Quantitative PCR is a highly sensitive technique that enables the absolute quantification 
of gene expression in biological samples. RT-PCR was used in my studies to establish 
the effect of PEs on the expression of genes involved in osteoblast, osteoclast and T 
cells formation and activity. Quantitative RT-PCR was performed using a 48 well Step 
One PCR system linked to Stepone v.2 analytical software (Applied Biosystems 
Warrington, Cheshire, UK) and using the DNA-binding dye SYBR green for detection 
of PCR products. β-actin was used as a house keeping gene to normalise mRNA levels. 
Reactions containing the following, 2μl of external plasmid standard or cDNA added to 
a final reaction volume of 25μl which contained 0.05U/μl Taq, SYBR green, PCR 
buffer (300 nM) reference dye (Rox) and specific sense and antisense primers (0.2μM). 
For the generation of standard curves, the corresponding cDNA was cloned into pGEM-
T Easy (Promega, UK) (see section 3.8.3.6). The concentration of DNA plasmid stock 
was determined by measurement of optical density at 260 nm. Copy number for each 
plasmid was calculated from these measurements. A 100 ng/ml of target insert solution 
was prepared and used as a stock to prepare serial dilutions to generate a standard curve 
with copy numbers from 500 to 5x10
6
 copies.
 
The linear range of the assay was 
determined by the amplification of log serial dilutions of external plasmid standard from 
500 to 5 x 10
6 
copies. The progress of the PCR amplification was monitored by real-
time fluorescence emitted from SYBR Green during the extension time. Reaction 
conditions were 94°C for 2 minutes, followed by 40 cycles of 94°C for 30 seconds, 
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60°C for 30 seconds and 72°C for 30 seconds. At the end of each PCR run, a melt curve 
analysis was performed to show the absence of non-specific bands. For each sample, 
mRNA levels were expressed as an absolute copy number normalized against 10
6
 β-
actin copy numbers. The mRNA copy number was calculated for each sample from the 
standard curves by the instrument’s software. Samples were analysed in triplicate.   
3.10.4 Preparation of internal standards for quantitative PCR  
To enable the quantification of absolute copy number of target genes the coding 
sequences of target genes were sub-cloned into a plasmid vector (pGEM-T Easy, 
Promega, UK). This vector is pre-linearized by EcoRI digestion and insertion of 
3’terminal thymidine to both ends prevents recircularisation and creates compatible 
overhanging bases for ligation of PCR products. Retroviral PBabe puromycin resistant 
vector was linearized using one restriction enzyme chosen according to the suitability 
with the DNA insert. Known copy numbers of these plasmids were then used to 
generate standard curves to enable the measurement of copy number in samples. 
The target cDNA was amplified by RT-PCR from cultures of osteoblasts or osteoclasts 
using specific primer pairs. Products were electrophoresed on 1% TAE agarose gel and 
bands detected by ultraviolet light (UV) using ethidium bromide staining. DNA 
fragments of correct size were excised from the gel using a sterile scalpel, placed into 
1.5 ml microcentrifuge tubes and DNA extracted using GenElute gel extraction kit 
(Sigma, Pool, Dorset, UK) according to the manufacturer’s instructions. Solubilisation 
solution was added to the gel slices which were then incubated in a water bath at 50-
60°C with vortexing every 2 minutes, until the gel slices were completely dissolved. 
Samples were then applied to DNA binding column and centrifuged at 13,000xg for 1 
minute. The column was then washed to remove remaining agarose and centrifuged at 
13,000xg for 1 minute. The DNA insert was eluted in 50μl of elution buffer and the 
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concentration and purity quantified using a nanodrop spectrophotometer and then stored 
at -20°C until the ligation reaction was performed.  
The DNA insert was then ligated into pGEM-T easy vector (Promega, UK) using T4 
DNA ligase. For maximal ligation efficiency, an insert : vector ratio of 3:1 was used. 
The amount of DNA fragment was calculated according to the following equation: 
                               
                   
                                                    
Ligation reactions also contained 2x T4 DNA ligase buffer, 1μl of T4 DNA ligase 
(3U/µl) and water up to 10μl final volume. Ligations were incubated overnight at 4°C. 
Control ligations were setup without insert DNA. Following ligation plasmids were 
transformed into competent JM109 bacteria cells (Escherichia coli DH5α, Promega, UK) 
which is capable of high efficacy transformation at 1x10
8
 CFU/μg. In brief, 50μl of 
thawed bacteria was added to 2μl of ligation reaction and incubated for 20 minutes in an 
ice bath. Bacteria were then heat-shocked in a water bath at 42°C for 50 seconds and 
incubated again on ice for 2 minutes. 950μl of SOC medium was added to the bacteria 
and incubated for 1.5 hours in a shaking water bath at 37°C. 100μl of transformed 
bacteria were then plated out on LB agar/ampicillin (100µg/ml)/x-gal (80µg/ml)/IPTG 
(0.5 mM) plate and incubated overnight at 37°C. On these plates transformed colonies 
appear white while colonies that don’t contain plasmid with an insert are blue. Several 
colonies were selected from the agar plate and used to inoculate 5 ml of LB/ampicillin 
broth and the culture incubated in water bath at 37°C overnight with shaking (150 rpm) 
to enable plasmid amplification prior to extraction.  
Following overnight culture a GeneElute HP plasmid miniprep kit (Sigma, UK) was 
used for extraction of plasmid DNA and to check for the presence of target insert. 
Bacterial cells were harvested from 3-5ml of culture and then transferred to a 1.5ml 
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microcentrifuge tube and centrifuged at 13,000xg for 5 minutes. Bacterial pellets were 
resuspended in 200μl of suspension solution, and then 200μl of lysis solution added to 
release the plasmid. Cell debris was precipitated by adding 350μl of 
neutralization/binding buffer and centrifuging the samples at maximum speed in a 
micro-centrifuge for 10 minutes. Subsequently, the supernatant was transferred onto 
binding column and centrifuged at maximum speed for 1 minute. The pellet containing 
plasmid DNA was then washed twice with wash solution and then resuspended in 50μl 
of elution buffer. An EcoRI restriction enzyme digest was then performed to check for 
the presence of target insert in the DNA vector. Digests were performed for 1 hour at 
37
o
C and then run on a 1% agarose TAE gel to check for the presence of target insert of 
the correct size. Successfully ligated plasmids were then streaked on LB/ampicillin agar 
plate and incubated overnight at 37°C. Colonies were selected from these plates and 
grown in 250ml of LB medium at 37°C. Plasmids were then purified from these cultures 
using a GenElute High performance plasmid midiprep kit according to manufacturer’s 
instructions (Sigma, UK). Plasmids were stored at -20°C. 
3.10.5 Molecular biology solutions  
3.10.5a Luria-Bertani (LB) broth 
20 g of LB broth was dissolved in 1 litre of distilled water, autoclaved and ampicillin 
added to a final concentration of 100 μg/ml.    
3.10.5b LB/ampicillin/x-Gal agar plate plates 
15g agar and LB broth were dissolved in 1 litre of distilled water, autoclaved then 
chilled at room temperature to approximately 50°C. Ampicillin (100µg/ml)/x-gal 
(80µg/ml)/IPTG (0.5 mM) were added to the LB agar media and poured into 94mm 
petri dish to a depth of 10mm of thickness , left to set, then stored at 4°C.  
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3.10.5c 10x Tris-acetate-EDTA (TAE) buffer  
0.4M Tris-base, 0.5M EDTA and 1M acetic acid was dissolved in 1L of d.H2O. The pH 
was adjusted to 8.5 and then diluted to make 1x TAE buffer.  
3.11 Statistical analysis 
Differences between groups were assessed using Fisher’s analysis of variance (Statview; 
Abacus concepts, USA) or Student’s T-test as appropriate. All data are analysed using 
SPSS program 18 (IBM SPSS Statistics software). A difference of P<0.05 was 
considered statistically significant. 
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4.1 Introduction  
Post-menopausal osteoporosis is characterized by low bone mass and increased fracture 
risk. Worldwide, osteoporotic fractures are a major health concern especially in 
countries with aging populations. Prior to menopause osteoblastsic bone formation and 
osteoclastic bone resorption are balanced such that there is little net bone loss during 
each remodelling cycle. E2 deficiency disrupts this equilibrium increasing bone 
turnover and skewing remodelling in favour of resorption. Recent evidence suggest that 
this is at least in part due to elevated levels of the potent pro-inflammatory cytokine 
TNF-α (Weitzmann and Pacifici, 2007). Several studies show increased TNF-α 
production by bone marrow and T cells following E2 deficiency in mice (Cenci et al., 
2003, Grassi et al., 2007). Furthermore, mice lacking T cells or TNF-α receptors are 
resistant to ovariectomy-induced bone loss (Roggia et al., 2001). Human peripheral 
blood mononuclear cells (PBMC) also display E2-dependent changes in TNF-α 
production, PBMC from post-menopausal or oophorectomised individuals synthesize 
elevated levels of TNF-α (D'Amelio et al., 2004), whereas E2 replacement suppresses 
PBMC TNF-α production in-vivo (Bernard-Poenaru et al., 2001). In addition to 
promoting post-menopausal bone loss TNF-α is also a key regulator of osteolysis 
associated with chronic inflammatory conditions such as rheumatoid arthritis (Boyce et 
al., 2005). TNF-α promotes osteoclast differentiation through several actions, it 
augments RANKL induced osteoclastogenesis and also directly stimulates osteoclast 
formation from human or mouse monocytes (Komine et al., 2001, Fox et al., 2008) and 
has been suggested to activate osteoclast formation independent of RANKL signalling 
(Kudo et al., 2002). Thus, TNF-α has a central role in post-menopausal bone loss 
directly promoting osteoclast formation and augmenting the response to other resorptive 
stimuli.   
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Post-menopausal women are typically prescribed bisphosphonates to prevent bone loss, 
however complications such as induction of the acute phase response and osteonecrosis 
of the jaw can occur (Cole et al., 2008). As a consequence, other potential therapeutic 
interventions have been examined including PEs. PEs are a diverse group of plant 
derived compounds with a structure and function similar to oestradiol that are used 
clinically to control tumour progression. Some epidemiological studies suggest that 
diets with high PEs content may be associated with a more robust skeleton; positive 
associations have been noted between soy protein intake and spinal and hip bone 
mineral density in Asian women (Horiuchi et al., 2000, Kim et al., 2002a, Mei et al., 
2001) and women with the highest dietary soy levels have the lowest resorption rates 
(Mei et al., 2001).  
Intervention studies have also noted beneficial actions of PEs on post-menopausal 
women’s spinal (Alekel et al., 2000, Atkinson et al., 2004), trochanter (Chen et al., 
2003b) and Ward’s triangle BMD (Wu et al., 2006). Decreases in resorption markers 
have also been described following PEs supplementation (Weaver et al., 2009). 
However, not all studies have observed beneficial actions of PEs on the skeleton 
(Gallagher et al., 2004), suggesting that the response may be dependent on the nature of 
the treatment regime or is modified by other lifestyle factors. While PEs may have a 
beneficial action on skeletal mass, the cellular and molecular mechanism mediating this 
response is not fully understood and is likely to differ depending on the PEs examined. 
Previous studies have shown that PEs reduce osteoclast formation by directly 
suppressing the response of monocytes to osteoclast-inductive stimuli and also 
indirectly by reducing osteoblastsic RANKL expression (Garcia Palacios et al., 2005, 
Gao and Yamaguchi, 1999b, Bandyopadhyay et al., 2006, Gao and Yamaguchi, 2000, 
Rassi et al., 2002, Uchiyama and Yamaguchi, 2007, Li and Yu, 2003). Surprisingly, in 
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spite of evidence showing that TNF-α has a crucial role in post-menopausal and 
inflammatory bone loss no study has examined the direct effect of PEs on TNF-α 
induced osteoclast differentiation. This is of importance as while there is an overlap 
between the intracellular signals activated by TNF-α and RANKL the early events in the 
their transduction cascades are dissimilar, each binding to a distinct receptor linked to 
different groupings of TRAF signalling factors. RANKL activates TRAFs 2, 3 and 6 
while TNF-α predominantly signals via TRAFs 2 and 3. Furthermore, RANKL activates 
a broader range of signal transduction pathways than TNF-α, which requires other co-
stimulatory factors to facilitate osteoclast formation (Fox et al., 2008). This raises the 
possibility that TNF-α and RANKL-induced osteoclast may respond differently to anti-
osteoclastic compounds that target initial stages of osteoclast differentiation. In keeping 
with this the anti-resorptive effect of bisphosphonates is blunted in inflammatory 
conditions associated with high TNF-α levels such as rheumatoid arthritis (Zhang et al., 
2005) and E2 at least partly suppresses RANKL-induced osteoclast formation via a 
TRAF6 dependent action (Robinson et al., 2009). The mechanism by which TNF-α can 
affect bone remodelling is complex as it can cooperate with other signalling pathways 
downstream of TNFR1.  
Thus, to determine if PEs are able to directly inhibit TNF-α-induced osteoclastogenesis 
and to establish the molecular mechanism of the anti-osteoclastic action I examined the 
effect of genistein, coumestrol and daidzein on TNF-α-induced osteoclast formation 
from the monocytic cell line RAW264.7. 
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4.2 Materials and methods 
All general materials and methods relating to cell culture and molecular biology 
experiments are described in chapter three. However, key methods relating to this 
chapter are described in detail below. 
4.2.1 Cell culture  
Extensive research proves that RAW264.7 cells are an excellent model to study 
osteoclast biology in-vitro due to the similar characteristics they have with primary 
human and animal osteoclastic precursors. Like primary monocytes RAW264.7 cells 
form osteoclast in response to a range of resorptive stimuli and readily form resorption 
pits on bone, in addition unlike primary cells they are a homogenous population 
enabling the direct study of osteoclast regulatory factors without the interference of 
other cell types (Abe et al., 2012, Collin-Osdoby and Osdoby, 2012, Cuetara et al., 
2006). RAW264.7 cells were cultured in phenol-free DMEM medium supplemented 
with 10% foetal calf serum, 2mmol/l glutamine, 100IU/ml benzylpenicillin and 
100mg/ml streptomycin. Cells were maintained by replacing half the medium with fresh 
medium every 2-3 days.  
4.2.2 Osteoclast differentiation  
To determine the direct effect of PEs on TNF-α-induced osteoclast differentiation, 
RAW264.7 cells were transferred to 24-well plates at a density of 10
5
 cells per well and 
cultured with combinations of TNF-α (50ng/ml), genistein (10-5 to 10-9 M), daidzein  
(10
-5
 to 10
-9 
M) or coumestrol (10
-5
 to 10
-9 
M) for 4 days with or without the E2 
antagonist ICI 182,780 (10
-6 
M). To determine the effect of PEs on mature TNF-α-
induced osteoclast, RAW264.7 cells were incubated in the presence of TNF-α (50ng/ml) 
for four days to generate osteoclast cultures which were then incubated for 24 hours 
with PE concentrations shown to inhibit osteoclast formation in the initial experiment 
                                                                                         Chapter 4 
 
101 
 
with or without the E2 antagonist ICI 182,780 (10
-5 
M). Raw264.7 cells were then fixed 
and stained for TRAP to determine osteoclast formation as explained in chapter three 
(3.4). The number of TRAP-positive cells was counted and the results expressed as the 
number of cells per cm
2
. All experiments were performed in triplicate. 
4.2.3 Bone resorption and NFATc1 immunofluorescent staining     
To assess the effect of PEs on TNF-α-induced bone resorption RAW264.7 cells were 
seeded onto 20mm
2
 slices of devitalised bovine bone in 24 well plates at a density of 
10
5
 cells per well. Cells were incubated in TNF-α (50ng/ml) with or without PEs for 
eight days in the presence or absence of ICI 182,780 (10
-5
M). After incubation cells 
were removed from the surface of bone slices and stained for assessment of bone 
resorption area using inverted light microscopy as described in chapter three (3.5). The 
percentage of bone surface resorbed was measured as a mean from three separate 
experiments.   
For NFATc1 immunofluorescent staining, RAW 264.7 cells were seeded overnight onto 
glass coverslips and then incubated in TNF-α (50ng/ml) with or without genistein      
(10
-7 
M), coumestrol (10
-7 
M) or daidzein (10
-5 
M). The distribution of NFATc1 protein 
24 & 48 hours after stimulation was assessed according to the procedure detailed in 
chapter three (3.6). 
4.2.4 Cell viability and apoptosis 
The effect of PEs on cell viability was assessed using an AQueous one solution cell 
proliferation assay (Promega UK). Cells were incubated with TNF-α (50ng/ml) or TNF-
α plus genistein, coumestrol or daidzein (10-4 to 10-9 M) for four days, proliferation was 
then assessed. The effect of anti-osteoclastic concentrations of PEs on apoptosis was 
assessed by incubating RAW cells with TNF-α (50ng/ml) or TNF-α plus genistein     
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(10
-7 
M), coumestrol (10
-7 
M) or daidzein (10
-5 
M) for 24 hours. Caspase 3/7 activity 
was then measured using the apo-One homogeneous caspase assay (Promega, UK).  
4.2.5 Real time quantitative PCR analysis 
Quantitative PCR was used to determine the expression of key regulators of osteoclast 
differentiation. All the results are expressed as a copy number normalised to 10
6β-actin 
mRNA copies. RAW264.7 cells (5 x 10
5
) were incubated in 25cm
2
 flasks for 24, 48 or 
96 hours with combinations of TNF-α (50ng/ml), genistein (10-7 M), coumestrol        
(10
-7 
M) or daidzein (10
-5 
M). Total RNA was extracted from these cultures using a 
Genelute RNA isolation kit and reversed transcribed with M-MLV reverse transcriptase 
and QPCR was carried out using SYBR Green DNA binding dye as described in 
chapter three (3.8.2). The sequences of the primers used are shown in (Table 4.1). The 
generation of standard curves was described in chapter three using the corresponding 
cDNA and cloned into pGEM-T Easy (Promega).  
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Table 4.1. Primer sequence of murine genes examined.  
Murine 
Genes 
5´-3´ Forward primer 3´-5´ Reverse primer 
 β-Actin GTCATCACTATTGGCAACGAG CCTGTCAGCAATGCCTGGTACAT 
NFATc1 CCGTTGCTTCCAGAAAATAACA TGTGGGATGTGAACTCGGAA 
c-fos CCATCAAGAGCATCAGCAA AAGTAGTGCAGCCCGGAGTA 
DC-
STAMP 
AAAACCCTTGGGCTGTTCTT GTTCCTTGCTTCTCTCCACG 
NFκB GTGGAGGCATGTTCGGTAGT GTCCAGAAGGCTCAGGTCAG 
 p38 CGACCACGTTCAGTTTCTCA AGGTCAGGCTCTTCCACTCA 
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4.2.6 Generation of c-fos expressing retroviral vector  
The role of c-fos in the effect of PEs on TNF-α-induced osteoclastogenesis was 
examined by infecting RAW264.7 cells with a c-fos expressing retroviral vector. 
Constitutively active c-fos (N-core-cfos) was transduced using a retroviral vector, 
pBabe puro, which expresses cDNA inserts under the control of a retroviral enhancer-
promoter (Morgenstern and Land, 1990). The coding region for the N terminal and core 
regions of c-fos were PCR amplified from total mouse RNA and cloned into PGEM T 
easy (Promega, UK). EcoRI digest fragments were then sub-cloned into pBabe puro.  
The resulting plasmid pBabe-cfos was sequenced (MWG Eurofins). The pBabe-cfos and 
pBabe-empty (control) vectors were then transfected into the Phoenix retroviral 
packaging cell line using FuGene (Roche, Indianapolis). After 48 hours stably 
transfected cells were selected by incubating with 2.5 μg/ml puromycin. Stably 
transfected clones were then picked 4-7 days later and grown to confluence in 25cm
2
 
flasks. After incubation in fresh medium for an additional 2 days, stably transfected 
cells were selected with puromycin for 2 days. 
4.2.7 Infection of RAW264.7 cells with c-fos expressing retroviruses 
Raw264.7 cells were added to the wells of 96 well plates (2x10
4
 cells/well) containing 
thermonax coverslips or slices of devitalized bovine bone and cultured for 24 hours 
prior to infection. Medium was then removed and replaced with filtered (0.45μm) 
supernatant from pBabe-cfos or pBabe-empty virus-producing Phoenix cells in the 
presence of 8μg/ml polybrene. Cultures were then incubated for 16 hours before the 
addition the treatment. After incubation for a further two days stably infected cells were 
selected by the addition of puromycin (2.5 μg/ml) for two days. Cells were then stained 
for TRAP and bone resorption as described earlier. To examine the effect of pBabe-cfos 
on NFATc1 expression, Raw264.7 cells were seeded into 25cm
2 
flasks and then 
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incubated with supernatant from pBabe-cfos or pBabe-empty virus-producing Phoenix 
cells in the presence of 8μg/ml polybrene. Cultures were then incubated for 16 hours 
before the addition of TNF-α (50ng/ml) with or without genistein (10-7M), daidzein (10-
5
M) or coumestrol (10
-7 M) in the presence of puromycin (2.5 μg/ml) for 48 hours. Total 
RNA was then isolated and NFATc1 levels determined by quantitative PCR as 
described above. 
4.2.8 Statistical analysis 
Differences between groups were assessed using Fisher’s one way analysis of variance 
(Statview; Abacus concepts, USA) or Student’s t-test as appropriate. A difference of 
p<0.05 was considered statistically significant. 
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4.3 Results 
4.3.1 Genistein, coumestrol and daidzein suppress TNF-α-induced osteoclast 
differentiation and bone resorption 
All PEs at 10
-4 
M significantly reduced cell viability whereas lower concentrations had 
no detrimental effect on proliferation (Figure 4.4) and for this reason subsequent 
experiments on osteoclast formation used PEs concentrations from 10
-5
 to 10
-9 
M.   
TNF-α directly stimulated the formation of strongly TRAP positive mononuclear and 
multinuclear osteoclasts within four days, which similar to previous findings readily 
formed resorption pits on bone slices (Figure 4.1A) (Fuller et al., 2002). Genistein, 
coumestrol and daidzein all directly suppressed TNF-α-induced osteoclast formation 
and bone resorption. Genistein at 10
-7
M significantly reduced TNF-α-induced osteoclast 
formation (11% of TNF-α treated group, 10-7 M; P<0.001) (Figure 4.1A) and inhibited 
TNF-α-induced bone resorption (19% of TNF-α treated group) (Figure 4.1B). Similar 
suppressive effects on osteoclast formation and resorption were noted with 10
-7 
M 
coumestrol (TRAP positive osteoclast formation 12% of TNF-α treated group, bone 
resorption area 22% of TNF-α treated group) (Figures 4.2 A&B). In contrast only the 
highest concentration of daidzein (10
-5 
M) suppressed osteoclast formation and bone 
resorption (TRAP positive osteoclast formation 13% of TNF-α treated group, bone 
resorption area 74% of TNF-α treated group) (Figures 4.3 A&B). In addition, anti-
osteoclastic concentrations of genistein, coumestrol and daidzein also significantly 
reduced TRAP expression in cultures of mature TNF-α-induced osteoclasts (Table 4.2). 
To determine if the anti-osteoclastic effect of PEs was mediated through an ER 
dependent mechanism cells were cultured in the presence of the E2 antagonist ICI 
182,780. ICI 182,780 prevented the suppressive action of genistein (10
-7 
M), coumestrol 
(10
-7 
M) and daidzein (10
-5 
M) on TNF-α-induced bone resorption and TRAP positive 
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osteoclast formation (Figure 4.1, 4.2, 4.3), suggesting that PEs suppress TNF-α-induced 
osteoclastogenesis via an ER dependent mechanism. In addition, in the presence of ICI 
182,780 genistein and coumestrol (10
-5
-10
-6 
M) also displayed a pro-osteoclastic effect, 
significantly augmenting TNF-α-induced osteoclast formation and bone resorption 
(Figure 4.1, 4.2, 4.3). In contrast, daidzein had no augmentative action on osteoclast 
differentiation or bone resorption at any concentration in the presence or absence of ER 
antagonist. Thus, genistein and coumestrol possess multiple antagonistic actions on 
osteoclast formation; however it is clear that when ER signalling is intact the anti-
osteoclastic action counteracts any potential pro-osteoclastic effect. Therefore all PEs 
studied only displayed a suppressive effect on TNF-α-induced osteoclast differentiation 
when delivered in isolation. 
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Figure 4.1. Genistein (10
-7 
M) significantly reduced TNF-α-induced TRAP positive osteoclast 
formation (A) and bone resorption (B), which was prevented by the ER antagonist ICI 182,780 
(solid grey bars). In the presence of ICI 182,780 higher concentrations of genistein (10
-5
, 10
-6 
M) 
increased osteoclast formation and bone resorption. RAW264.7 cells treated with TNF-α 
(50ng/ml) and phytoestrogens (10
-5
-10
-9 
M), and after four days TRAP-positive cells was 
scored, while the percentage of bone surface displaying resorption pits was analysed after eight 
days. Values are expressed as the mean ± SEM of three separate experiments n=18, * P< 0.05 
versus TNF-α treated group. 
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Figure 4.2. Coumestrol (10
-7
M) significantly reduced TNF-α-induced TRAP positive osteoclast 
formation (A) and bone resorption (B), which was prevented by the ER antagonist ICI 182,780 
(solid grey bars). In the presence of ICI 182,780 higher concentrations of genistein (10
-5
, 10
-6 
M) 
increased osteoclast formation and bone resorption. RAW264.7 cells treated with TNF-α 
(50ng/ml) and phytoestrogens (10
-5
-10
-9 
M), and after four days TRAP-positive cells was 
scored, while the percentage of bone surface displaying resorption pits was analysed after eight 
days. Values are expressed as the mean ± SEM of three separate experiments n=18, * P< 0.05 
versus TNF-α treated group. 
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Figure 4.3. Daidzein (10
-5 
M) significantly reduced TNF-α-induced TRAP positive osteoclast 
formation (A) and bone resorption (B), which was prevented by the ER antagonist ICI 182,780 
(solid grey bars). RAW264.7 cells treated with TNF-α (50ng/ml) and phytoestrogens (10-5-10-9 
M), and after four days TRAP-positive cells was scored, while the percentage of bone surface 
displaying resorption pits was analysed after eight days. Values are expressed as the mean         
± SEM of three separate experiments n=18, * P< 0.05 versus TNF-α treated group. 
 
T
R
A
P
 p
o
s
it
iv
e
 c
e
ll
s
 (
c
m
2
)
0
1000
2000
3000
4000
Plus ICI 182,780
*
Control TNF
Dai
-5M
Dai
-6M
Dai
-8M
Dai
-9M
Dai
-7M
TNF TNF TNF TNF TNF
B
o
n
e
 r
e
s
o
rp
ti
o
n
 (
%
)
0.0
0.1
0.2
0.3
0.4
0.5
*
Control TNF
Dai
-5M
Dai
-6M
Dai
-8M
Dai
-9M
Dai
-7M
TNF TNF TNF TNF TNF
A
B
                                                                                         Chapter 4 
 
111 
 
Table 4.2. PEs significantly reduced the number of TRAP positive mature osteoclasts. TNF-α 
50 ng/ml, genistein (10
-7 
M), coumestrol (10
-7 
M), daidzein (10
-5 
M) * P<0.05 versus TNF-α.  
 
Groups  
TRAP positive cells 
(cm2) 
TRAP positive cells 
(cm2) + ICI 182,780 
 Mean SEM Mean SEM 
Control 0 0 0 0 
TNF-α  317 55 296 42 
Genistein and TNF-α 14
*
 8 238 34 
Coumestrol and TNF-α 0
*
 0 250 63 
Daidzein and TNF-α 160
*
 35 307 42 
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4.3.2 Anti-osteoclastic concentrations of PEs have no effect on cell viability or 
apoptosis 
I then went on to determine the cellular and molecular mechanism through which 
genistein, coumestrol and daidzein suppressed TNF-α-induced osteoclast formation. As 
shown in (Figure 4.4) anti-osteoclastic PE concentrations (genistein 10
-7 
M, daidzein 10
-
5 
M and coumestrol 10
-7 
M) had no detrimental effect on cell viability and an increase in 
cell number was noted with genistein (10
-6
 to 10
-7 
M), coumestrol (10
-5
 to 10
-7
M) and 
daidzein (10
-6
 to 10
-7 
M). Furthermore, caspase 3/7 activity was also unaffected by these 
concentrations (Figure 4.5), suggesting that the reduction in osteoclast formation and 
activity noted was mediated via an action on osteoclast differentiation. 
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Figure 4.4. Genistein, coumestrol and daidzein (10
-4 
M) significantly decreased RAW264.7 cell 
viability after four days of incubation. All other concentrations had no detrimental effect on 
monocyte number. RAW264.7 cells treated with TNF-α (50ng/ml) and phytoestrogens (10-4-10-9 
M), and after four days, the number of viable cells was quantified using an MTS assay. Values 
are expressed as the mean ± SEM of 3 separate experiments n=18, * P< 0.05 versus TNF-α 
treated group. 
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Figure 4.5. Anti-osteoclastic concentrations of PEs had no effect on monocyte caspase 3/7 
activity. Values are expressed as the mean ± SEM mean from five replicate experiments. 
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4.3.3 Genistein, coumestrol and daidzein suppress the expression of regulators of 
osteoclast differentiation 
Osteoclast differentiation is controlled by a network of signalling factors that regulate 
the expression of genes typical of osteoclasts such as TRAP and DC-STAMP. Central to 
this is the c-fos dependent induction of NFATc1 expression. Mice deficient in either 
NFATc1 or c-fos lack osteoclasts and are severely osteopetrotic as a consequence. 
Evidence also suggests that NFATc1 is sufficient stimulus on its own to promote 
osteoclast formation (Matsuo et al., 2004). Therefore to determine the effect of PEs on 
this master regulatory system I analysed changes in c-fos and NFATc1 expression using 
real time quantitative PCR. TNF-α induced a significant 3.82-fold increase in NFATc1 
expression and a significant 2.82- fold increase in c-fos expression within 48 hours 
(Figure 4.6A & 4.7A). TNF-α-induced NFATc1 and cfos expression was significantly 
suppressed in the presence of concentrations of genistein (10
-7
M) (Figure 4.6 A & B), 
coumestrol (10
-7 
M) (Figure 4.7 A&B) or daidzein (10
-5 
M) (Figure 4.8 A & B) shown 
to reduce osteoclast formation and bone resorption in my earlier experiments. These 
values were not significantly different from non-treated control. No other concentrations 
had any significant inhibitory effect. The suppressive action of genistein, coumestrol 
and daidzein was prevented by ICI 182,780 suggesting that the reduction in mRNA 
expression was ER dependent. In keeping with the decrease in NFATc1 mRNA 
expression genistein, coumestrol and daidzein also suppressed TNF-α-induced NFATc1 
nuclear translocation as shown by a significant reduction in the number of nuclei 
displaying TNF-α-induced NFATc1 immunostaining (Figure 4.9). 
Interestingly, in the presence of ICI 182,780 genistein and coumestrol (10
-5
 to 10
-6 
M) 
significantly augmented TNF-α-induced NFATc1 expression again suggesting that high 
concentrations of these compounds have additional ER independent actions (Figure 
4.6A, 4.7A). However in keeping with the changes in osteoclast differentiation and 
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bone resorption described earlier no augmentation of NFATc1 expression was noted in 
the absence of ICI 182,780, suggesting that genistein’s and comestrol’s ER-mediated 
inhibitory action negates any stimulatory effect. Furthermore, no increase in c-fos 
expression was noted with any combination of PEs and E2 antagonist suggesting that 
the increase in NFATc1 expression generated by high concentrations of genistein and 
coumestrol was not mediated via changes in c-fos transcription or turnover.  
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Figure 4.6. TNF-α-induced NFATc1 (A) and c-fos (B) expression is suppressed by genistein  
(10
-7 
M) in an ER dependent manner. RAW264.7 cells were incubated in combinations of TNF-
α (50ng/ml), genistein (10-5-10-9 M) in the presence or absence of ICI 182,780 and after four 
days the expression of NFATc1 and c-fos was then assessed by quantitative real time PCR. Data 
is expressed normalized to 10
6
 copies of β-actin and represent the mean ± SEM from three 
separate experiments. * P<0.05 versus TNF-α treated group. 
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Figure 4.7. TNF-α-induced NFATc1 (A) and c-fos (B) expression is suppressed by coumestrol 
(10
-7 
M) in an ER dependent manner. RAW264.7 cells were incubated in combinations of TNF-
α (50ng/ml), coumestrol (10-5-10-9 M) in the presence or absence of ICI 182,780 and after four 
days the expression of NFATc1 and c-fos was then assessed by quantitative real time PCR. Data 
is expressed normalized to 10
6
 copies of β-actin and represent the mean ± SEM from three 
separate experiments. * P<0.05 versus TNF-α treated group. 
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Figure 4.8. TNF-α-induced NFATc1 (A) and c-fos (B) expression is suppressed by daidzein (10-
5  
M) in an ER dependent manner. RAW264.7 cells were incubated in combinations of TNF-α 
(50ng/ml), daidzein (10
-5
-10
-9 
M) in the presence or absence of ICI 182,780 and after four days 
the expression of NFATc1 and c-fos was then assessed by quantitative real time PCR. Data is 
expressed normalized to 10
6
 copies of β-actin and represent the mean ± SEM from three 
separate experiments. * P<0.05 versus TNF-α treated group. 
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Figure 4.9. NFATc1 immunofluorescent staining in RAW264.7 cells cultured for 24 or 48 hours 
in the presence of combinations of TNF-α, genistein, coumestrol or daidzein. PEs reduced the 
intensity of TNF-α-induced NFATc1 cytoplasmic staining and significantly reduced the number 
of cells displaying NFATc1 nuclear localization. * P<0.05 versus TNF- α-treated group. 
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While c-fos and NFATc1 are master regulators of osteoclast differentiation, other 
signalling pathways have been shown to modify osteoclast differentiation. Therefore, to 
determine the potential role of these pathways, I examined the effect of anti-osteoclastic 
concentrations of genistein, coumestrol and daidzein on p38 and NFκB expression. 
TNF-α-induced a significant 3.8 fold increase in NF-κB expression within 24 hours 
(Figure 4.10) which was prevented in the presence of genistein (10
-7 
M), coumestrol        
(10
-7 
M) or daidzein (10
-5 
M) in an ER dependent manner (Figure 4.10). In contrast anti-
osteoclastic concentrations of PEs had no effect on TNF-α-induced p38 expression 
(Table 4.3). In addition to changes in transcription factor levels I also noted a significant 
inhibitory action on the expression of the essential regulator of osteoclast aggregation 
and fusion DC-STAMP. TNF-α induced a significant 4.3 fold increase in DC-STAMP 
expression 48 hours after stimulation, which was prevented in the presence of genistein 
(10
-7 
M), coumestrol (10
-7 
M) or daidzein (10
-5 
M) (Table 4.3). 
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 Figure 4.10. Genistein, coumestrol and daidzein inhibit NFkB expression. RAW264.7 cells 
were incubated in combinations of TNF-α (50ng/ml), genistein, coumestrol or daidzein (10-5-10-
9
 M) and then mRNA expression was assessed after four days of treatment by quantitative real 
time PCR. Data expressed normalized to 10
6
 copies of β-actin and represent the mean ± SEM 
from three separate experiments. * P<0.05 versus TNF-α treated group. 
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Table 4.3. Genistein, coumestrol and daidzein inhibit DC-STAMP but not p38 expression. 
RAW264.7 cells were incubated in combinations of TNF-α (50ng/ml), genistein (10-5 M), 
coumestrol (10
-7 
M) or daidzein (10
-5 
M) and then mRNA expression was assessed by 
quantitative real time PCR. Data expressed normalized to 10
6
 copies of β-actin and represent the 
mean ± SEM from three separate experiments. a P<0.05 versus TNF-α treated group. 
  
P38 mRNA copies 
per 10
6 β-actin copies 
DC-STAMP mRNA 
copies per 10
6
 β-actin 
copies 
 Mean SEM Mean SEM 
Control 10535 1239 3026 368 
TNF-α 18577 2314 12994 3040 
Genistein and TNF-α 18258 2629 7064 
a
 1696 
Coumestrol and TNF-α 15775 1059 5658
 a
 355 
Daidzein and TNF-α 19550 2254 9207 
a
 1642 
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4.3.4 Retroviral c-fos expression prevents the inhibitory effect of PEs on TNF-α- 
induced NFATc1 expression, osteoclast formation and resorption   
The initial stimulus for the cytoplasmic accumulation of NFATc1 is provided by c-fos. 
NFATc1 is subsequently activated by Ca
2+
 calmodulin dependent signals leading to 
nuclear translocation and auto-amplification of its expression. Without these separate 
stimuli insufficient NFATc1 levels are generated to promote osteoclast differentiation. 
The ability of PEs to substantially reduce c-fos expression raises the possibility that this 
represents a key molecular mechanism mediating their action on osteoclast formation. 
To assess this I generated monocytic precursors (c-fos-pBabe) expressing constitutively 
active c-fos under the control of a retroviral expression vector and exposed them to 
concentrations of PEs shown to suppress osteoclast formation in my earlier 
experiments. This study found that retroviral driven c-fos expression increased basal 
NFATc1 mRNA levels 3.25-fold and led to a significant 4-fold increase in TNF-α-
induced NFATc1 expression (Figure 4.11).  
Moreover, constitutive c-fos expression prevented the inhibitory effect of anti-
osteoclastic concentrations of PEs on TNF-α-induced osteoclastogenesis and bone 
resorption (Figures 4.12), suggesting that PEs suppress TNF-α-induced osteoclast 
formation through a c-fos dependent action. 
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Figure 4.11. Constitutive c-fos expression prevents the anti-osteoclastic effects of PEs on TNF-
α-induced NFATc1 expression. RAW 264.7 cells were infected with control or c-fos (c-fos 
pBabe) expressing retroviruses and the effect of TNF-α (50 ng/ml), genistein (10-7 M), 
coumestrol (10
-7 
M) and daidzein (10
-5 
M) on NFATc1 expression was examined. Experiments 
were performed in triplicate. 
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Figure 4.12. Constitutive c-fos expression prevents the anti-osteoclastic effects of PEs on   
TNF-α -induced osteoclast formation and bone resorption. RAW 264.7 cells were infected with 
control or c-fos (c-fos pBabe) expressing retroviruses and the effect of TNF-α (50 ng/ml), 
genistein (10
-7 
M), coumestrol (10
-7 
M) and daidzein (10
-5 
M) on TRAP positive osteoclast 
formation and bone resorption was examined. Experiments were performed in triplicate. 
  
B
on
e 
su
rf
ac
e 
re
so
rb
ed
 (
%
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Genistein
Daidzein
Coumestrol
TNF
c-fos pBabe
 -        +      +      +      +                -       +      +       +      +
 -        -    10-7M  -       -                -        -    10-7M   -      -
 -        -       -   10-5M   -                -        -      -    10-5M  -
 -        -        -      -    10-7M           -        -      -       -     10-7M
-        -       -       -       -                +       +      +       +      +
T
R
A
P
 p
os
iti
ve
 c
el
ls
 (
cm
2
)
0
50
100
150
200
250
300
350
Genistein
Daidzein
Coumestrol
TNF
c-fos pBabe
p<0.0001
p=0.01
p=0.0007
Non significant
0 0
 -        +       +      +      +                -       +       +       +      +
 -        -     10-7M  -       -                -        -     10-7M   -      -
 -        -       -   10-5M   -                 -        -       -    10-5M  -
 -        -        -      -    10-7M            -        -       -       -     10-7M
-        -        -       -       -                +       +       +       +      +
Non significantp=0.017
p=0.03
p=0.01
                                                                                         Chapter 4 
 
127 
 
4.4 Discussion 
An increasing body of evidence implicates TNF-α-induced osteoclast formation in post-
menopausal and inflammatory bone loss. TNF-α directly stimulates the formation of 
resorptive osteoclast from human monocytes in the presence of OPG (Kudo et al., 
2002), whereas blockade of TNF-α using a range of biological agents reduces osteoclast 
number and prevents bone destruction in-vivo (Barnabe and Hanley, 2009). Therefore, 
an understanding of how potential antiresorptive therapies such as PEs modify TNF-α-
induced osteoclastogenesis is essential. Genistein, coumestrol and daidzein have 
previously been shown to suppress RANKL-induced osteoclast differentiation (Gao and 
Yamaguchi, 1999b, Garcia Palacios et al., 2005, Rassi et al., 2002). Comparable 
concentrations of these PEs also reduced TNF-α-induced osteoclast differentiation and 
bone resorption in my study, with genistein and coumestrol having a more potent effect 
than daidzein. This anti-osteoclastic action was mediated via a direct effect on 
monocyte differentiation and not via in-direct osteoblastsic actions as suggested in 
previous studies using mixed cell populations (Chen et al., 2003a). Genistein, 
coumestrol and daidzein also directly reduced TRAP expression in mature TNF-α-
induced resorptive osteoclasts. These results strengthen the data for the use of PEs as 
agents in the treatment of post-menopausal bone loss and inflammatory osteolytic 
diseases where they may suppress TNF-α-induced osteoclast formation and resorptive 
activity. 
Serum concentrations of PEs vary between populations with Asians having significantly 
higher levels than Westerners (Morton et al., 2002). This has been suggested to 
contribute to the lower incidence of osteoporotic fractures in Asian women. 
Interestingly, the antiresorptive concentration of genistein and coumestrol noted in my 
study is similar to levels measured in Asian populations but higher than those achieved 
by Western diets (Morton et al., 2002). In contrast, both Asian and Western diets are 
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unable to generate serum concentrations of daidzein similar to those shown to suppress 
TNF-α-induced osteoclastogenesis in my studies. However, these concentrations could 
be achieved with daidzein supplementation which generates tissue levels several orders 
of magnitude higher than dietary sources (Gardner et al., 2009). The antiresorptive 
effect of genistein and coumestrol was noted over a narrow concentration range with 
doses higher or lower than this having no effect on differentiation or resorption. This 
response likely reflects antagonistic interactions between genistein’s and coumestrol’s 
multiple biological actions. For instance in addition to its classical oestrogenic effect 
genistein also inhibits tyrosine kinase activity (Aggarwal and Shishodia, 2006) and 
alters redox states which are known to have a bimodal effect on osteoclast formation 
(Kim et al., 2006). Similarly, coumestrol activates MAPK activity which promotes 
osteoclast differentiation (Jeng et al., 2009). Furthermore, the ER-independent actions 
of genistein and coumestrol tend to have higher EC50, thus it is conceivable that while 
concentrations of 10
-7 
M stimulate ER dependent anti-osteoclastic actions higher 
concentrations activate antagonistic non-oestrogenic effects that promote osteoclast 
formation and bone resorption. This assertion is strengthened by the increase in 
osteoclast formation and resorption noted when ER signalling was inhibited with ICI 
182,780 at higher concentrations of coumestrol and genistein (10
-5
 to 10
-6 
M). These 
concentrations also promoted NFATc1 expression in the presence of E2 antagonist 
indicating that increased osteoclast number most likely resulted from enhanced levels of 
this key osteoclastic transcription factor. In contrast, daidzein which acts exclusively via 
ER did not augment osteoclast formation, bone resorption or NFATc1 expression in the 
presence of ICI 182,780 at any concentration examined. The precise nature of the ER 
independent action which augments NFATc1 transcription is unclear but would not 
appear to be mediated via an increase in c-fos or NFκB expression as neither genistein 
nor coumestrol increased levels of these transcription factors. Furthermore, while ICI 
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182,780 prevented the suppressive action of all PEs there is a possibility that other ER-
independent actions may still have a role in the inhibitory effect. 
Importantly, while coumestrol and genistein appear to possess pro and anti-resorptive 
actions my data suggests that the antiresorptive action predominates with no 
augmentative effect apparent when ER signalling is intact. Genistein and coumestrol 
could therefore be used at relevant doses to decrease resorption in post-menopausal 
osteoporosis or inflammatory osteolysis with little theoretical chance of them enhancing 
resorption if this dose was exceeded. However, it does indicate caution in the use of 
genistein and coumestrol as antiresorptive agents in women with ER-positive breast 
tumours that have preferentially metastasized to the skeleton. ER antagonists are often 
prescribed to these patients to reduce fracture risk and therefore in this setting high 
doses of genistein and coumestrol could potentially augment tumour associated 
osteolysis and increase the occurrence of skeletal related events. 
Previous data suggest that PEs suppress RANKL-induced osteoclastogenesis by 
enhancing precursor apoptosis and disrupting intracellular signals regulating osteoclast 
differentiation (Gao and Yamaguchi, 1999b, Garcia Palacios et al., 2005, Rassi et al., 
2002, Uchiyama and Yamaguchi, 2007). In contrast my data suggest that their 
suppressive action on TNF-α-induced osteoclast formation is predominantly mediated 
via an effect on differentiation with no impact on viability or apoptosis. This may relate 
to differences in the strength of survival signals stimulated by TNF-α and RANKL. 
Evidence suggests that TNF-α but not RANKL is able to induce levels of anti-apoptotic 
factors, such as Bcl-xL, sufficient to induce resistance to subsequent apoptotic stimuli 
(Zhang et al., 2005). In keeping with this antiresorptives such as alendronate and 
pamidronate are relatively ineffective at preventing focal inflammatory bone loss in 
rheumatoid arthritis where high TNF-α levels are the predominate resorptive driver 
(Lodder et al., 2003). Alternatively, the PEs examined in my studies may induce 
                                                                                         Chapter 4 
 
130 
 
apoptosis via a TRAF6 mediated action, which would be expected to modify RANKL 
but not TNF-α-induced survival signals. Whatever the answer it is clear that unlike their 
dual suppressive action on RANKL-induced osteoclastogenesis the predominant effect 
of PEs on TNF-α-induced resorption is mediated via suppression of osteoclast 
differentiation.  
TNF-α-induced osteoclastogenesis is dependent on the coordinated expression of 
transcription factors that drive differentiation along the osteoclast lineage. Pivotal to this 
is NFATc1 which has been suggested to be sufficient for osteoclast formation due to its 
ability to promote expression of osteoclastic genes such as TRAP and DC-STAMP 
(Matsuo et al., 2004). NFATc1 displays a biphasic expression pattern during 
osteoclastogenesis; initially there is a small cytoplasmic increase followed by a larger 
increase in expression after nuclear translocation and autoregulation of its own gene. 
These processes are controlled by separate signals, cytoplasmic expression is c-fos 
dependent whereas nuclear accumulation is Ca
2+ 
calmodulin dependent (Grigoriadis et 
al., 1994). In addition auto-amplification of NFATc1 expression is dependent on the 
presence of c-fos to stabilize NFATc1’s interaction with its own promoter (Asagiri et 
al., 2005). This places c-fos centrally in the regulation of NFATc1 and osteoclast 
differentiation. My studies suggest that genistein, coumestrol and daidzein may directly 
inhibit osteoclast differentiation by suppressing c-fos levels. The mechanism leading to 
a reduction in c-fos transcription is uncertain, but this could arise as a consequence of a 
direct ER mediated effect on the c-fos gene or indirectly via modification of an 
upstream regulator. The PEs-induced reduction in c-fos would in turn be expected to 
prevent NFATc1 reaching levels sufficient to enable osteoclast differentiation, 
maintaining precursors in a non-committed state or allowing them to differentiate 
towards alternative macrophage lineages. This conclusion is strengthened by the 
inability of all PEs to inhibit osteoclast formation and bone resorption in cells 
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constitutively expressing high levels of c-fos. However, while it is clear that c-fos 
suppression is associated with the inhibitory action of PEs the levels generated by 
retroviral constructs are likely to be higher than those induced by TNF-α and may not 
therefore represent a physiological response. 
While previous studies noted similar actions of genistein on NFATc1 expression during 
RANKL-induced osteoclast formation (Uchiyama and Yamaguchi, 2007); this to my 
knowledge is the first report of an inhibitory effect of coumestrol, genistein or daidzein 
on monocytic c-fos expression. This is also the first report of an action of these 
compounds on DC-STAMP. DC-STAMP has a key role in later stages of osteoclast 
differentiation, its expression is elevated on mononuclear osteoclasts and it is enables 
their subsequent aggregation and fusion to form large multinuclear osteoclast. Mice 
lacking DC-STAMP develop a mild osteopetrosis and have no multinuclear osteoclasts 
(Kukita et al., 2004, Miyamoto, 2006). The PE-induced reduction in DC-STAMP most 
likely occurs as a secondary consequence of decreased NFAT and c-fos expression 
which would be expected to lower DC-STAMP promoter activity (Yagi et al., 2007). 
In conclusion, genistein, coumestrol and daidzein directly suppressed TNF-α induced 
osteoclast formation and bone resorption. The concentration of genistein and coumestrol 
required to suppress resorption are achievable by diets containing high soy content, 
whereas to achieve effective daidzein levels would require dietary supplementation. The 
anti-osteoclastic action is at least in part mediated by suppression of c-fos expression in 
osteoclast precursors which would prevent nuclear accumulation of NFATc1 a key 
regulator of osteoclast formation. These results provide further evidence that PEs are 
potential therapeutic candidates in the prevention of bone loss associated with aberrant 
TNF-α levels in post-menopausal osteoporosis and inflammatory osteolysis. 
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5.1 Introduction 
The skeleton constantly remodels in response to changes in mechanical load, serum 
calcium and micro-damage (Martin and Seeman, 2008, Henriksen et al., 2009). This 
dynamic process generates a bone mass and structure optimised to current physical and 
mineral requirements. At a cellular level, remodelling is performed by osteoblasts that 
secrete and mineralise new bone matrix and osteoclasts that resorb bone. Osteoblasts 
and osteoclasts activity is tightly regulated such that during each remodelling cycle 
osteoblasts formation is temporally coupled to resorption ensuring there is little net 
bone loss. However, this balance is disrupted in many skeletal disorders such as post-
menopausal osteoporosis and osteomyelitis (Manolagas et al., 2002, Nair et al., 1996). 
In post-menopausal women the reduction in circulating E2 increases bone turnover and 
skews remodelling in favour of osteoclastic resorption (Manolagas et al., 2002). The 
resulting bone loss increases fracture risk at elements with a high trabecular content 
such as the femoral neck and distal radius and ulna. 
HRT has been shown to prevent the increase in osteoclast formation and thereby reduce 
fracture risk (Writing Group for the Women's Health Initiative Investigators, 2002). 
HRT also has an anabolic action increasing bone formation and volume in rats and 
humans (Khastgir et al., 2003, Chow et al., 1992). This contrasts with other 
antiresorptive drugs, such as bisphosphonates, which typically only suppress osteoclast 
activity. However, the widespread use of HRT has been re-assessed in light of large 
scale clinical trials that showed a substantial increase in the risk of breast cancer and 
coronary heart disease in older women prescribed combination HRT (Writing Group for 
the Women's Health Initiative Investigators, 2002). Therefore, several alternative 
compounds with oestrogenic actions have been examined for their antiresorptive and 
anabolic potential, these include PEs. Some epidemiological studies suggest that diets 
with high PE content such as soy rich diets may generate a more robust skeleton. A 
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positive association between soy consumption and BMD has been noted in Asians (Mei 
et al., 2001, Horiuchi et al., 2000, Kim et al., 2002a) and supplements have also been 
shown to have beneficial effects on BMD (Alekel et al., 2000, Morabito et al., 2002, 
Atkinson et al., 2004, Wu et al., 2006). Genistein has also been shown to increase the 
expression and activity of the osteoblastsic marker ALP, alter the OPG and RANKL 
expression by osteoblasts (Sugimoto and Yamaguchi, 2000a). Moreover, genistein (10
-
6
-10
-7 
M) increased osteoblast formation in preosteoblastsic KS483 cells via an ER-
dependent mechanism (Dang et al., 2002). However, not all studies note a positive 
effect at all skeletal sites and efficacy varies depending on the PEs and dose studied 
(Ricci et al., 2010)  
The protective effect of PEs is thought to occur through a combination of osteoclast and 
osteoblast mediated actions. Several studies note decreases in resorption markers 
following PEs supplementation (Mei et al., 2001, Weaver et al., 2009) and in-vitro 
studies show a direct suppressive effect of PEs on cytokine-induced osteoclast 
differentiation (Karieb and Fox, 2011, Gao and Yamaguchi, 1999b). In addition to 
suppressing resorption, PEs have also been shown to increase bone formation markers 
such as serum ALP and osteocalcin levels in post-menopausal women (Morabito et al., 
2002, Roudsari et al., 2005). Genistein has also been shown to increase mineral 
apposition and bone formation rates in ovariectomised rats (Dai et al., 2008) and PEs 
stimulate osteoblast differentiation and mineralisation in-vitro (Kanno et al., 2004, 
Yadav et al., 2011, Wu et al., 2009).  
In addition, other nutritional factors have been shown to influence remodelling activity. 
Zn
2+
 promotes osteoblasts activity in-vitro (Kwun et al., 2010). Zn
2+
 deficiency is 
associated with osteopenia in men (Hyun et al., 2004) and Zn
2+
 supplements prevent 
exercise-induced falls in long bone mass in rats (Seco et al., 1998). Osteoclast activity is 
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also decreased by Zn
2+
 (Yamaguchi and Uchiyama, 2004, Uchiyama and Yamaguchi, 
2007). The ability of dietary factors to not only prevent further bone resorption but 
replace bone already lost is desirable; however studies have not fully examined the 
effect of combinations of dietary factors on bone cell differentiation and activity. 
Similarly, the effect of these factors on osx mRNA expression which regulates the 
formation of mature osteoblasts has not been investigated. Therefore, this study 
examined the effect of genistein, coumestrol and daidzein in the presence of Zn
2+
 on 
osteoblast and osteoclast differentiation, function and bone matrix formation in-vitro. 
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5.2 Material and methods  
5.2.1 Cell culture 
SaoS-2 human osteoblast like cells were obtained from ECACC, Porton Down, UK 
(ECACC cat. num. 89050205) and cultured in phenol red free RPMI1640 supplemented 
with 10% charcoal stripped foetal calf serum (Autogen Bioclear, UK), 2 mmol/l 
glutamine, 100 IU/ml benzylpenicillin and 100 mg/ml streptomycin (all from Sigma, 
UK). RAW264.7 monocytes (ATCC, UK, cat. num. TIB-71) were incubated in phenol 
red free Dulbecco’s minimum essential medium supplemented with 10% charcoal 
stripped foetal calf serum (Autogen Bioclear, U.K.), 2 mmol/l glutamine, 100 IU/ml 
benzylpenicillin and 100 mg/ml streptomycin (all from Sigma, UK). All incubations 
were performed at 37
o
C in 5% CO2, and cultures fed every 2–3 days by replacing half 
of the culture volume with fresh medium. Zinc sulfate heptahydrate (zinc) was obtained 
from Sigma (Poole, Dorset, UK). The non-selective E2 antagonist ICI 182,780 was 
obtained from Tocris Biosciences (Bristol, UK). Recombinant murine TNF-α was 
purchased from Insight Biotechnology (Wembley, UK). All other reagents and kits were 
obtained from Sigma (Poole, Dorset, UK) unless stated. 
5.2.2 Measurement of mineralisation and alkaline phosphatase (ALP) activity 
Preliminary studies established that concentrations of zinc sulphate less than 10
-5 
M 
showed no interaction with PEs. All subsequent studies therefore used zinc at a 
concentration of 10
-5
 M. The effect of coumestrol, daidzein and genistein (10
-5
 to 10
-9 
M) 
in the presence or absence of zinc sulphate (10
-5 
M) on ALP activity was assessed as 
described in chapter three (3.8). SaoS-2 cells were incubated in 96 well plates with 
relevant treatments in the presence of β-glycerophosphate (β-GP) (10 mM) and L-
ascorbic acid (L-AA) (50 mg/l) for four days. ALP activity was measured by staining 
cultures with p-nitrophenyl phosphate (1 mg/ml) and the absorbance was measured at 
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405 nm and results were then normalised to total cell number and expressed as the 
amount of ALP required to liberate 1 mmol of p-nitrophenol / min / 10
4
 cells.  
Mineralisation was assessed using a modification of Hale’s methodology (Hale et al., 
2000) by measuring calcein incorporation as described in chapter three (3.8). Briefly, 
cells were treated with β-GP (10 mM) and L-AA (50 mg/l) in the presence of genistein, 
daidzein or coumestrol (10
-5
-10
-9 
M) with or without zinc sulphate (10
-5
M). After 18 
days of incubation the monolayer was incubated in culture medium containing 1 µg/ml 
calcein for four hours at 37ºC, and fluorescence measured by a cytofluor II fluorescence 
multiwell plate reader (Perseptive Biosystem, USA) at 485 nm excitation and 530 nm 
emission. 
5.2.3 Cell Proliferation 
SaoS-2 cells were cultured in 96 well plates at a density of 1x10
4
 cells per well in the 
presence of coumestrol (10
-5
 to 10
-9 
M), daidzein (10
-5
 to 10
-9 
M) or genistein (10
-5
 to 
10
-9 
M) with or without zinc sulphate (10
-5 
M) for 4 days. Proliferation was then 
assessed using a commercial AQueous one solution cell proliferation assay (Promega, 
UK) according to manufacturer’s instructions described in chapter three (3.6).  
5.2.4 Real time quantitative PCR analysis 
SaoS-2 cells (5 x 10
5 
per well) were incubated in 6 well plates for 24, 48 or 96 hours 
with coumestrol (10
-7 
M), genistein (10
-7
M) or daidzein (10
-5
M) with or without (10
-5
 M) 
of zinc sulphate. Total RNA was extracted from these cultures as described in chapter 
three (3.8.1) and reversed transcribed with M-MLV reverse transcriptase using random 
nonamer primers. Real time-PCR was performed on a StepOne PCR system (Applied 
Biosytems, UK) using the DNA-binding dye SYBR green. Primers used for each human 
transcription factor are shown in (Table 5.1). The generation of standard curves was 
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described in chapter three (3.8.2) using the corresponding cDNA and cloned into 
pGEM-T Easy (Promega, UK).  
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Table 5.1. Primer sequence of osteoblastsic transcriptional factors.  
Genes 5´-3´ Forward primer 3´-5´ Reverse primer 
β-Actin GCGCGGCTACAGCTTCACCA TGGCCGTCAGGCAGCTCGTA 
Runx2 AGACCCCAGGCAGGCACAGT GCGCCTAGGCACATCGGTGA 
Osterix GCACCCTGGAGGCAACTGGC GAGCTGGGTAGGGGGCTGGA 
Type I 
collagen 
CCTGGCAGCCCTGGTCCTGA CTTGCCGGGCTCTCCAGCAG 
Osteocalcin CCCAGCGGTGCAGAGTCCAG CCTCCCTCCTGGGCTCCAGG 
RANKL 
ACAGGCCTTTCAAGGAGCT 
GTGC 
ACCAGATGGGATGTCGGTGGC 
 
OPG AATCGCACCCACAACCGCGT 
AGCAGGAGACCAAAGACACTGC
A 
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5.2.5 Osteoclast differentiation and bone resorption assays 
To examine the direct effect of zinc on the anti-osteoclastic action of PEs, RAW264.7 
cells were transferred to 96-well plates at a density of 1x10
4
 cells per well. The effect of 
Zn
2+
 on the anti-resorptive action of PEs was assessed by seeding 10
4
 RAW264.7 cells 
onto 20mm
2
 slices of devitalised bovine bone in 96 well plates. Cells and bone slices 
were then incubated with combinations of TNF-α (50ng/ml), genistein (10-5 - 10-9M), 
daidzein (10
-5
 - 10
-9 
M) or coumestrol (10
-5 
-10
-9 
M) with or without zinc sulphate (10
-5
 
M) for four days for assessment of TRAP-positive osteoclast formation or eight days for 
bone resorption. Cells were stained for TRAP positive cells using naphthol AS-BI 
phosphate as a substrate as mentioned in chapter three (3.4). Bone resorption area was 
assessed in bone slices after staining with the protocol described in chapter three (3.5) 
and the percentage of bone resorbed was quantified by reflected light microscopy. All 
experiments were performed in triplicate.  
5.2.6 Statistical analysis  
Differences between groups were assessed using Fisher’s one way analysis of variance 
(Statview; Abacus concepts, USA) or Student’s t-test as appropriate. A difference of 
P<0.05 was considered statistically significant. 
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5.3 Results  
5.3.1 Zinc has no effect on the direct anti-osteoclastic action of phytoestrogens 
Excessive resorption is central to bone loss in several skeletal disorders including post-
menopausal osteoporosis. As has been shown previously, PEs possess antiresorptive 
actions, directly suppressing cytokine-induced osteoclast differentiation and bone 
resorption (Karieb and Fox, 2011). However, the effect of combinations of PEs and 
Zn
2+
 on this direct anti-osteoclastic action has not been examined. Thus to establish if 
the direct action of PEs is modified in the presence of other nutritional factors, 
RAW264.7 monocytes were cultured with genistein, coumestrol or daidzein and a 
concentration of Zn
2+
 shown in preliminary studies to modify the effect of PEs. As 
shown in the previous chapter, coumestrol, daidzein and genistein all significantly 
suppressed TRAP positive osteoclast formation and bone resorption. The dose response 
for the PEs matched previous results with maximal suppression noted with coumestrol 
(10
-7 
M), daidzein (10
-5 
M) and genistein (10
-7 
M). In contrast, TRAP positive osteoclast 
formation and bone resorption were unaffected in the presence of Zn
2+
 alone. 
Furthermore, the anti-osteoclastic action of all PEs was not affected by the addition of 
Zn
2+
 (Figures 5.1, 5.2, 5.3). 
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Figure 5.1. Zinc has no effect on the direct anti-osteoclastic action of genistein on TRAP cell 
formation (A) and bone resorption (B). RAW264.7 cells were incubated in the presence of 
TNF-α (50 ng/mL) for 4 days plus genistein (10-5-10-9 M) in the presence or absence of zinc  
(10
-5 
M). Osteoclast formation was assessed by TRAP staining, while bone resorption was 
determined by the percentage of bone surface displaying resorption pits analysed by reflected 
light microscopy. Values are expressed as mean (± SEM) of three separate experiments. 
Differences between groups were assessed by one-way analysis of variance. * Values were 
significantly different versus TNF-α treated group P < 0.05. 
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Figure 5.2. Zinc has no effect on the direct anti-osteoclastic action of coumestrol on TRAP cell 
formation (A) and bone resorption (B). RAW264.7 cells were incubated in the presence of 
TNF-α (50 ng/mL) for four days plus coumestrol (10-5-10-9 M) in the presence or absence of 
zinc (10
-5 
M).  Osteoclast formation was assessed by TRAP staining, while bone resorption was 
determined by the percentage of bone surface displaying resorption pits analysed by reflected 
light microscopy. Values are expressed as mean (± SEM) of three separate experiments. 
Differences between groups were assessed by one-way analysis of variance. * Values were 
significantly different versus TNF-α treated group P < 0.05. 
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Figure 5.3. Zinc has no effect on the direct anti-osteoclastic action of daidzein on TRAP cell 
formation (A) and bone resorption (B). RAW264.7 cells were incubated in the presence of 
TNF-α (50 ng/mL) for 4 days plus daidzein (10-5-10-9 M) in the presence or absence of zinc (10-5 
M). Osteoclast formation was assessed by TRAP staining, while bone resorption was 
determined by the percentage of bone surface displaying resorption pits analysed by reflected 
light microscopy. Values are expressed as mean (± SEM) of three separate experiments. 
Differences between groups were assessed by one-way analysis of variance. * Values were 
significantly different versus TNF-α treated group P < 0.05. 
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5.3.2 Zinc augments the suppressive action of PEs on osteoblastsic RANKL/OPG 
ratio 
PEs may also indirectly suppress osteoclast formation by modifying expression of the 
key osteoblasts derived regulators of osteoclastogenesis RANKL and OPG. To assess 
the effect of combinations of PEs and Zn
2+
 on RANKL and OPG mRNA ratio, I 
incubated osteoblasts with Zn
2+
 and the concentration of PEs shown to have the 
maximal suppressive effect on osteoclastogenesis. I found that RANKL/OPG expression 
ratio was significantly reduced by Zn
2+
 (4.16 fold), coumestrol (1.88 fold) and genistein 
(3.57 fold) in comparison to control. Furthermore, combinations of Zn
2+
 and genistein 
or coumestrol induced a further significant reduction in RANKL/OPG gene expression 
in comparison to Zn
2+
 or PEs alone (Figure 5.4). In contrast, although daidzein lowered 
RANKL/OPG expression this did not reach statistical significance and in the presence of 
daidzein the suppressive action of Zn
2+
 was not noted (Figure 5.4). 
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Figure 5.4. PEs and zinc suppressed the osteoblast derived stimulus for osteoclast formation. 
Human SaoS-2 cells were incubated with coumestrol (10
-7 
M), daidzein (10
-5
 M) or genistein 
(10
-7 
M) in the presence or absence of zinc (10
-5 
M). Total RNA was extracted and the 
expression of RANKL and OPG quantified by real time PCR. Data was normalized to β-actin 
and expressed as a ratio of RANKL to OPG expression in comparison to control. Values are 
expressed as a mean (± SEM) from two separate experiments. Differences between groups were 
assessed by one-way analysis of variance, * Values were significantly different versus control 
group P < 0.05, # values were significantly different versus zinc relevant PE treated group alone 
P < 0.05.  
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5.3.3 Zinc augments the stimulatory effect of PEs on osteoblasts mineralisation  
The effect of PEs and Zn
2+
 on mineralisation was assessed in cultures of SaoS-2 cells 
incubated in the presence of differentiation agents (L-AA and β-GP). Genistein, 
daidzein and coumestrol all enhanced mineralisation, with coumestrol having the most 
pronounced effect (Figure 5.6). Zn
2+
 alone had no significant effect on mineralisation as 
assessed by calcein incorporation into mineralised nodules. Coumestrol (10
-5
 to 10
-7
M) 
significantly enhanced osteoblastsic mineralisation with maximal effects noted at 10
-6 
M, 
which induced a 1.62 fold increase in mineralisation. Daidzein (10
-5
 to 10
-6 
M) also 
significantly enhanced mineralisation with a maximal 1.43 fold increase noted at 10
-5 
M 
(Figure 5.7). Genistein stimulated a significant 1.39 fold increase in calcein 
incorporation at the highest dose studied (10
-5 
M) (Figure 5.5). The addition of Zn
2+
 
augmented the anabolic effect of all PEs and significantly increasing mineralisation 
compared to cultures treated with PEs alone, coumestrol (10
-5
 to 10
-7 
M), daidzein (10
-5
 
to 10
-6 
M) and genistein (10
-5
 to 10
-7 
M).  
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Figure 5.5. Zinc augments the effect of genistein on osteoblasts mineralisation and 
differentiation.  SaoS-2 cells were incubated with genistein (10
-9
-10
-5 
M) with or without zinc 
(10
-5 
M) for 18 days. Mineralisation measured using calcein incorporation. Values are expressed 
as a mean (± SEM) from three experiments. Differences between groups were assessed by one-
way analysis of variance. * P < 0.05 versus (LAA+GP) group, # P<0.05 versus relevant PE 
treated group. 
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Figure 5.6. Zinc augments the effect of coumestrol on osteoblasts mineralisation and 
differentiation. SaoS-2 cells were incubated with coumestrol (10
-9
-10
-5 
M) with or without zinc 
(10
-5 
M) for 18 days. Mineralisation measured using calcein incorporation. Values are expressed 
as a mean (± SEM) from three experiments. Differences between groups were assessed by one-
way analysis of variance. * P < 0.05 versus (LAA+GP) group, # P<0.05 versus relevant PE 
treated group. 
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Figure 5.7. Zinc augments the effect of daidzein on osteoblasts mineralisation and 
differentiation. SaoS-2 cells were incubated with daidzein (10
-9
-10
-5 
M) with or without zinc 
(10
-5 
M) for 18 days. Mineralisation measured using calcein incorporation. Values are expressed 
as a mean      (± SEM) from three experiments. Differences between groups were assessed by 
one-way analysis of variance. * P < 0.05 versus (LAA+GP) group, # P<0.05 versus relevant PE 
treated group. 
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5.3.4 PEs augment bone mineralisation by an ER-dependent mechanism  
To assess whether the augmentative action of genistein, coumestrol and daidzein was 
mediated by an E2 dependent or independent mechanism, SaoS-2 cells were cultured 
with concentrations of PEs shown to enhance mineralisation in the presence or absence 
of the E2 antagonist ICI 182,780 (10
-6 
M). The antagonist had no effect on 
mineralisation in control cultures but prevented the augmentative effect of PEs in the 
presence or absence of Zn
2+
 (Figure 5.8), suggesting that PEs directly enhance 
osteoblastsic mineralisation by an ER-dependent mechanism.  
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Figure 5.8. The E2 antagonist ICI 182,780 abolished the augmentative effect of PEs on 
mineralisation in the presence or absence of zinc. SaoS-2 cells were cultured with coumestrol 
(10
-7
 M), daidzein (10
-5
 M), genistein (10
-7
 M) with or without ICI 182,780 (10
-6 
M). 
Mineralisation has been suppressed in the presence of ICI 182,780 (10
-6 
M). Values are 
expressed as the mean (± SEM) from three separate experiments. Differences between groups 
were assessed by one-way analysis of variance. * Values are significantly different from non-
ICI 182,780 treated group P < 0.05. 
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5.3.5 Zinc enhanced the stimulatory effect of PEs on ALP production  
To determine the cellular mechanism by which Zn
2+
 and PEs enhanced mineralisation, I 
examined their effect on osteoblasts proliferation and ALP expression. As shown 
previously SaoS-2 cells constitutively express detectable levels of ALP in the presence 
of L-AA and β-GP, which was significantly elevated in the presence of Zn2+ for four 
days. The augmentative action of Zn
2+
 was further enhanced in the presence of genistein 
(10
-5
 to 10
-7 
M) (Figure 5.9), coumestrol (10
-5
 to 10
-7 
M) (Figure 5.10) or daidzein (10
-
5
M to 10
-9 
M) (Figure 5.11). Peak interactions were noted at 10
-5 
M daidzein, 10
-6 
M 
coumestrol and 10
-6 
M genistein which induced a significant 1.34, 1.24 and 1.21 fold 
increase in ALP activity compared to Zn
2+
 treated cultures.   
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Figure 5.9. Zinc augments the effect of genistein on osteoblastsic ALP activity. SaoS-2 cells 
were incubated with genistein (10
-9
-10
-5 
M) with or without zinc (10
-5 
M) for 4 days. Alkaline 
phosphatase activity was assessed using p-nitrophenol phosphate as a substrate (1mg/ml). 
Values are expressed as a mean (± SEM) from three experiments. Differences between groups 
were assessed by one-way analysis of variance. *P<0.05 versus control group, # P<0.05 versus 
relevant PE treated group. 
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Figure 5.10. Zinc augments the effect of coumestrol on osteoblastsic ALP activity. SaoS-2 cells 
were incubated with coumestrol (10
-9
-10
-5 
M) with or without zinc (10
-5 
M) for 4 days. Alkaline 
phosphatase activity was assessed using p-nitrophenol phosphate as a substrate (1mg/ml). 
Values are expressed as a mean (± SEM) from three experiments. Differences between groups 
were assessed by one-way analysis of variance. *P<0.05 versus control group, # P<0.05 versus 
relevant PE treated group. 
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Figure 5.11. Zinc augments the effect of daidzein on osteoblastsic ALP activity. SaoS-2 cells 
were incubated with daidzein (10
-9
-10
-5 
M) with or without zinc (10
-5 
M) for 4 days. ALP 
activity was assessed using p-nitrophenol phosphate as a substrate (1mg/ml). Values are 
expressed as a mean (± SEM) from three experiments. Differences between groups were 
assessed by one-way analysis of variance. * P<0.05 versus control group, # P<0.05 versus 
relevant PE treated group. 
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5.3.6 Zinc had no effect on osteoblasts proliferation  
Zn
2+
 alone had no effect on osteoblasts number (Figure 5.12). Similarly coumestrol on 
its own or in combination with Zn
2+
 had no proliferative effect although there was a 
trend towards lower osteoblasts number in all groups (Figure 5.13). Genistein (10
-6
 to 
10
-9 
M) induced a modest but significant increase in cell number and Zn
2+
 increased the 
effect of the highest genistein concentration examined (10
-5 
M) (Figure 5.12). 
Concentrations of daidzein shown to enhance mineralisation also had no effect on 
proliferation although increases in osteoblasts number were observed in the presence of 
daidzein with or without Zn
2+
 at 10
-6
 and 10
-9 
M (Figure 5.14).  
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Figure 5.12. Zinc had no effect on genistein’s stimulatory effect on osteoblasts proliferation.  
SaoS-2 cells were incubated with genistein (10
-5
-10
-9 
M) with or without zinc (10
-5 
M) for 4 days. 
Proliferation was then assessed using an MTS assay. Values are expressed as a mean (± SEM) 
from three experiments. Differences between groups were assessed by one-way analysis of 
variance. * P<0.05 versus control group.   
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Figure 5.13. Zinc and coumestrol had no effect on osteoblasts proliferation. SaoS-2 cells 
were incubated with coumestrol (10
-5
-10
-9 
M) with or without zinc (10
-5 
M) for 4 days. 
Proliferation was then assessed using an MTS assay. Values are expressed as a mean (± 
SEM) from three experiments. Differences between groups were assessed by one-way 
analysis of variance. 
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Figure 5.14. Zinc had no effect on the stimulatory effect of daidzein on osteoblasts proliferation.  
SaoS-2 cells were incubated with daidzein (10
-5
-10
-9 
M) with or without zinc (10
-5 
M) for four 
days. Proliferation was then assessed using a MTS assay. Values are expressed as a mean         
(± SEM) from three experiments. Differences between groups were assessed by one-way 
analysis of variance. * P<0.05 versus control group.   
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5.3.7 Zinc blunts the augmentative action of PEs on type I collagen and osteocalcin 
expression 
Bone matrix comprises two major elements, inorganic hydoxyapatite and a range of 
organic constituents. The organic component consists primarily of type I collagen and 
several non-collagenous proteins such as osteocalcin. During formation, osteoblasts first 
secrete organic elements to form osteoid which is subsequently mineralised during 
maturation. Aberrant osteoid formation or inadequate mineralisation as occurs in 
vitamin D associated rickets or osteomalacia, compromises skeletal integrity and can 
lead to an increased fracture risk. Thus to assess the effects of compounds on bone 
quality both the level of mineralisation and organic constituents has to be considered. 
Therefore, this study examined the effect of Zn
2+
 alone or in combination with PEs 
concentrations shown to augment mineralisation on type I collagen and osteocalcin 
mRNA expression. Zn
2+
 alone had no effect on type I collagen or osteocalcin 
expression (Tables 5.2). In contrast all PEs significantly enhanced type I collagen 
mRNA expression, a marker that is expressed from progenitor stages of osteoblast 
differentiation; coumestrol (10
-7 
M) stimulated a 12.04-fold increase, daidzein (10
-5 
M) a 
14.39 fold-increase and genistein (10
-7 
M) a 7.35 fold increase (Table 5.2). PEs also 
enhanced osteocalcin expression, a marker of mature osteoblast; coumestrol induced a 
2.1 fold- increase, daidzein a 16.7-fold increase and genistein a 3.1-fold increase.   
Interestingly, the addition of Zn
2+
 blunted the stimulatory effect of PEs on type I 
collagen and osteocalcin expression, although mRNA levels were still significantly 
above that of control (Table 5.2). Thus, in contrast to a positive interaction with PEs on 
mineralisation Zn
2+
 appears to blunt the stimulatory action of PEs on organic 
components of bone matrix.    
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Table 5.2. Zinc blunts the stimulatory effect of PEs on the expression of organic components of 
bone matrix.  
 
Type I collagen mRNA copies 
per 10
6 β-actin copies 
Osteocalcin 
mRNA copies per 
10
6
 β-actin copies 
 Mean SD Mean SD 
Control 35048 13799 64 19 
Zinc (10
-5
M) 20017 8045 41 11 
Coumestrol (10
-7
M) 422137 
a
 127678 136 
a
 19 
Coumestrol (10
-7
M) and 
Zn
2+
 
86339 
a b
 2529 92 
a b
 9 
Daidzein (10
-5
M) 504560 
a
 11805 1066 
a
 389 
Daidzein (10
-5
M) and 
Zn
2+
 
119396 
a b
 9980 321 
a b
 13 
Genistein (10
-7
M) 257731 
a
 86054 200 
a
 34 
Genistein (10
-7
M) and 
Zn
2+
 
51177 
b
 12014 96 
a b
 9 
a P<0.05 versus control, b P<0.05 versus relevant PE alone. 
  
                                                                                         Chapter 5 
 
163 
 
5.3.8 Zinc augments the effect of PEs on Runx2 expression but suppresses osterix 
expression 
Osteoblast differentiation is regulated by a network of transcription factors that control 
gene expression. These include Runx2 and osx which are expressed in a temporally 
defined manner. Runx2 expression is elevated during early stages of osteoblast 
differentiation, when it promotes formation of immature osteoblasts from mesenchymal 
stem cells. Runx2 expression is then downregulated during the formation of mature 
osteoblasts (Marie, 2008). Whereas osx expression is restricted to mature osteoblasts 
(Marie, 2008). To examine the potential molecular mechanism mediating the effect of 
Zn
2+
 and PEs on osteoblast differentiation, I therefore examined the effect of PEs and 
Zn
2+
 on RUNX2 and osx expression.  
In keeping with their lack of effect on mineralisation Zn
2+
 or genistein (10
-7 
M) alone 
had no effect on Runx2 or osx expression (Table 5.3). However, genistein 
concentrations shown to promote mineralisation (10
-5 
M) did significantly increase osx 
and Runx2 expression (data not shown). Similarly, coumestrol (10
-7 
M) and daidzein 
(10
-5 
M) enhanced Runx2 and osx expression. Interestingly the addition of Zn
2+
 had a 
differential effect on PEs-induced Runx2 and osx expression. PEs-induced Runx2 
expression was significantly enhanced by Zn
2+
, whereas Zn
2+
 suppressed the 
augmentative effect of coumestrol and daidzein on osx expression. 
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Table 5.3. Zinc augments the effect of PEs on Runx2 and osterix expression. 
Groups 
Runx2 mRNA copies per 
10
6
 β-actin copies 
Osterix mRNA copies 
per 10
6
 β-actin copies 
 Mean SD Mean SD 
Control 7152 2320 9037 862 
Zinc (10
-5
M) 8952 1377 7693 362 
Coumestrol (10
-7
M) 23114 
a
 1678 13856 
a
 1505 
Coumestrol (10
-7
M) and 
Zn
2+
 
34591 
a
 7006 10291 
b
 443 
Daidzein (10
-5
M) 19705 
a
 1599 39273 
a
 1498 
Daidzein (10
-5
M) and Zn
2+
 44631 
ab
 8695 17651 
b
 3610 
Genistein (10
-7
M) 7148 778 11049 1492 
Genistein (10
-7
M) and 
Zn
2+
 
18179 
ab
 1169 10107 12 
a P<0.05 versus control, b P<0.05 versus relevant PE alone. 
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5.4 Discussion 
Bone remodelling the coupled process of osteoclastic bone resorption and osteoblastsic 
bone formation generates a skeleton optimised to current mechanical and mineral 
requirements. During a normal remodelling cycle bone resorption and formation are 
balanced such that there is little net bone loss. However, this balance is disrupted in 
disorders associated with an increased fracture risk such as post-menopausal 
osteoporosis and osteomyelitis. Numerous studies suggest that dietary factors such as 
Zn
2+
 and PEs have a positive impact on bone cell activity (Karieb and Fox, 2011, 
Poulsen and Kruger, 2008, Seo et al., 2010, Yamaguchi, 2010); however the cellular 
mechanism mediating this action is unclear and few studies have examined the effect of 
combinations of these factors on osteoclast and osteoblast activity in-vitro. This study 
aimed to clarify the cellular mechanism through which these dietary factors may interact 
and suggests that appropriate combinations of Zn
2+
 and PEs may augment 
mineralisation and further suppress bone resorption. These results strengthen the data 
for the use of combinations of Zn
2+
 and PEs in the treatment of skeletal disorders. 
Bone resorption is regulated by osteoblast/stromal derived signals that stimulate 
osteoclast differentiation from monocytic precursors. Resorptive stimuli such as a fall in 
circulating calcium increase the expression of osteoblastsic RANKL while decreasing 
OPG expression (Boyce and Xing, 2008). The subsequent binding of RANKL to its 
receptor RANK on the surface of non-committed monocytes activates a network of 
intracellular signals that induce the expression of osteoclastic genes such as TRAP and 
cathepsin K. In the absence of pro-osteoclastic stimuli osteoblastsic RANKL expression 
decreases and OPG concentrations rise, OPG than sequesters RANKL and thereby 
prevents RANK activation and osteoclast differentiation. Elevated RANKL levels and 
the presence of pro-osteoclastic inflammatory cytokines such as TNF-α is a hallmark of 
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many osteolytic disorders (Nanes, 2003, Somayaji et al., 2008). At a cellular level, it is 
therefore possible to suppress osteoclast formation by either directly inhibiting the 
osteoclast precursor response to cytokine activation or alternatively by an indirect action 
on osteoblasts to lower RANKL/OPG ratios.  
Previous studies suggest that PEs suppress osteoclast formation through both 
mechanisms. Coumestrol, daidzein and genistein directly inhibit osteoclast formation in 
response to pro-osteoclastic cytokines in-vitro as found in chapter four of this study 
(Garcia Palacios et al., 2005) and decreased osteoblastsic RANKL/OPG ratios have 
been noted following treatment with a range of PEs (Wu et al., 2009, Chen and Wong, 
2006). Genistein and daidzein also reduce osteoblastsic expression of other inducers of 
osteoclast differentiation including IL-6 (Chen et al., 2002). Zn
2+
 has also been shown 
to reduce osteoclast formation in-vitro (Holloway et al., 1996, Yamaguchi and 
Weitzmann, 2011, Uchiyama and Yamaguchi, 2007), whereas Zn
2+
 deficiency is 
associated with increased levels of osteoclast formation and bone resorption (Fong et al., 
2009). However, the cellular mechanism by which Zn
2+
 suppresses osteoclast 
differentiation is unclear, as previous studies used heterogeneous bone marrow cultures 
(Uchiyama and Yamaguchi, 2007) or have shown inconsistent osteoclastic responses to 
changes in Zn
2+
 status (Fong et al., 2009, Windisch et al., 2002, Eberle et al., 1999). 
Similarly, interactions between Zn
2+
 and PEs have not been widely investigated.  
To help clarify this I examined the direct effect of Zn
2+
 on homogenous RAW264.7 
monocytic cultures and the indirect action on osteoblastsic RANKL/OPG ratios. I noted 
no direct effect of Zn
2+
 on TNF-α-induced osteoclast formation in RAW264.7 cells and 
Zn
2+
 also had no effect on the anti-osteoclastic action of coumestrol, daidzein or 
genistein in these cultures. This differs from results using mouse bone marrow cultures 
where Zn
2+
 significantly suppressed PTH-induced osteoclast formation and 
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combinations of Zn
2+
 and genistein decreased RANKL-induced osteoclastogenesis 
(Uchiyama and Yamaguchi, 2007). The suppressive action noted in these studies may 
be due to an indirect effect of Zn
2+
 mediated through stromal cells present in bone 
marrow cultures which are absent from RAW264.7 cultures. In keeping with this I 
noted that Zn
2+
 alone suppressed osteoblastsic RANKL/OPG gene expression ratio and 
also augmented the suppressive effect of PEs. This assertion is strengthened by the 
studies of Holloway in which Zn
2+
 suppressed bone resorption in the presence of added 
osteoblasts (Holloway et al., 1996). Thus Zn
2+
 associated changes in osteoclast number 
are most likely mediated through an indirect action on osteoblasts rather than a direct 
effect on monocyte differentiation and appropriate concentrations of Zn
2+
 and 
coumestrol or genistein may have a more pronounced anti-osteoclastic effect than either 
alone. 
Serum PE concentrations differ between populations and are dependent on an 
individual’s diet. Asians who typically have a soy-rich diet have significantly higher 
PEs concentrations compared to Westerners (Morton et al., 2002). The range of PEs 
concentrations examined in my study reflect those measured in Asians (10
-6
-10
-7
M) and 
Westerners (10
-8 
M). The anti-osteoclastic concentration of genistein and coumestrol 
seen in this study is similar to those shown previously (Karieb and Fox, 2011) and are in 
the range of levels measured in Asian populations but higher than those achieved by 
Western diets (Morton et al., 2002). In contrast, typical Asian and Western diets are 
unable to generate serum concentrations of daidzein similar to those shown to suppress 
TNF-α-induced osteoclastogenesis in my studies. However, these concentrations could 
be achieved with daidzein supplementation which generates tissue levels several orders 
of magnitude higher than dietary sources (Gardner et al., 2009). Serum Zn
2+
 
concentration also varies between populations with diets that lack animal sourced foods 
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leading to a high risk of Zn
2+
 deficiency (Hotz, 2007). The Zn
2+
 concentration used in 
my studies is similar to previous in-vitro experiments and is within normal serum 
reference ranges reflecting those achieved by healthy Western diets (Yamaguchi et al., 
2008, Martín-Lagos et al., 1998). Thus, Zn
2+
 tissue levels at this concentration could 
augment the anti-osteoclastic effect of coumestrol and genistein, which in turn could 
limit the excessive resorption associated with post-menopausal osteoporosis and 
osteomyelitis. However, suppression of resorption would only address part of the 
underlying pathology as this would not prevent the reduction in osteoblasts function 
(Raisz, 2005). A reduction in resorption would also fail to restore bone that has already 
been lost and may in the long term lead to atypical fractures, as normal remodelling 
rates are required to repair micro damage (Shane et al., 2010). An ideal therapeutic 
strategy would therefore rectify defects in both osteoclast and osteoblast activity. 
Osteoblastsic bone formation is a tightly regulated process in which an organic 
extracellular matrix consisting primarily of type I collagen and other non-collagenous 
proteins such as osteocalcin and osteonectin is initially secreted (Golub, 2009). Non-
collagenous proteins may then have a role in controlling the subsequent mineralisation 
of the matrix regulating the nucleation and appropriate growth of hydroxyapatite 
crystals within osteoid. I found that Zn
2+
 enhanced the stimulatory effect of coumestrol, 
daidzein and genistein on osteoblasts mineralisation in-vitro. Combinations of 
coumestrol and Zn
2+
 and genistein and Zn
2+
 had the most potent effect (10
-7 
M) whereas 
effects with diaidzein were only noted at 10
-6 
M and above.   
In contrast to the beneficial action on mineralisation, Zn
2+
 partly blunted the stimulatory 
effect of coumestrol, daidzein and genistein on type I collagen and osteocalcin mRNA 
expression. However, expression levels were still significantly above control indicating 
that matrix formation was still enhanced. Thus, appropriate combinations of Zn
2+
, 
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coumestrol, daidzein or genistein augment osteoblasts function in-vitro enhancing the 
expression of components of the organic matrix and stimulating mineral deposition. 
The augmentative action of Zn
2+
 would at least in part appear to be due to increased 
expression of the marker of osteoblast differentiation ALP. Osteoblasts derived matrix 
vesicles contain high ALP levels and mutations in ALP lead to the genetic disorder 
hypophosphatasia which is characterised by poorly mineralised bone (Fedde et al., 
1999). ALP promotes the initial stage of mineralisation by hydrolysing inhibitory 
pyrophosphate to generate inorganic phosphate needed for the initiation of 
hydroxyapatite deposition (Golub, 2009). Thus elevated ALP activity would be 
expected to enhance mineral formation. In contrast, the augmentative effect of PEs 
alone would not appear to be mediated through an effect on ALP as levels remained 
near control. Similarly although daidzein and genistein stimulated a modest increase in 
osteoblasts number this was only seen at concentrations other than those shown to 
enhance mineralisation.  
To further examine the mechanism by which PEs and Zn
2+
 augment osteoblasts function 
this study examined the expression of key intracellular regulators of osteoblast 
differentiation. Osteoblastsogenesis is a sequential process involving multiple 
transcription factors that stimulate mesenchymal precursors to form immature pre-
osteoblasts and ultimately mature osteoblasts (Jensen et al., 2010). The initial stage of 
osteoblastsic lineage commitment is controlled by the selective expression of Runx2 
which promotes the formation of immature osteoblasts characterised by the production 
of organic extracellular matrix components including type I collagen and osteocalcin. 
Homozygous loss of Runx2 is lethal due to the lack of osteoblasts and skeletal elements  
in mice (Otto et al., 1997), whereas heterozygous loss leads to cleidocranial dysplasia in 
humans and is associated with abnormal osteoblasts development in mice (Otto et al., 
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1997, Mundlos et al., 1997). With the formation of mature osteoblasts capable of 
mineralising osteoid Runx2 expression falls whereas levels of osx increase (Komori, 
2010).  
Previous studies have shown that Zn
2+
 enhances Runx2 expression (Yamaguchi et al., 
2008) but to date no study has examined the effect of Zn
2+
 on osx expression. I found 
that anti-osteoclastic concentrations of coumestrol (10
-7 
M) and daidzein (10
-5 
M) 
significantly enhanced Runx2 expression and Zn
2+
 significantly enhanced this response. 
On the other hand, Zn
2+
 blunted the stimulatory action of coumestrol and daidzein on 
osx expression. Therefore, Zn
2+
 appears to promote the expression of a transcription 
factor profile typical of early mature osteoblasts with high Runx2 and low osx levels. 
This profile is likely to explain the observed changes in organic matrix protein 
expression. The studies of Liu et al showed that Runx2 maintains osteoblasts in an 
immature state with transgenic Runx2 expression suppressing type I collagen and 
osteocalcin production and preventing the formation of mature osteoblasts (Liu et al., 
2001b). Osteocalcin levels are comparatively low in pre-osteoblasts when Runx2 
expression peaks, osteocalcin levels subsequently rise as Runx2 expression decreases in 
mature osteoblasts. Thus, the blunting of type I collagen and osteocalcin expression is in 
keeping with Zn
2+
 promoting the formation of early rather than late stages of mature 
osteoblast differentiation.  
My data show that Zn
2+
 augments the indirect anti-osteoclastic action of coumestrol and 
genistein at concentrations typically generated by soy-rich diets. Interactions between 
Zn
2+
 and anti-osteoclastic PEs concentrations were also noted for osteoblast 
differentiation and function. Appropriate combinations of Zn
2+
 and PEs increased ALP 
activity, extracellular matrix expression and mineralisation. This effect may be due to 
Zn
2+
 inducing the formation of an early mature stage of osteoblast differentiation. These 
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findings suggest that PEs have an anabolic action on osteoblast differentiation and bone 
formation markers, and combinations of Zn
2+
 and PEs may be more effective than either 
alone. This result strengthens data for the use of combinations of nutritional factors as a 
supplementary treatment of skeletal disorders. 
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6.1 Introduction 
The interaction between immune cells such as Thelper1 (CD4
+
) cells and osteoclast is 
thought to be critical for bone loss in post-menopausal women (Pfeilschifter et al., 
2002). Co-culture of murine spleen cells and human T cells augments osteoclast 
formation and RANKL mRNA expression (Horwood et al., 1999), and activated T cells 
enhance osteoclast formation in RAW264.7 cultures (Wyzga et al., 2004). The ability of 
T cells to induce osteoclast formation also provides a new insight into the mechanism 
supporting bone resorption in diseases such as rheumatoid arthritis. The increase in 
osteoclastogenesis is at least in part dependent on TNF-α (Cenci et al., 2000). TNF-α 
levels are increased in peripheral blood cells of post-menopausal women and 
ovariectomised animals, whereas E2 reduces this expression (Pacifici et al., 1991, 
Ralston et al., 1990, Kimble et al., 1996). Ovariectomy increases TNF levels which E2 
prevents (Tyagi et al., 2012). Furthermore, TNF-α-deficient mice or mice lacking T 
cells are resistant to ovariectomy-induced bone loss (Roggia et al., 2001, Lee et al., 
2006b).  
This increase in TNF levels is thought to be due to expansion of the T cell population.  
E2 deficiency modulates T cell activation, proliferation and life span by modifying the 
cytokine environment in bone ultimately leading to increased MHC II expression and T 
cell antigen presentation (Li et al., 2011). MHCII expression is stimulated following an 
E2 dependent increase in IL-7 and decrease in TGF-β level. E2 promotes TGF-β 
expression as the gene encoding TGF contains several ERE (Gao et al., 2004). Thus E2 
deficiency decreases TGF-β expression. E2 also represses IL-7 expression as IL-7 levels 
are elevated in ovariectomized mice (Ryan et al., 2005, Weitzmann et al., 2002) and  
IL-7 neutralising antibodies prevent bone loss due to the suppression of TNF-α and 
IFN-γ production (Ryan et al., 2005). Moreover, TGF-β and IL-7 inversely regulate the 
production of each (Huang, 2002), and therefore reduced TGF-β levels stimulates 
                                                                                         Chapter 6 
 
174 
 
further IL-7 production. The net result of these changes is to create an inflammatory 
state which is characterised by elevated IFN-γ levels. IFN-γ in turn promotes the 
expression of class II transactivator (CIITA) (Pacifici, 2008) which enhances MHCII 
levels on APC. The subsequent presentation of unknown antigens to T cells leads to 
activation, clonal expansion and elevated TNF-α production. The mechanism by which 
E2 deficiency modulates cytokine-producing T cells is summarised in Figure 6.1. T 
cells also express RANKL (Kong et al., 1999), and osteopetrosis in RANKL-knockout 
mice was rescued after crossing with mice expressing RANKL-producing CD4
+
 T cells 
(Kim et al., 2000). In addition, T cells also release IL-1, IL-17, IL-4 and IFN-γ 
(Weitzmann and Pacifici, 2006a, Huang et al., 2006) which are also regulators of bone 
cell activity (Teitelbaum, 2004, Rifas and Arackal, 2003) 
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Figure 6.1. Oestrogen deficiency induced TNF-α-producing T cells in bone marrow which 
caused enhancement of RANKL-induced osteoclastogenesis. From (Pacifici, 2008).  
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Several studies suggested that PEs might be useful in the prevention of skeleton 
disorders associated with aging. In the previous chapter data indicated that PEs have a 
direct beneficial effect on osteoclasts and osteoblasts activity. However data on their 
potential impact on immune modulation of bone cell activity is sparse. Genistein 
reduced thymus weight in ovariectomised mice, which was accompanied by a decrease 
in thymocyte number and T cell apoptosis (Yellayi et al., 2002). Genistein was 
proposed to effect immune cell function through ER-dependent and independent 
mechanisms (Suenaga et al., 1998), for instance genistein’s tyrosine kinase activity was 
suggested to inhibit lymphocyte proliferation (Sakai and Kogiso, 2008), and genistein 
also inhibited B cell activation in OVX mice (Ishimi et al., 1999). Additionally, 
genistein and daidzein have growth inhibitory effects on leukaemia cells through DNA 
damage in-vivo and in-vitro (Yamasaki et al., 2007), and genistein via an ER dependent 
mechanism induces T-cell leukaemia apoptosis via caspase-3 activation, (Yamasaki et 
al., 2010). 
Further studies are needed to clarify whether this effect of PEs on T cells could further 
protect against post-menopausal bone loss. Alternatively, PEs could augment the 
expression of inflammatory cytokines and thereby antagonise their inhibitory action on 
osteoclast formation. Therefore, the aim of this part of the study is to investigate the 
effect of PEs on pro-inflammatory cytokine and RANKL production by T cells to 
enhance our understanding of the potential impact of these compounds on bone 
remodelling. 
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6.2 Material and methods  
6.2.1 Culture of Jurkat E6.1 cells   
Jurkat E6.1 T cells, a human leukemic T cell line were obtained from ECACC, Porton 
Down, UK (ECACC cat. num. 88042803) and cultured in phenol-red free RPMI 
supplemented with 10% charcoal stripped foetal calf serum (Autogen Bioclear, UK), 2 
mmol/l glutamine, 100 IU/ml benzylpenicillin and 100 mg/ml streptomycin (all from 
Sigma, UK). RAW264.7 monocytes (ATCC, UK, cat. num. TIB-71) were incubated in 
phenol red free Dulbecco’s minimum essential medium supplemented with 10% 
charcoal stripped foetal calf serum (Autogen Bioclear, U.K.), 2 mmol/l glutamine, 100 
IU/ml benzylpenicillin and 100 mg/ml streptomycin (all from Sigma, UK). All 
incubations were performed at 37
o
C in 5% CO2 in a humidified incubator. Cultures were 
fed every 2–3 days by replacing half of the culture volume with fresh medium. 
Concanavalin A (Con A) and all other reagents and kits were obtained from Sigma 
(Poole, Dorset, UK) unless stated. Anti-human TNFα antibodies were purchased from 
Insight Biotechnology, Wembley, UK. 
6.2.2 Real time quantitative PCR analysis of pro-inflammatory cytokine expression 
in Jurkat E6.1 T cells  
To assess the effect of PEs on T cell function, Jurkat cells were treated with and without 
the T cell activator concavalin A (Con A) in the presence or absence of PEs. T cells 
were cultured for four days with RPMI phenol red free cell culture medium in six well 
plates and treated with genistein (10
-7
-10
-9 
M), coumestrol (10
-7
-10
-9 
M), or daidzein 
(10
-7
-10
-9 
M) in the presence of Con A (10μg/ml). Total RNA was extracted and 
reversed transcribed with M-MLV reverse transcriptase, and real time-PCR performed 
on a StepOne PCR system (Applied Biosytems, UK) using the DNA-binding dye SYBR 
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green as a fluophore as described in chapter three (3.8.1). Primers used for each 
transcription factor are shown in (Table 6.1).  
6.2.3 Cell proliferation assay 
Jurkat E6.1 T cells were cultured in 96 well plates at a density of 1x10
4
 cells per well 
and treated with Con A (10μg/ml) in the presence of coumestrol (10-5 to 10-9 M), 
daidzein (10
-5
 to 10
-9 
M) or genistein (10
-5
 to 10
-9 
M) for four days. Proliferation was 
then assessed using a commercial AQueous one solution cell proliferation assay 
(Promega, UK) according to manufacturer’s instructions, as described in chapter three 
(3.6).  
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Table 6.1. Primer sequences  
Genes 5´-3´ Forward primer 3´-5´ Reverse primer 
Human     
β-Actin 
GCGCGGCTACAGCTT 
CACCA 
TGGCCGTCAGGCAGCTCGTA 
   
Human     
TNF-α 
GCTCCAGTGGCTGAA  
CCGCC 
AGCACATGGGTGGAGGGGCA 
   
Human     
IL-6 
TCAATGAGGAGACTTGCCTGG 
TGA 
TCTGCAGGAACTGGATCAGGAC
TT 
   
Human     
IL-1β 
ACGCTCCGGGACTCA  
CAGCA 
TGAGGCCCAAGGCCACAGGT 
   
Human     
RANKL 
ACAGGCCTTTCAAGGAGCTGTG
C 
ACCAGATGGGATGTCGGTGGC 
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6.2.4 The effect of phytoestrogens on the pro-osteoclastic action of T cells 
T cells were cultured in RPMI medium and treated with genistein (10
-7 
M), coumestrol 
(10
-7 
M) or daidzein (10
-5 
M) in the presence of con A (10μg/ml) for four days. Cells 
were then centrifuged, washed in medium and resuspended in appropriate volumes of 
RPMI to remove con A and PEs. T cell number was then counted using a Neubauer cell 
chamber. 1x10
5
 T cells were added to 96 well plates containing RAW264.7 cells (2x10
4
 
cell/well). TRAP+ mono and multinucleated cell formation was evaluated as previously 
described in chapter three (3.4) after 7 days of incubation. The experiment was 
performed in triplicate (n=15). To determine if the pro-osteoclastic effect of T cells was 
mediated through TNF-α production, neutralising mouse anti-human TNF-α antibodies 
(5µg/ml) was added to replicate wells.  
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6.3 Results  
6.3.1 Phytoestrogens blunt the augmentative effect of activated T-cells on 
osteoclast formation 
To examine the effect of activated T cells on osteoclast differentiation RAW264.7 cells 
were co-cultured with Jurkat E6.1 which had or hadn’t been treated with PEs. No 
TRAP+ osteoclasts were seen in cultures of T cells whether they had been activated 
with con A or not. Similarly, osteoclasts were rarely seen in RAW264.7 cells without T 
cells, while this number was increased following addition of non-activated T cells. 
Osteoclast formation was further augmented by co-culture with con A activated T cells.  
Interestingly, the effect of T cell activation on TRAP+ cell number was reversed by 
incubating T cells with anti-resorptive concentrations of genistein (10
-7 
M), coumestrol 
(10
-7 
M) or daidzein (10
-5 
M) (Figure 6.2). Osteoclast formation in these cultures was 
reduced to that seen in cultures containing un-stimulated T cells. 
To examine the role of TNF-α in the T cell mediated induction of osteoclast formation, 
cultures were also incubated with anti-human TNF-α antibody to block TNF activity. 
Neutralisation of TNF had no effect on osteoclast formation induced by un-stimulated T 
cells. However there was a significant reduction in TRAP+ cell number with anti TNF-α 
treatment in cultures containing con A activated T cells. Osteoclast formation in these 
cultures was reduced to that induced by un-stimulated cells. Addition of antibodies to 
PEs treated cultures did not further suppress osteoclast formation (Figure 6.2). 
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Figure 6.2. Genistein, coumestrol and daidzein blunt TRAP
+
 cell formation induced by activated 
T cells in co-culture with RAW264.7 cells. T cells alone cultured in the presence or absence of 
conA and genistein (10
-7 
M), coumestrol (10
-7 
M) and daidzein (10
-5
M) and incubated for 4 days. 
RAW264.7 cells (2x10
4
) cultured in 96- well plates and Jurkat (T cells) at (1x10
5
) cell/well 
added after treatment and incubated for 5 days. Anti-human TNF antibodies were used at         
(5 μg/ml) to neutralise TNF effect in co-culture experiment. Osteoclast formation was assessed 
by TRAP staining. Values are expressed as mean (± SEM) of three separate experiments. 
Differences between groups were assessed by one-way analysis of variance. * Values were 
significantly different versus non-stimulated T cells treated group P < 0.05. # P< 0.05 versus 
stimulated T cells treated group. ** P<0.05 versus corresponding group without anti-TNF 
antibody.  
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6.3.2 The effect of phytoestrogens on viable T cell number  
An MTS assay was used to examine the effect of PEs on con A induced T cell 
proliferation. The results show that that genistein, coumestrol or daidzein can suppress 
T cell proliferation at relevant concentrations (Figure 6.3). Genistein at (10
-5 
M) 
decreased T cell proliferation, while coumestrol at all concentrations decreased T cell 
number. Daidzein decreased T cell proliferation at (10
-5 
M). This suggests that the anti-
osteoclastic effects of daidzein and coumestrol noted in the previous study were at least 
in part due to an inhibition of viable T cell number. In contrast the anti-osteoclastic (10
-7 
M) concentration of genistein had no effect on cell number suggesting that it inhibits T 
cell induced osteoclast formation through an alternate mechanism. 
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Figure 6.3. Genistein (A), coumestrol (B) and daidzein (C) decreased T cell proliferation. Jurkat 
E6.1 T cells were incubated in combination of conA (10μg/ml), genistein (10-5-10-9 M), 
coumestrol (10
-5
-10
-9 
M) or daidzein (10
-5
-10
-9 
M) for 4 days. Proliferation was then assessed 
using MTS assays. Values are expressed as a mean (± SEM) from three experiments. 
Differences between groups were assessed by one-way analysis of variance. * P<0.05 versus 
con A treated group.  
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6.3.3 Effect of phytoestrogens on pro-osteoclastic cytokine expression  
It is well established that T cells express a range of proinflammatory cytokines that may 
be responsible for inducing bone loss in post-menopausal women. In keeping with this, 
my study revealed that con A stimulated T-cells exhibited a 2.63 fold increase in TNF-α 
mRNA expression and this was prevented in the presence of PEs. Genistein (10
-5
-10
-9 
M), daidzein (10
-6
, 10
-7 
and 10
-9 
M) and coumestrol (10
-6
-10
-9 
M) all significantly 
suppressed con A-induced TNF-α expression (Figure 6.4). In contrast to the 
predominantly suppressive effect of PE daidzein (10
-5 
M) augmented TNF-α production. 
Similar effects of PEs were seen on IL-1β expression. T cell activation induced a 
significant 2.12 fold increase in IL-1β mRNA which was suppressed in the presence of 
genistein (10
-5
-10
-9 
M), daidzein (10
-6
-10
-9 
M) or coumestrol (10
-6
-10
-9 
M) (Figure 6.5). 
The lowest concentrations of daidzein and coumestrol showed a trend towards a less 
potent action whereas similar to their effect on TNF-α expression the highest 
concentrations were unable to prevent the increase in T cell IL-1β production. 
IL-6 expression was enhanced in activated T cells and this expression was significantly 
blunted by PEs treatment in a dose-dependent fashion. Genistein (10
-5
, 10
-6
, 10
-8
 and 10
-
9
M), daidzein (10
-6
, 10
-7
, 10
-9
 M) and coumestrol (10
-7 
and 10
-9 
M) decreased IL-6 
expression. Once more, no suppressive effect of daidzein and coumestrol was seen at 
10
-5 
M and in this case there was a significant 3.4 and 7.9 fold increase in IL-6 
expression (Figure 6.6).  
T cells express RANKL and this is reported to stimulate osteoclast formation in RA and 
E2 deficiency bone loss. Therefore, I examined the effect of PEs on RANKL expression 
in T cells. As shown in (Figure 6.7), RANKL mRNA expression did not differ in 
control and activated T cells. Copy number was also low in all groups; nonetheless 
expression was further reduced in the presence of genistein (10
-6
-10
-9 
M) or daidzein 
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(10
-6
 M). Additionally, daidzein and coumestrol at (10
-5 
M) increased RANKL 
expression as compared to control and activated T cells. However RANKL copy 
numbers still remained relatively low which raises the question of whether any changes 
would lead to a significant physiological effect. 
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Figure 6.4. Genistein (A), coumestrol (B) and daidzein (C) reduced TNF-α expression in 
activated Jurkat T cells. Jurkat E6.1 T cells were incubated in combination of con A (10μg/ml), 
genistein (10
-5
-10
-9 
M), coumestrol (10
-5
-10
-9 
M) or daidzein (10
-5
-10
-9 
M) for 4 days. The 
expression was assessed by quantitative real time PCR and data normalised to 10
6
 copies of β-
actin and expressed as mean (± SEM). * P<0.05 versus conA treated group, # P<0.05 versus 
control group.   
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Figure 6.5. Genistein (A), coumestrol (B) and daidzein (C) blunted IL-1β expression in 
activated Jurkat T cells. Jurkat E6.1 T cells were incubated in combination of con A (10μg/ml), 
genistein (10
-5
-10
-9 
M), coumestrol (10
-5
-10
-9 
M) or daidzein (10
-5
-10
-9 
M) for 4 days. The 
expression was assessed by quantitative real time PCR and data normalised to 10
6
 copies of β-
actin and expressed as mean ± SEM. * P<0.05 versus conA treated group, # P<0.05 versus 
control group.          
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Figure 6.6. Genistein (A), coumestrol (B) and daidzein (C) reduced IL-6 expression in activated 
Jurkat T cells. Jurkat E6.1 T cells were incubated in combination of conA (10μg/ml), genistein 
(10
-5
-10
-9 
M), coumestrol (10
-5
-10
-9 
M) or daidzein (10
-5
-10
-9 
M) for 4 days. The expression was 
assessed by quantitative real time PCR and data normalised to 10
6
 copies of β-actin and 
expressed as mean (± SEM). * P<0.05 versus conA treated group, # P<0.05 versus control 
group.          
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Figure 6.7. Genistein (A), coumestrol (B) and daidzein (C) inhibited RANKL expression in 
activated Jurkat T cells. Jurkat E6.1 T cells were incubated in combination of conA (10μg/ml), 
genistein (10
-5
-10
-9 
M), coumestrol (10
-5
-10
-9 
M) or daidzein (10
-5
-10
-9 
M) for 4 days. The 
expression was assessed by quantitative real time PCR and data normalised to 10
6
 copies of β-
actin and expressed as mean ± SEM. * P<0.05 versus con A treated group, # P<0.05 versus 
control group. 
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6.4 Discussion  
There is accumulating evidence indicating that bone resorption is modified by immune 
cells and their products (Pacifici, 2010). E2 deficiency augments bone resorption at least 
in part by up regulating proinflammatory cytokines production, whereas TNFα, IL-1β 
and IL-6 expression is suppressed by E2 in peripheral blood cells isolated from post-
menopausal women (Rogers and Eastell, 2001). E2 deficiency accelerates the 
proliferation of T-cells including CD4
+
 and CD8
+
 (Roggia et al., 2001, Weitzmann and 
Pacifici, 2007) whereas HRT decreases CD8
+
 T lymphocyte number (Kumru et al., 
2004). T and B lymphocytes may also express RANKL in inflammatory diseases 
(Kawai et al., 2006).   
The previous chapters showed that PEs have an inhibitory effect on osteoclast formation. 
However, this effect could be overridden if PEs promote T cell proliferation or augment 
pro-osteoclastic cytokine production. Therefore, this part of the study aimed to examine 
the effect of PEs on T cell-induced osteoclast formation, T cell number and pro-
osteoclastic cytokine expression using Jurkat E6.1 T cells as a model. Co-culture of T 
lymphocytes with RAW264.7 cells enhanced osteoclast formation and con A stimulated 
T cells augmented this effect, similar to previous reports (Wyzga et al., 2004, Kawai et 
al., 2006). This augmentative action of activated T cells was significantly blunted by 
genistein (10
-7 
M), coumestrol (10
-7 
M) and daidzein (10
-5 
M).   
The nature of the T cell derived stimulus promoting osteoclast formation in un-
stimulated T cells is not known, but would not appear to be due to an effect of TNF-α, 
as neutralising TNF-α antibodies had no effect on osteoclast differentiation. This may 
result from the ability of un-stimulated cells to express IL-6 and low levels of RANKL 
which could augment osteoclast formation. However, RANKL expression was 
comparatively low in un-stimulated cultures and may not represent a major pro-
                                                                                         Chapter 6 
 
192 
 
osteoclastic stimulus. Alternatively, T cells may promote the production of other pro-
osteoclastic cytokines or up-regulate RANK expression in RAW cells themselves which 
could act in an autocrine manner to promote differentiation. Low levels of RANKL 
have also previously been shown to augment RAW cells M-CSF production leading to 
elevated RANK expression and augmentation of osteoclast formation (Islam et al., 
2008). A further potential mechanism is that T cells may induce pro-osteoclastic 
cytokines expression in the monocytes themselves, as T cells have been suggested to 
induce macrophage TNF-α, IL-6 and IL-1β secretion in rheumatoid arthritis (Beech et 
al., 2006). The ability of T cells to modify monocytic cytokine synthesis may be 
dependent on a reciprocal interaction in which the monocytic induction of T cell CD40L 
expression promotes monocytic IL-6 and TNF expression (Li et al., 2011). This may be 
the case but is difficult to assess in the current co-culture experiments.  
In contrast TNF-α appears to mediate the augmentative effect of con A as neutralising 
TNF-α antibodies significantly reduced the osteoclastogenic stimulus provided by 
activated T cells, although osteoclast formation did not completely return to that of un-
stimulated T cell cultures. Con A also enhanced the expression of a range of other pro-
osteoclastic inflammatory cytokines although their importance in the pro-osteoclastic 
action is secondary to that of TNF, as neutralising TNF-α antibodies restored osteoclast 
number to near un-stimulated levels. The change in cytokine profile is consistent with 
the results of Kawai et al. (2006), which showed that activated T lymphocytes expressed 
significantly greater levels of TNF-α, IL-1β and IL-6 followed by increases in the 
ability of T cells to induce osteoclast formation. Surprisingly no increase in RANKL 
expression was noted in my studies as T cell RANKL expression has been suggested to 
be one mechanism promoting osteoclastogenesis in inflammatory disorders (Horwood 
et al., 1999). The reason for this is unclear as RANKL expression is increased in Jurkart 
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cells by T cell activators such as bacterial exotoxins (Belibasakis et al., 2008). Thus the 
lack of RANKL expression in my studies may represent a limitation of con A activation 
in contrast to more physiological stimuli. 
The suppressive effect of genistein (10
-7 
M), coumestrol (10
-7 
M) and daidzein (10
-5 
M) 
on T cell-induced osteoclast formation is mediated through separate cellular actions.  
Genistein at this concentration had little effect on T cell viability whereas it reduced con 
A stimulated TNF-α, IL-1β and RANKL expression. Higher concentrations (10-5 M) 
however decreased T cell number as reported previously (Yamasaki et al., 2007), which 
is thought to be mediated through an ability to cause mitochondrial damage (Baxa et al., 
2005), although this concentration was not examined in the co-cultures due to its 
previously demonstrated direct stimulatory effect on TNF-α-induced osteoclast 
formation. In light of the significant effect of anti-TNF-α antibodies on 
osteoclastogenesis, it is likely that the ability of genistein to reduce TNF-α expression 
represents the most important aspect of this effect, although this does not preclude a 
further contribution from decreased IL-6 or RANKL expression, as genistein treated 
cultures had fewer osteoclast than co-cultures of activated T cells administered TNF-α 
antibodies. On the other hand, the anti-osteoclastic action of coumestrol may arise from 
a combination of decreased cell viability and reduced TNF-α, IL-6 and IL-1β expression 
although surprisingly no greater effect on osteoclast formation was noted in comparison 
to genistein. In contrast the anti-osteoclastic effect of daidzein was mediated through a 
significant decrease in the number of viable T cells rather than suppression of cytokine 
production, as daidzein augmented TNF-α, IL-6 and RANKL expression. This increase 
in pro-osteoclastic cytokines expression however did not compensate for the decrease in 
T cell number, an assertion that is supported by the inability of anti TNF-α antibodies to 
further decrease osteoclast formation in these cultures. Thus, while individual T cells 
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may synthesise more TNF-α, the net concentration generated is lower due to the smaller 
pool of viable T cells. Similar effects of daidzein on immune cell number and cytokines 
levels have previously been reported; daidzein suppressed ovariectomy-induced 
increases in T lymphocyte number, which was associated with lower TNF-α expression. 
This study found that daidzein reduced TNF-α expression through effects on CD4+ 
CD28null T cell proliferation (Tyagi et al., 2011). Similarly ovariectomy-induced 
RANKL expression has been shown to be blunted in the presence of daidzein (Tyagi et 
al., 2011). The mechanism thorough which PEs reduce cytokines expression is not 
known and could potentially be meditated through several effects. It may be ER 
dependent or alternatively it could be caused by the antioxidant action of PEs which 
could modify the redox status and inhibit TNF-α secretion. The effect of genistein could 
also be mediated through its ability to suppress tyrosine kinase signalling which plays 
an important role in inflammation (Duan et al., 2003). 
In conclusion, the data shows an inhibitory effect of genistein, coumestrol and daidzein 
on activated T cell-induced osteoclast formation. This effect is observed at 
concentrations shown to directly inhibit osteoclast formation and promote bone matrix 
formation in previous chapters. This provides evidence that a further mechanism 
through which PEs may inhibit bone loss in-vivo is via a reduction in T lymphocyte 
driven remodelling. PEs could therefore prove useful in the attenuation of bone 
destruction in not only post-menopausal osteoporosis but also in other inflammatory 
disorders such as rheumatoid arthritis. 
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7.1 Discussion  
Bone is a dynamic tissue that is constantly remodelled in response to changes in 
mechanical loading, serum calcium and micro-damage. Bone remodelling is dependent 
on the co-ordinated activity of osteoclasts, osteoblasts and osteocytes. During a normal 
remodelling cycle local and systematic factors orchestrate a balance between bone 
formation and resorption, such that there is little net loss of bone mass (Nanes, 2003, 
Kwak et al., 2005, Weitzmann and Pacifici, 2005). This balance is disrupted in many 
skeletal diseases including post-menopausal osteoporosis where a fall in circulating E2 
is associated with decreased bone mass and elevated fracture risk. The fall in E2 
generates an imbalance between bone formation and resorption; such that there is an 
increased loss of bone during each remodelling cycle. E2 has been shown to regulate 
bone remodelling through several mechanisms, it can directly modify osteoclast life-
span and via the modification of cytokines production by osteoblasts and immune cells 
it can stimulate osteoclast formation and activity (Pfeilschifter et al., 2002, Weitzmann 
and Pacifici, 2006a). 
 Several anti-resorptive therapies have been developed to try and limit bone resorption 
in post-menopausal women. These include HRT, however following the publication of 
large scale studies indicating that HRT is associated with a greater risk of developing 
cancer and cardiovascular disease HRT is not now typically prescribed for post-
menopausal osteoporosis (Chlebowski et al., 2010, Chlebowski et al., 2003). 
Alternatives to HRT have been sought and several publications suggest that PEs could 
have a beneficial effect on bone mass with fewer side effects. Asian populations whose 
diet is rich in PEs in comparison to Western populations have a lower incidence of 
fractures, breast cancer and cardiovascular disease (Morton et al., 2002, Peeters et al., 
2003). Consumption of PEs has been shown to improve bone density in animal models 
                                                                                         Chapter 7 
 
197 
 
(Lee and Choi, 2005, Yuebin et al., 2006, Uchiyama and Yamaguchi, 2007). These 
positive actions have been postulated to be mediated via effects on both osteoclast and 
osteoblasts activity. However the molecular mechanism through which PEs act is not 
clear, similarly the mechanism through which a fall in circulating E2 promotes 
osteoclast formation is still open to debate. One potential mechanism is increased TNF-
α production, TNF-α has been shown to induce bone loss associated with ovariectomy 
through direct stimulation of osteoclast formation and indirectly by regulating the 
production of various pro-inflammatory cytokines (Kimble et al., 1997). Despite the 
central role of TNF-α in menopausal bone loss no study had examined the effect of PEs 
on TNF-α-induced osteoclast formation, therefore this study aimed to examine this and 
to determine the cellular mechanism by which PEs may modify TNF-α-induced bone 
resorption.  
Chapter four's results provide new evidence that PEs directly suppress TNF-α-induced 
osteoclast differentiation via inhibition of c-fos-dependent NFATc1 expression. The 
mechanism leading to a reduction in c-fos transcription is uncertain, but this could arise 
as a consequence of a direct ER mediated effect on the c-fos gene or indirectly via 
modification of an upstream regulator. The PE-induced reduction in c-fos would in turn 
be expected to prevent NFATc1 reaching levels sufficient to enable osteoclast 
differentiation, maintaining precursors in a non-committed state or allowing them to 
differentiate towards alternative macrophage lineages. Furthermore, PEs also inhibited 
DC-STAMP expression, an essential regulator of mononuclear osteoclast aggregation 
and cell fusion. PEs also decreased NFkB expression which may also effect osteoclast 
differentiation signalling. On the other hand in contrast to some earlier studies PEs had 
no effect on osteoclast viability. These results assert the positive relationship between 
PE administration and a reduction in bone resorption, and also provide new evidence 
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that PEs in addition to suppressing RANKL-induced osteoclast formation also blunt 
TNF-α-induced osteoclast formation. This inhibitory effect is mediated via an action on 
the differentiation pathways promoting the formation and fusion of osteoclast 
precursors rather than modifying the pool of precursors available to form osteoclast or 
reducing the life span of mature osteoclast themselves. This anti-osteoclastic effect was 
seen at concentrations of genistein and coumestrol generated by consuming a diet 
containing high soy content, whereas to achieve effective daidzein levels would require 
dietary supplementation. This may make geneistien and coumestrol a more attractive 
strategy than daidzein. 
In addition to the direct inhibitory effect of PE on osteoclast formation PEs may also 
indirectly reduce the osteoblastsic stimulus for resorption. I found that genistein and 
daidzein in the presence of Zn
2+
 suppressed osteoblastsic RANKL/OPG ratios and may 
therefore reduce osteoclast differentiation. In contrast to PEs Zn
2+
 had no direct effect 
on TNF-α-induced osteoclast formation and did not modify the direct suppressive action 
of PEs on osteoclastogenesis.  
Osteoblast and osteoclast activity is tightly coupled during each remodelling cycle, such 
that bone resorption is spatially linked to a subsequent formative phase. This coupling is 
lost in post-menopausal women, which contributes to the bone loss during both the 
initial and later stages of the disorder. An ideal therapy would rectify this imbalance 
preventing excessive bone loss during each cycle; furthermore an ability to augment 
formation beyond normal levels could restore bone that had already been lost. Thus the 
effect of a therapy on osteoblasts activity is arguably as important as its action on 
osteoclast function; therefore this study examined the effect of PEs on osteoblast 
differentiation and bone matrix formation. The results of chapter five indicate that PEs 
stimulate osteoblast differentiation; increasing ALP activity and enhancing organic and 
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non-organic bone matrix formation including hydroxyapatatite formation and type I 
collagen and osteocalcin mRNA expression. Thus, PEs directly increase bone formation 
in-vitro.  An ability to decrease resorption and at the same have the capacity to enhance 
bone formation in-vivo would be beneficial in maintaining or restoring bone after E2 
deficiency. The effect of PEs on osteoblast and osteoclast activity appear to be mediated 
through an ER dependent mechanism as both actions were abolished in the presence of 
the E antagonist ICI 182,780.    
Several studies suggest that other nutritional factors such as vitamin D, Zn
2+
 and 
calcium may reduce the effect of E2 deficiency (Li et al., 2011, Uchiyama and 
Yamaguchi, 2007). Zn
2+
 plays an important role in supporting osteoclast and osteoblast 
function; Zn
2+
 has been shown to inhibit osteoclast formation whereas Zn
2+
 deficiency 
is associated with reduced osteocalcin and type I collagen expression (Sun et al., 2011). 
However no study has examined if combinations of PEs and Zn
2+
 could improve bone 
formation; thus this study examined if Zn
2+
 and PEs could improve osteoblast 
differentiation and bone nodule formation. It was found that Zn
2+
 augmented the 
stimulatory effect of PEs on osteoblast differentiation and bone nodule formation, while 
no substantial effect of these factors on osteoblasts proliferation was noted. Furthermore, 
PEs and Zn
2+
 enhanced Runx2 expression, a transcriptional factor responsible for 
regulating the initial aspects of osteoblast differentiation. However, Zn
2+
 blunted the 
positive action of PEs on type I collagen and osteocalcin expression although levels 
were still significantly above control. This suggests that the stimulatory effect of Zn
2+
 is 
predominantly mediated at the initial stages of osteoclast differentiation, increasing 
Runx2 and augmenting the early stages of bone formation. These findings assert that 
zinc has an additive effect on the stimulatory effect of PEs on osteoblast differentiation 
and bone matrix formation. Thus, appropriate combination of PEs and zinc may 
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increase bone formation in-vivo. The concentrations of PE shown to have this anabolic 
effect were similar to those that inhibited osteoclast formation and therefore the 
generation of these concentrations in-vivo would appear to be potentially desirable.  
 Aberrant T cell number and TNF-α production is central to the pathogenesis of E2 
dependent bone loss (Tyagi et al., 2012, Weitzmann and Pacifici, 2006b). The impact of 
PEs on T cell formation and activity has not been extensively studied.  If PEs stimulate 
T cell proliferation or promote cytokine production then this could antagonise their 
inhibitory effect on osteoclast differentiation. I therefore examined the effect of PEs on 
T cell function. All PEs prevented the augmentative effect of activated T cells on 
osteoclast formation.  However their mechanism of action varied, genistein reduced con 
A stimulated TNF-α, IL-1 and RANKL expression, coumestrol decreased cell viability 
and cytokine expression whereas the inhibitory effect of daidzein was mediated via 
suppression of viable T cell number. This likely reflects differences in the mechanism of 
action of these compounds or differing affinity for ER. However, the concentrations of 
genistein, coumestrol and daidzein displaying these inhibitory actions were similar to 
those that reduced osteoclast and increased osteoblast differentiation. This further 
suggests that concentrations of genistein and coumestrol that can be achieved by 
consuming a soy-rich diet could have a beneficial effect on bone cell activity through 
multiple actions. In contrast there would be insufficient levels of daidzein from the diet 
to generate concentrations able to modify osteoblast, osteoclast or T cell activity and 
therefore supplements would have to be taken.   
While this in-vitro data suggests that dietary interventions may be an alternative 
strategy further in-vivo data is needed to clarify their beneficial effect on bone cell 
activity and immune status in animal models and humans. In light of their lower affinity 
for ER it may be the case that PEs exerts a weaker effect on bone metabolism in 
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comparison to E2, however this may be sufficient during the early stage of E2 
deficiency-dependent osteoporosis to reduce the rate of bone loss and prolong the time 
before bone mineral density falls into the osteoporotic window. In addition in-vivo 
experiments would enable the study of routes of administration, effective concentrations, 
and the safety of long term usage. For instance PEs may modify endogenous sex 
hormone production or impact on the progression of ER positive tumours.  
In conclusion this study provides novel and important results regarding the mechanisms 
by which PEs regulate bone cell activity and suggest that PE-rich diets may aid in the 
treatment of hormone-dependent disease. They directly inhibit the pro-osteoclastic 
stimulus provided by T cells, directly and indirectly inhibit osteoclast formation and 
also have a direct stimulatory effect on osteoblast formation. If similar effects are 
elicited in-vivo this would be expected to have a beneficial effect on skeletal health in 
post-menopausal osteoporosis and osteolytic inflammatory disorders such as 
rheumatoid arthritis. 
7.2 Future studies  
Several areas still need further investigation to clarify the precise effect of PEs and zinc 
on bone cell activity. PEs have multiple actions and thus the understanding of their 
potential beneficial effect is far from complete. In-vivo mouse and rat models of bone 
loss and remodelling would greatly increase the robustness of the data. They would also 
enable the further refinement of doses necessary to modify osteoblast and osteoclast 
activity during normal and inflammatory-induced remodelling. It is important to choose 
suitable routes of administration and also enable control of the doses administered; 
therefore these studies would use oral gavage as a route of administration. This data 
would also provide a starting point for initial concentrations ranges for human studies.   
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The results of this study showed that PEs exert their agonist effects in part through an 
ER-dependent mechanism. PEs differ in their ER binding affinity, therefore the 
assessment of relative binding affinity with the ligand-ER binding and ER-promoter 
binding assays will provide information about binding affinity for ERα and ERβ. In 
addition, utilising ERα and ERβ-knockout mice will give crucial information about the 
contribution of ERα and ERβ to the regulatory action in-vivo. Moreover, measurement 
of serum levels of PEs and other steroidal hormones in animals after controlled 
administration will give insights about the daily amounts required to generate serum 
PEs concentrations in humans relevant to their biological actions noted in this study. 
However, the bioavailability of these compounds in humans varies between individuals, 
which pose a further challenge for testing the activity of PEs in-vivo. For instance, many 
PEs are metabolised in-vivo by intestinal bacteria, for instance daidzein is metabolised 
to equol and O-desmethylangolesin which has a greater oestrogenic activity than 
daidzein. The formation of these metabolites depends on the presence of these bacteria 
in the gut flora and therefore the ability of individuals to metabolise PEs should 
incorporated into any investigation. In addition, the determination of risks and other 
side effects which may occur with treatment will provide information on safety profiles. 
Several minerals and vitamins are describing as having a positive effect on bone. This 
study found that Zn
2+
 had an additive effect on PE-augmented osteoblast differentiation 
and mineralisation while having no detrimental action on osteoclast formation. 
Therefore, it would be interesting to see if combinations of these factors were able to 
blunt the loss of bone in mouse modules of ovariectomy-induced resorption. Effects on 
osteoclast and osteoblast formation and activity could be ascertained using dynamic and 
static histomorphometry and the mechanical competence of long bones assessed by 
measuring ash content and mechanical failure properties. 
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In addition to Zn
2+
 several other vitamins such as vitamin K2 have a beneficial effect on 
bone formation and resorption. Investigation of combinations of these factors would be 
of interest to establish further beneficial effects on remodelling and immune cell activity. 
In addition many PEs-rich foods contain more than PE, and thus investigation of the 
effect of combined PEs compound on bone cells differentiation and activity in-vitro and 
in-vivo would be useful. 
The immune system has an important role in post-menopausal and inflammatory bone 
loss and the current studies found that PEs reduced pro-osteoclastic cytokines expressed 
by T cells such as TNF-α. Therefore it would be interesting to see the effect of PEs in 
the presence or absence of Zn
2+
 or vitamins on circulating and local levels of 
inflammatory cytokine production in animal models of inflammatory disease such as 
collagen-induced arthritis and bacterial osteomyelitis. This could then be related to 
changes in osteoclast and osteoblast activity to identify relationships between cytokine 
levels and bone cell activity to determine the contribution of direct and indirect PE 
actions. Ultimately, this could be resolved using T cell deficient mouse models such as 
nude mice, which lack all circulating T cells; this would enable the direct comparison of 
the response to PE in with or without T cell inputs. 
In conclusion, further experiments to test for the potential beneficial effect of PEs on 
bone and immune cells are needed to understand the precise effect of these compounds 
on bone health, establish effective concentration ranges in-vivo and determine any risks 
associated with long-term use. 
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